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    ABSTRACT  
This study describes developments and in vitro characterisation of lipid microparticles prepared 
using spray-drying for drug delivery to the lung via dry powder inhalers. Bioadhesive 
formulations such as prochitosome or chitosome powders have been introduced to overcome the 
drawbacks of liposome instability and potentially provide significant increase in the residence 
time of drug in the lung.    
Mannitol or lactose monohydrate (LMH) aqueous solutions were spray dried at inlet 
temperatures of 90, 130, 170 or 210ºC. Soy phosphatidylcholine and cholestrol (1:1 mole ratio) 
were used in all formulations. Cholesterol was added to increase vesicle membrane rigidity. 
Proliposomes containing salbutamol sulphate (SS) were prepared by incorporating various 
lipid:carrier (mannitol or LMH; 1:2, 1:4, 1:6, 1:8 and 1:10 w/w). Prochitosomes including SS or 
beclomethason dipropionate (BDP) were prepared by adding various chitosan glutamate:lipid 
ratios of 1:10, 2:10, 3:10 and 5:10 w/w. Chitosomes, including various cryoprotectants 
(mannitol, LMH, trehalose or sucrose), were prepared by including chitosan glutamate to 
liposomes generated from ethanol-based proliposomes in the ratio of 3:10 w/w chitosan to lipid. 
The spray-drying parameters for generation of dry powders were optimised by using an inlet 
temperature of 120ºC, outlet temperature of 73 ± 3°C, aspirator rate of 100%, suspension feed 
rate of 11%, and spray flow rate of 600 L/h using B-290 Buchi mini spray-dryer. 
The production yields were 48.1±2.84%, 69.73±2.05%, 61.33±2.51% and 58.0±3.0% for 
mannitol and 50.66±3.51%, 68.0±2.0%, 73.66±1.52%, 59.0±2.64% for LMH at 90, 130, 170 or 
210ºC, respectively. The size of the particles were smaller than 5 µm for both carriers at of 90 
and 130 ºC, whilst larger than 5 µm at inlet temperatures of 170 and 210 ºC. Particles had 
smooth, spherical and smaller size at 90 and 130 ºC than inlet temperatures of 170 and 210 ºC. 
Mannitol kept its crystalline properties after spray-drying, whilst LMH changed to amorphous at 
all drying temperatures. 
Mannitol-based proliposome particles were uniform, small and spherically shaped. In contrast, 
LMH-based proliposome particles were irregular and large. Entrapment efficiency of SS was 
higher for LMH-based proliposomes, however, fine particle fraction (FPF) was higher for 
proliposomes containing mannitol. Higher FPF was obtained for proliposome containing lipid to 
mannitol ratio of 1:6 (FF= 52.6%). Vesicles size decreased with increasing carrier ratio and the 
zeta potential was slightly negative for all formulations studied. 
Prochitosomes were small, porous and spherically shaped particles. Higher FPF was achieved 
for prochitosome powders containing chitosan to lipid ratio of 3:10 and 5:10 for both SS (FPF = 
58.12±2.86% and 70.25±2.61% respectively) and BDP (FPF = 61.89±9.04% and 61.56±3.13% 
respectively). Zeta potential and the fraction of mucin adsorbed on the vesicles increased upon 
increasing chitosan concentration. Vesicle size decreased with increasing chitosan 
concentration. Entrapment efficiency (EE) of the formulations containing BDP was higher than 
that for SS. Moreover, the drug EE was higher using chitosomes compared to liposomes. 
LMH and trehalose-based liposome or chitosome particles were spherical with less tendency of 
agglomeration compared to mannitol and sucrose-based particles. Powders containing LMH, 
trehalose or sucrose were amorphous, whilst mannitol-based powder was crystalline. The FPF 
values were 14.39±1.81%, 32.29±0.15, 48.99±2.22% and 50.79±3.19% for mannitol, sucrose, 
LMH and trehalose-based liposome formulations, respectively. However, FPF% values were 
higher for chitosomes, being 23.48±3.38%, 33.89±0.66%, 54.88±1.85% and 55.9±2.74% for 
mannitol, sucrose, LMH and trehalose-based chitosomes, respectively. The EE of SS was 
increased upon coating liposome surface with chitosan regardless of cryoprotectant type.  
In conclusion, the findings of this study have demonstrated the potential of lipid microparticles 
in pulmonary drug delivery and that prochitosomes or chitosomes may offer great potential for 
enhancing drug resident time in the lung. 
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1.1 Pulmonary drug delivery 
Drug delivery is a rapidly growing field of research, and pulmonary drug delivery has 
attracted tremendous scientific and biomedical interest in recent years both in terms of 
inhaler design and advances in particle engineering (Edwards et al., 1998; Bailey and 
Berkland, 2009). As technologies become more adept at characterising and 
manipulating microscopic and submicron materials, the ability to reliably produce 
entities on this scale continually improves. The therapeutic benefits of drug given by 
inhalation have been appreciated for several decades for the treatment of respiratory 
diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic 
fibrosis, and pulmonary infections, as well as for the systemic delivery of anaesthetic 
agents (Dale and Brown, 1987; Anderson, 2005; Laube, 2005). 
  
1.2 Anatomy and physiology of respiratory tract 
Respiratory system consists of two main parts, the upper and lower respiratory tracts 
(Figure 1.1) (Kleinstreuer et al., 2008; Tu et al., 2012). Air enters through the nostrils 
where it is moistened, filtered and warmed. The particles entering through the nose may 
also be entrapped by the mucosa. Cilia move the insoluble particles towards outside to 
be cleared from the respiratory tract via swallowing or expectoration. The air moves 
from mouth to the pharynx (i.e. nasopharynx, oropharynx and hypopharynx) (Bassett, 
2005; Van de Graaff, 2013) followed by larynx and trachea. Trachea is a flexible 
cartilage which separates the respiratory tract into two parts, the right and left lung. 
Whereas left lung is divided into 2 lobes and the right lung is divided into 3 lobes 
(Bassett, 2005).  
Lung is divided by carina into primary bronchia called the first generation of trachea-
bronchial tree (TBT) which leads to the second secondary bronchi (lobar bronchia or 
second generation) and in turns into third generation called the bronchioles (Bassett, 
2005; Van de Graaff, 2013). Bronchioles lead the route to the terminal bronchioles 
where the air and gas exchange begins. The final part is the alveolar region (contain 
alveolar sacs) and particles with aerodynamic diameter of 1-5 µm may reach that area 
(Bosquillon et al., 2004). 
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                   Figure 1.1: A schematic presentation of respiratory system (Adapted from Tu et al., 2012).
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1.3 Pulmonary administration of drugs 
Drug administration via the pulmonary route is used either for the treatment of local 
diseases in the lung or for the treatment of systemic diseases following drug absorption 
through the lung epithelium. 
 
1.3.1 Drugs for local administration 
For many years the pulmonary route has been used for local administration of drugs to 
treat lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) 
(Anderson, 2005). Pulmonary drug delivery allows local drug targeting and thereby 
administration of low doses and decreased drug concentrations systemically, resulting in 
reduced systemic side effects. In addition to β2-agonists, corticosteroids, antibiotics and 
mucolytics and the licensed topical drugs, new classes of drugs are being studied for 
direct administration to the lungs. Systemic chemotherapy for the treatment of primary 
or metastatic lung cancers may produce low clinical efficacy, which may be related to 
low drug distribution to the tumour tissue in the lung. Aerosolised chemotherapy could 
increase exposure of the lung tumour to the chemotherapeutic agent, whilst minimising 
systemic side effects (Gagnadoux et al., 2008). Another example of local drug 
administration is pulmonary gene therapy where DNA or siRNA are delivered directly 
to lung cells. Potential applications of genes include treatment of gene disorders such as 
cystic fibrosis, inflammatory diseases such as asthma and COPD, infections and cancers 
(Laube, 2005). Administration of vaccines to the lungs is an efficacious strategy to 
induce mucosal as well as systemic immunity against infectious microorganisms that 
are inhaled and cause tuberculosis, measles flu, etc. The pulmonary route is a non-
invasive route that might be equivalent to injections in providing systemic immune 
responses using inhalable vaccines. Pulmonary vaccination might be especially 
interesting for mass-immunisation campaigns against cancers (Laube, 2005; Minne et 
al., 2007). 
 
1.3.2 Drugs for systemic administration 
For the last two decades the lung has been investigated as a ‗needle-free‘ route for sys-
temic administration of drugs. It has unique anatomical and physiological features that 
make it attractive for drug delivery into the bloodstream, including the large epithelial 
surface area, the thin alveolar epithelium and the high vascularisation (Patton and 
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Byron, 2007). Although the alveolar epithelium is tighter than the intestinal epithelium 
(Van Itallie and Anderson, 2006), the local enzymatic activity in the alveolar region is 
lower, and first-pass hepatic metabolism is evaded following pulmonary drug delivery.  
Small molecules may be absorbed rapidly from the lung and have high bioavailability. 
Drug delivery to the lung is particularly beneficial to relieve acute symptoms such as 
pain, migraine and nausea. Small drug molecules include opioids (morphine and 
fentanyl) for the treatment of pain, or ergotamine for the treatment of migraine (Farr and 
Otulana, 2006; Patton and Byron, 2007). Therapeutic peptides and proteins might be 
absorbed better from the lung than other non-invasive routes of drug administration. 
 
1.4 Mechanism of particle deposition 
Respiratory system is responsible for exhalation and inhalation. The trapped foreign 
particles can be removed by alveolar macrophages unless they are too small to be 
recognized. The aerodynamic diameter of particles is vital to the specific target area of 
deposition in the respiratory tract (Bennett and Smaldone, 1987). The deposition of 
particles in different areas of respiratory tract (upper, central and alveolar part) depends 
upon the particle size and their flow rate (Labiris and Dolovich, 2003; Pilcer and 
Amighi, 2010). The mechanism by which particles deposit in the respiratory tract 
(Figure 1.2) are inertial impaction, sedimentation and Brownian diffusion (Hillery et al., 
2001;  Carvalho et al., 2011). 
 
 
Figure 1.2: Drug deposition mechanisms in the airways (Taken from Hillery et al., 2001). 
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1.4.1 Inertial impaction 
Inertial impaction is responsible for particle deposition in the upper respiratory tract 
because of the high velocity, large size and high density of particles (Pilcer and Amighi, 
2010). During inhalation particles enter with a high speed, which makes them unable to 
change their path or flow tract, which causes deposition in the upper respiratory tract. 
Impaction rate in the upper respiratory tract is more likely to happen for particles having 
a size larger than 5 µm (Darquenne and Prisk, 2004; Pilcer and Amighi, 2010). Hence, 
the deposition of particles will increase if they have high density or delivered into the 
respiratory tract at high velocity. 
 
1.4.2 Sedimentation 
Sedimentation is a time dependant type of deposition (Darquenne and Prisk, 2004; 
Carvalho et al., 2011) where the particle moves according to their gravity in both central 
and alveolar region. Holding the breath can increase the sedimentation rate (Byron, 
1986). Particles move by  gravitational force in the absence of inspiration and expiration 
(Carvalho et al., 2011). Particles with the size range of 0.5 - 5 µm are more likely to 
deposit by sedimentation (Stahlhofen et al., 1980; O‘Callaghan and Barry, 1997; 
Darquenne and Prisk, 2004; Pilcer and Amighi, 2010). 
 
1.4.3 Brownian diffusion 
Brownian diffusion is the method by which small particles deposit by random motion 
into the very last alveolar region by the bombardment of particles (Carvalho et al., 
2011). However, a slow speed particles and large volume of aerosol increase the 
deposition in the lung (Pavia et al., 1977; Newman et al., 1982). The velocity and 
particle size decrease as the particles pass from the upper respiratory tract to the lower 
regions by passing through different parts and finally reach the alveolar region where 
the velocity is almost zero. The particle reaches this part is less than 0.5 µm and the 
individual particles deposit via diffusion (Darquenne and Prisk, 2004; Pilcer and 
Amighi, 2010). 
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1.5 Devices used for pulmonary drug delivery 
The lung has been a route of drug administration for thousands of years with origin of 
inhaled therapies traced dating back to 4000 years ago to India, where leaves of Atropa 
belladonna plant were smoked to suppress cough. In the 19
th
 and early 20
th
 centuries, 
asthmatic patients used to smoke anti-asthma cigarettes that contained stramonium 
powder mixed with tobacco to treat the symptoms of their disease. The delivery of 
medicines to the lung occurs by means of specialised devices that operate using a range 
of mechanisms. Thus, a variety of modern devices are used to generate aerosols for 
medical inhalation, namely nebulisers, pressurised metered dose inhalers and dry 
powder inhalers. 
 
1.5.1 Nebulisers 
Nebulisers are devices that convert liquid solutions or suspensions into an aerosol 
suitable for inhalation. Unlike pMDIs and DPIs, nebulisers can deliver relatively large 
volumes of propellant-free liquid formulations. Based on their mechanism of 
atomisation, medical nebulisers can be divided into three types: air-jet, ultrasonic, and 
vibrating-mesh nebulisers. 
 
 Air-jet nebulisers 
Air-jet nebuliser is also called jet, pneumatic or air-blast nebuliser, or some times also 
called compressor nebuliser has been used for many years to deliver aerosols to the 
respiratory tract. These old-fashioned nebulisers generated  aerosols of wide particle 
size distribution and much of their output was non-respirable (Muers, 1997), 
necessitating the development of new generation of more efficient air-jet nebulisers.
 
Modern jet nebulisers convert liquid into aerosols by employing compressed gas forced 
at high velocity through a ventur nozzle (with a diameter of about 0.3-0.7 mm), creating 
an area of negative pressure within the nebuliser reservoir, resulting in pulling the liquid 
via the ―Bernoulli effect‖ (Mc Callion et al., 1996a). The liquid is drawn into the 
airstream as fine ligaments, which then collapse into primary aerosol droplets under the 
effect of surface tension (O‘Callaghan and Barry, 1997). These primary droplets usually 
have a very large particle size (15-500 µm) (Nerbrink et al., 1994). Baffling inside the 
nebuliser, allows only a proportion of the droplets to leave the nebuliser and enter the 
airstream as secondary inhalable aerosols whilst primary aerosols are recycled into the 
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reservoir for further atomisation (Figure 1.3) (O‘Callaghan and Barry, 1997). Jet-
nebulisation can cause solvent evaporation, resulting in concentration of the solutes in 
the reservoir (Ferron et al., 1976), and a drop in the temperature of the nebuliser 
solution by up to 15ºC (Clay et al., 1983; Cockcroft et al., 1989). 
The design and operating parameters of jet-nebulisers affect the aerosol performance, 
including the output and droplet size (Loffert et al., 1994). A major limitation of the 
conventional air-jet nebuliser is that very large amount of aerosols wasted during 
expiration (Figure 1.3). Several nebulisers designs have been developed to resolve this 
problem (Hess, 2000), including the use of reservoir bags (e.g. Circulair, westmed, 
USA), open vent nebulisers (e.g. Sidestream, Medic-Aid, UK), breath-enhanced 
nebulisers (e.g. Pari LC Plus, Pari GMBH, Germany) or breath-actuated nebulisers (e.g. 
AeroEclipse nebuliser, Monaghan Medical Corporation, USA) (Rau et al., 2004). 
 
 
Figure 1.3: Design of a conventional air-jet nebuliser and the movement of the droplets 
inside the nebuliser following inspiration and expiration. (Taken from O’Callaghan and 
Barry, 1997). 
 
Ultrasonic nebulisers 
Ultrasonic nebulisers were introduced in the late 1950s and they use a piezoelectric 
crystal transducer vibrating at high frequency (1.2.5 MHz) to atomise liquid into 
aerosols (Flament et al., 1999). Two mechanisms describe aerosol generation by 
ultrasonic nebulisers, which are capillary-wave theory and cavitation bubble formation 
(Figure 1.4). At low frequencies, cavitation is the main mechanism leading to droplet 
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formation. At high frequency vibrations, the bulk of the liquid generates capillary waves 
leading to the formation of peaks and a central geyser (Figure 1.4) (Taylor and 
McCallion, 1997;  Barreras et al., 2002). When the amplitude of the applied energy is 
sufficiently high, the crests of the capillary waves break off, and droplets are formed 
(Taylor and McCallion, 2002). Both mechanisms have been suggested to contribute to 
droplet formation, whereby cavitation bubbles are postulated to initiate and drive 
capillary waves (Boguslaskii and Eknadiosyants, 1969; Taylor and McCallion, 1997). 
Like air-jet nebulisers, ultrasonic nebulisers contain baffles in their reservoirs, hence 
large droplets are possibly recycled to the reservoir whilst smaller droplets (secondary 
aerosols) are released for inhalation (Elhissi et al., 2011b). Furthermore, oppositely to 
air-jet nebulisers, ultrasonic nebulisers heat the medical fluid, hence increasing its 
temperature is a major limitation when thermo-labile drugs or protein are to be 
nebulised (Taylor and Hoare, 1993).  
 
 
Figure 1.4: Mechanisms of aerosol generation using ultrasonic nebulisers. (A) droplet 
formation via cavitation theory; (B) droplet formation via capillary wave theory. (Taken 
from Taylor and McCallion, 2002). 
 
Vibrating-mesh nebulisers 
Vibrating-mesh nebulisers, also called electronic nebulisers or perforated membrane 
nebulisers, employ a vibrating-mesh or a plate with multiple apertures to generate the 
aerosol, and all are hand-held and can be operated using batteries (Dhand, 2002). 
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Several manufactures have designed different devices that use this mechanism of 
operation. (Steve Newman, 2005; Elhissi et al., 2011). 
One example is the Omron Microair NE-U22 vibrating-mesh nebuliser which 
incorporates a piezoelectric crystal (e.g. quartz) attached to a transducer horn. In front of 
this there is a perforated plate consisting of around 6000 tapered holes, each of 3 µm in 
diameter. When an electrical current is applied, the piezoelectric crystal vibrates at high 
frequency, which is then transmitted to the transducer horn. The transmitted vibration 
induces passive upward and downward vibrations in the perforated plate, which causes 
the extrusion of the fluid through the holes and generation of the aerosol (Figure 1.5). 
Nebulisers using this operation principle are: Omron NE-U03, Omron NE-U22 (Omron 
Healthcare, Japan), and Prodose Handheld (Profile Therapeutics Plc, UK).  
 
 
Figure 1.5: The design of a passively vibrating-mesh nebuliser illustrating the generation 
of the aerosol from the mesh plate (Taken from Ghazanfari et al., 2007). 
 
1.5.2 Pressurised metered dose inhalers  
Pressurised metered dose inhalers (pMDIs), introduced in the 1950s, are the most 
commonly used inhalation devices for the treatment of respiratory diseases (Rathbone et 
al., 2003; Smyth and Hickey, 2011). Formulations are comprised of a canister 
containing the therapeutic ingredient, a liquified propellant and other inactive 
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ingredients such as preservatives, surfactants and dispersing agents (Hess et al., 2011) 
(Figure 1.6). Typically, 200 actuations can generate aerosol via a pMDI, and by each 
puff a drug dose of 0.02-5 mg in metered volumes of 25-100 µl can be delivered 
(Kleinstreuer et al., 2008).  
 
 
Figure 1.6: The design of a pressurised metered dose inhaler device (Taken from 
Pritchard, 2005). 
 
Propellants in pMDIs are liquefied compressed gases that are non-toxic, non-
flammable, stable and compatible with the drug and inner walls of the canister. 
Propellants used in pMDIs have very low boiling points in the range of -15 to -30ºC. 
Chlorofluorocarbons (CFCs) were introduced as the first propellant systems (Noakes, 
2002). CFCs are now banned because of their damaging effect on the ozone layer 
(Molina, 1974). Therefore, some non-ozone depleting propellants gases such as 
tetrafluoroethane (HFA-134a) and heptafluoropropane (HFA-227) were found to be 
suitable replacements, and are now widely used in the market of pMDIs (Newman, 
2005). 
pMDIs offer the advantage of protecting their contents from bacteria and atmospheric 
conditions, being highly portable and relatively cheap compared to other inhalation 
devices (Abdelrahim, 2009).  However, the major limitation of pMDIs is the limited 
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fraction of the drug dose that might be delivered to the lung (typically only 10–20% of 
the emitted dose is deposited in the peripheral airways). The high velocity and large 
particle size of the aerosol causes approx 50–80% of the drug to impact in the 
oropharyngeal region (Newman et al., 1981). Lack of ―Hand–mouth‖ coordination is 
another obstacle in the use of pMDIs. Crompton (1982) has found that 51% of patients 
experienced problems with co-ordinating the actuation of the device with inhalation, 
24% of patient‘s halted inspiration upon firing the aerosol into the mouth, and 12% 
inspired through the nose instead of the mouth when the aerosol was actuated into the 
mouth. Another problem with the use of pMDIs is the difficulty of determining the 
remaining dose inside the pMDI canister. Rubin and Durotoye (2004) have reported that 
74% of 50 patients questioned did not know how many actuations left in their pMDI 
device.  
 
1.5.3 Dry powder inhalers  
Dry powder inhalers (DPIs) were first introduced in the market in the late 1960s with 
the introduction of the Spinhaler
® 
device by
 
Fisons. GlaxoSmithKlin (GSK) also 
introduced the Rotahaler
®
 and Diskhaler
®
 in the late 1970s and early 1980s. Astra 
Zeneca developed the first multidose gravity feed DPI in 1988, the Turbuhaler
®
 
(Crompton, 2004). 
DPIs eliminate the co-ordination problems of the pMDIs; therefore, no coordination by 
the patient is needed since DPI devices are intrinsically breath activated and propellant 
free. DPIs may also offer high patient compliance, high dose carrying capacity, 
enhanced drug stability, and may achieve higher pulmonary deposition than pMDIs 
(Crompton, 2004; Rubin, 2010). However, DPIs are complex since their performance 
depends on many factors including the design of inhaler, the powder formulation 
characteristics and airflow generated by the patient (Ashurst et al., 2000; Frijlink and De 
Boer, 2004; Chan, 2006). 
 
Dry powder inhaler devices 
DPI systems performance is dependent on the powder formulation and the design of the 
inhaler. However, these devices have not been explored extensively compared to 
powder formulations (Chan, 2003). A variety of passive (breathe driven) and active 
(power driven) single or multiple dose DPI devices are available. Passive devices driven 
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by the inspiratory flow rate of the patient for powder dispersion into individual particles 
dominate.  
The air flow resistance varies with each device and determines the inspiratory effort 
required by the patient. The higher the resistance of the device, the greater the difficulty 
in generating an inspiratory flow required to deliver the dose from the inhaler (Prime et 
al., 1997; Chan and Chew, 2003). Hence, the deposition of particles in the lung may 
decrease when using high-resistance inhalers (Maa and Prestrelski, 2000). 
Despite the development of new DPI devices, the concept of powder interaction with 
the device is poorly understood. These include, the relative influence of air turbulence, 
mechanical impaction (particle-particle and particle-device) for managing powder 
dispersion in the device and the role of the in situ fitted capsule and influence of airflow 
are still not well explored (Voss and Finlay, 2002). 
Dry powder inhaler devices are subdivided by dose type into single-unit dose (e.g. 
Aerolizer, Rotahaler), multi-dose (e.g. Turbuhaler), and multi-unit dose (e.g. Diskhaler, 
Diskus), as illustrated in Figure 1.7. For single-unit dose devices, the drug formulations 
involve a micronised drug powder and carrier system as individual gelatin capsules. 
These are placed into the inhaler for a single dose for active inhalation delivery. The 
empty capsule is then removed and discarded (Daniher and Zhu, 2008). Multi-dose 
devices are of two types, which are reservoir type devices and multi-unit dose devices. 
The multi-dose reservoir type device stores the formulation in bulk, and has a built-in 
mechanism to meter individual doses from the bulk upon actuation. The multi-unit dose 
device utilizes factory metered and sealed doses packaged in a manner that the device 
can hold multiple doses without having to be reloaded. Typically, the packaging 
comprises of replaceable disks or cartridges, or strips of foil-polymer blister packaging 
that may be reloadable. This pre-packaged does offers protection from the environment, 
and ensuring adequate control of dose uniformity (Daniher and Zhu, 2008). 
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Figure 1.7: Schematic diagram of dry powder inhaler devices design (taken from Daniher 
and Zhu, 2008). 
 
Dry powder inhaler formulations 
DPI formulations should offer uniform drug distribution, small dose variation, good 
flowability, physical stability upon storage (Keller and Rudi, 2000) and good emitted 
dose and fine particle fraction performance. Dry powder aerosol system performance 
was significantly improved via particle engineering by lowering the aerodynamic 
diameter of the delivered particles, lowering particle density (by increasing porosity of 
particles) (Staniforth, 1995; Edwards et al., 2005), and manipulating particle shape (e.g. 
designing elongated particles) (Calhoun et al., 1998) and surface morphology (e.g. by 
CHAPTER 1 
 
15 
 
generating rough surface to increase the air drag force). Improved performance was also 
achieved by blending and using ternary mixtures (by using fine carriers and ternary 
components) (Embleton, 2000), by lowering the bulk density of the powder (loose 
particle packing to reduce particle contacts) (Edwards et al., 2005), via lowering the 
inter-particulate forces in between the particles via creating rough particle surfaces (to 
reduce particle interaction) and by lowering the surface energy through changing the 
surface composition of particles (Chiesi and Pavesi, 1987; Chan, 2006). Techniques 
such as spray drying the drug with phospholipid constituents generate powdered 
formulations that are highly suitable for pulmonary drug delivery (Kim and Kim, 2001). 
 
Liposome and lipid-based dry powder inhalers 
The drug entrapped in liposomes is dispersed into a carrier (e.g. lactose) and transfered 
into DPIs after spray drying or freeze drying. Liposome powders after inhalation are 
rehydrated by the physiological environment of the lung and release drug over a period 
of time (Chougule et al., 2007). Delivery of opioid analgesic agents entrapped by 
liposomes to the pulmonary route may provide local or systemic analgesia superior to 
the solution form of these agents given by parenteral or oral routes (Bystrom and 
Nilsson, 2000). New steroidal derivatives obtained by modification of corticosteroid, 
with fatty acid esters were entrapped in liposomes for delivery to the lung via 
inhalation, resulting in steroid retention over a prolonged period of time in the 
respiratory tract using experimental animals (Radhakrishnan, 1991). A high dose of the 
drug in liposome aerosols include drugs such cyclosporine-A, budesonide, anti-fungal 
compounds, antibiotic molecules, anti-viral agents, or anti-cancer compounds for 
delivery to the lung (Melanie et al., 1999). 
Proliposome powders which are composed of the drug and lipid or mixtures with phase 
transition temperature of lesss than 37ºC for inhalation have been manufactured by 
Bystrom and Nilsson, (2000). It has been postulated that after inhalation, the drug will 
spontaneously be encapsulated into lipid vesicles upon hydration in situ within the lung. 
The resultant inhalable formulation could be potentially useful against anthrax infection 
(Weers et al., 2005). 
For the controlled release and delivery of steroids into deep lung a novel formulation of 
lipid particle has been designed. The main advanteages include: prolonged drug release, 
improved theraputic index of the drug, lower drug toxicity and improved drug stability 
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over several months. Hence, the formulation may be desirable for the treatment of lung 
diseases (Radhakrishnan, 1991). 
 
1.6 Liposomes 
In 1965, Bangham and co-workers discovered liposomes when investigating the role of 
phospholipids on blood and blood clots. Phospholipids were found to form spherical 
vesicles in aqueous dispersions (Bangham et al., 1965). For a few decades, liposomes 
for controlled drug delivery and targeting have attracted considerable interest 
(Crommelin and Sindelar, 1997). It has been found that more than 95% of new drug 
molecules have poor pharmacokinetics (Brayden, 2003). Liposomes are considered as a 
milestone in solving problems related to drug delivery and targeting, as they may 
modify the in vivo distribution of the entrapped materials and improve their theraputic 
index by increasing their efficacy or reducing their toxicity (Nastruzzi, 2004). The 
phospholipids used in the formulation of liposomes maximise the drug concentration at 
the target area in the lung, offering considerable advantages over conventional 
inhalation therapies. 
Liposomes are spherical microscopic membrane vesicles composed of single or 
multiple concentric bilayers. Due to their amphiphilic nature, liposomes have the ability 
to entrap both hydrophilic and hydrophobic molecules (Payne et al., 1986a; Payne et al., 
1986b; Blazek-Welsh and Rhodes, 2001; Darwis and Kellaway, 2001). As liposomes 
can be made from synthetic or natural lipids, this gave them a great diversity with 
variation in performance (Sharma and Sharma, 1997). The size range of liposomes is 
approx between 25 nm and 20 µm (Taylor and Morris, 1995). Each Phospholipid type 
has its own spesific phase transition temperature (Tm) and should be hydrated above 
that temperature to allow the assembly of phospholipid molecules into liposomes. At 
this temperature, an ordered/packed gel state of the phospholipid converts into less 
ordered/packed crystalline state where phospholipid bilayer becomes more leaky and 
flexible (Taylor and Morris, 1995; M‘Baye et al., 2008). Liposomes are biodegradable 
and biocompatible, which expands their potential for drug delivery for a variety of 
theraputic materials like antimicrobial drugs, antineoplastic agents, steroidal drugs and 
vaccines (Gregoriadis and Florence, 1993).  
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1.7 Molecular composition of liposomes 
Liposomes consist of phospholipids (natural or synthetic) with or without cholesterol. 
Phospholipids are essential components of cell membranes and generally consist of 
phosphate group (molecule of phosphoric acid) diglycerides and an organic molecule 
(choline) (Figure 1.8). The diglyceride part is a glyceride with two fatty acid chains, 
which are covalently bonded to a solo glycerol molecule via an ester link. The three 
hydroxyl groups (-OH) in glycerol (C3H3O3) are responsible for the hydrophilicity of 
phospholipid, and glycerol links both phosphate groups and fatty acids (hydrocarbon 
chains) (Vemuri and Rhodes, 1995). Fatty acid (hydrocarbon chains) can have variable 
level of saturation and are hydrophobic. Thus, the amphiphilic characteristic of 
liposomes makes them applicable in variety of fields and suitable to entrap materials 
with different levels of solubility (Blazek-Welsh and Rhodes, 2001; Darwis and 
Kellaway, 2001). A single lamellar or bilayer structure is created when a tail of one 
fatty acid layer faces the tail of other fatty acid layer and the polar head groups face the 
aqueous phase. 
 
 
Figure 1.8: Phospholipid molecular structure and the assembly of phospholipids into 
bilayer (lamellar) structures (taken from http:/www.bioteach.ubc.ca/Bio-industry/index/. 
Artist: Jane Wang). 
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Phospholipids may be divided into synthetic like dimyristoylphosphatidylcholine 
(DMPC) and dipalmitoylphosphatidylcholin (DPPC) (Figure 1.9), or natural 
phospholipids like egg (EPC) or soya (SPC) phosphatidylcholines. 
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Figure 1.9: Chemical structure of synthetic phospholipids (DPPC). 
 
Cholestrol (Figure 1.10) is the predominant sterols in mammals (Law, 2000), and it 
might be incorporated into liposome bilayer to bring about major changes in the 
membrane properties, manipulating the fluidity and improving the stability of the 
bilayer in order to reduce or enhance the permeability of water-soluble molecules across 
the bilayer membranes (Vemuri and Rhodes, 1995). Liposomes containing cholestrol 
may therefore improve the retention time of the drug and its permeation through body 
membranes (Coderch et al., 2000). Cholestrol also enhances the rigidity of liposomes 
(Kirby et al., 1980), possibly by filling the gapes between the phospholipid molecules in 
the bilayer structure (Figure 1.11). 
 
HO  
Figure 1.10: Chemical structure of cholesterol. 
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Figure 1.11: Phospholipid bilayer with cholesterol incorporated into the membrane 
(Taken from http://www.uic.edu/classes/bios/bios100/lecturesf04am/lecto8.htm). 
 
The phenomenon of spontaneous self-assembly of phospholipid molecules into 
liposomes was first observed by Bangham (1965). Amphipathic phosphatidylcholine 
molecules are insoluble in water. Hence they align themselves closely in planar bilayer 
sheets in aqueous media to minimise the unfavourable interactions between the bulk 
aqueous phase and the long fatty acid chains. These interactions are eliminated when the 
sheets fold themselves to form sealed vesicles (Figure 1.12) (New, 1990).  
  
 
Figure 1.12: The assembly of phospholipids into liposomes (Taken from Reusch, 1999). 
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1.8 Classification of liposomes 
Liposomes are classified either by the number of bilayers present (morphology), their 
size or the method of their preparation (Vemuri and Rhodes, 1995). Based on their 
morphology liposomes are small unilamellar vesicles (SUVs), large unilamellar vesicles 
(LUVs), multilamellar vesicles (MLVs), oligolamellar vesicles (OLVs) or 
multivesicular liposomes (MVLs) (Figure 1.13).  
 
 
Figure 1.13: Classification of liposomes based on their microscopic morphology (Taken 
from Jesorka and Orwar, 2008). 
 
1.8.1 Multilamellar liposomes  
Multilamellar liposomes (MLVs) consist of multiple concentric phospholipid bilayers 
(Figure 1.13) with a typical size range of 0.1 to 20 µm (Lasic, 1988). They are prepared 
by simple hydration of a thin phospholipid film followed by shaking; this method is 
referred to as thin film hydration method (Bangham and Horne, 1964; Bangham et al., 
1965; Szoka and Papahadjopoulos, 1980; du plessis et al., 1996). Thin film is formed by 
evaporating organic solvent from a phospholipid solution under vacuum using rotary 
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evaporator, followed by hydration above the Tm of the employed lipid, and shaking to 
generate MLVs (Figure 1.14).  
 
Figure 1.14: Schematic presentation of MLVs formation from thin lipid film (Taken from 
Lasic, 1988). 
 
1.8.2 Large unilamellar liposomes  
Large unilamellar liposomes (LUVs) (Figure 1.13) have a single phospholipid bilayer 
and are in the size range of 0.1 to 1 µm (Szoka and Papahadjopoulos, 1980; Lasic, 
1988). LUVs provide higher entrapment of hydrophilic materials in its internal aqueous 
core. LUVs may entrapped 60-65% of the drug when prepared by reverse phase 
evaporation method (Paternostre et al., 1988; du plessis et al., 1996). 
 
1.8.3 Oligolamellar liposomes (OLVs) 
Oligolamellar liposomes (OLVs) have two to five phospholipid bilayers (Figure 1.13) 
(New, 1990). OLVs together with LUVs may be prepared by reverse phase evaporation 
method to generate what are called as reverse evaporation vesicles (REVs) (Szoka and 
Papahadjopoulos, 1978). REVs are prepared by formation of w/o emulsion containing 
aqueous phase, with phospholipid dissolved in organic solvent. After evaporation of the 
organic solvent produces a gel which in turn collapses to generate LUVs and OLVs. 
Liposomes prepared using this method may offer entrapment of up to 62% of the 
aqueous phase (Szoka and Papahadjopoulos, 1978). 
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1.8.4 Small unilamellar liposomes (SUVs) 
Small unilamellar liposomes (SUVs) (Figure 1.13) have a single phospholipid bilayer 
and a size range of 20-100 nm (Lasic, 1988). They may be prepared by probe sonication 
of multilamellar liposomes above the phase transition temperature (Tm) of the 
phospholipids (New, 1990).  
 
1.9 Stability of liposomes 
Liposomes can not be stored for a long period of time because of their chemical, 
physical and microbiological instabilities. Degradation during storage particularly via 
oxidation and hydrolysis of phospholipid molecules in liposomes, in addition to vesicle 
sedimentation, aggregation and subsequent leakage of the originally entrapped 
therapeutic agent should not happen if liposomes are developed for potential clinical use 
(Wong and Thompson, 1982; Yadav et al., 2011).  
Unsaturated fatty acids of phospholipids may undergo oxidation. The shelf-life and 
permeability of liposomes might thus be affected (Vemuri and Rhodes, 1995). The 
peroxidation of lipids can be minimised by optimising the size distribution of the 
vesicles, pH and ionic strength of the liposome preparation, and by inclusion of 
antioxidants and chelating agents (e.g. butaylated hydroxyl toluene or α-Tocopherol) 
within formulation. In addition, preparation of liposomes should be done in absence of 
light (Vemuri and Rhodes, 1995; Yadav et al., 2011). Hydrolysis of the lipid causes the 
production lyso-PC (lyso-lecithin) that increases the permeability of liposomes. 
Therefore, it is important to keep minimum level of lyso-phospholipids during 
preparation and storage of liposomes (Kensil and Dennis, 1981; Riaz, 1995; Vemuri and 
Rhodes, 1995). Furthermore, oxidation and hydrolysis of lipids may lead to the 
appearance of short-chain lipids and then soluble derivatives can form in the bilayers, 
resulting in compromised quality of liposomes (Yadav et al., 2011). 
Physical instabilities such as aggregation/flocculation and fusion/coalescence affect the 
size, size distribution, appearance and shelf-life of liposomes and may cause leakage of 
the originally encapsulated drug (Yadav et al., 2011). Several strategies have been used 
to increase the stability of liposomes which are freeze-drying (lyophilization), spray-
drying and proliposome technologies. 
Freeze thaw approach or freeze drying technology minimise lipid hydrolysis during 
storage, hence increasing liposomes shelf-life (Nounou et al., 2005). Unfortunately, 
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during freeze drying or upon rehydration of the freeze-dried liposomes, leakage of the 
originally entrapped theraputic agent may occur; this can be minimised by the addition 
of sugar cryoprotectants (Crommelin and van Bommel, 1984; Desai et al., 2002; 
Nounou et al., 2005; Stark et al., 2010). Cryoprotectants are carbohydrate molecules 
such as sucrose, lactose, trehalose, etc (Crommelin and van Bommel, 1984; Crowe et 
al., 1986), cycloinulohexaose, or glycerol (Ozaki and Hayashi, 1996). Keeping the 
residual water content of the lyophilised formulation at minimal levels may increase the 
shelf-life of lyophilised liposomes and prevent the increase of vesicle size upon 
rehydration (Van Winden and Crommelin, 1997). The properties of liposome bilayers 
based upon the freezing temperature and the process can be studied by investigating the 
phase transition of liposomes, so phospholipid can be converted from an ordered (gel) 
phase to liquid crystalline (disordered) phase. Differential scanning calorimetry (DSC) 
has been used to measure thse thermal events changes of liposomes (Vemuri and 
Rhodes, 1995; Elhissi et al., 2006). 
Spray-drying may also be employed to manufacture stable liposomes which is a one 
step process that can convert liquid feed of the drug into a dry powder. The feed can be 
solution, emulsion or suspension (e.g. liposome), which is atomised to a spray form that 
is subject to thermal contact using hot gas, resulting in rapid evaporation of the droplets 
to form solid constituents. Dried particles are then seperated from the gas by means of a 
cyclone, an electrostatic precipitator or a filter bag (Figure 1.15). 
Skalko-Basnet et al. (2000) reported that size distribution of liposomes and entrapment 
efficiency of the drug verapamil or metronidazole were preseved when the vesicles were 
spray-dried even after a year of storage. Stable spray-dried liposomes conatining 
superoxide dismutase were produced by using sucrose as lyoprotectant (Lo et al., 2004). 
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Figure 1.15: Diagram of spray-dryer and its essential compartments (Taken from Cordln 
et al., 2010). 
 
Spray-drying has the ability to manipulate and control a variety of parameters such as 
solvent composition, solute concentration, solution and gas feed rates, temperature and 
relative humidity, droplet size, in order to optimise powder characterstics such as 
particle size, size distribution, shape, morphology and density. In addition, characteristic 
such as bulk density, flowability and dispersibility of the resultant particles can be 
engineered using spray drying (Van Oort and Sacchetti, 2006). 
As an alternative to freeze-drying and spray drying, proliposomes represent an 
economical and convenient approach. Proliposomes introduced by Payne et. al. (1986a; 
1986b), are dry free flowing granueles of phospholipid with carbohydrates which, on 
addition of aqueous phase, form MLVs. Proliposomes are classified into two main types 
based on the method of their preparation, which are particulate-based proliposomes 
(Payne et al., 1986a; Payne et al., 1986b; Elhissi et al., 2005) and solvent-based 
proliposomes (Perrett et al., 1991; Elhissi et al., 2006a). 
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Particulate-based proliposomes 
Particulate-based proliposomes are free flowing granules consisting of lipid and drug 
mixture coated onto soluble carrier particles. With the addition of aqueous medium the 
proliposomes can generate liposome suspensions (Payne et al., 1986a; Payne et al., 
1986b). Various sugar carriers have been studied for their suitability in the manufacture 
of proliposomes, such as lactose (Shah et al., 2006; Elhissi et al., 2012) mannitol (Yan-
yu et al., 2006; Gupta et al., 2008), fructose, sorbitol (Payne et al., 1986a; Ahn et al., 
1995; Ning et al., 2005) and sucrose (Elhissi and Taylor, 2005; Elhissi et al., 2012). The 
carrier is selected on the basis of its solubility, ability of accomodating phospholipid 
within its structure, and particle size or porosity. The size and polydispersity of the 
generated liposome may be influenced by the particle size of the carrier (New, 1990). 
Studies have reported that the entrapment efficiency of hydrophobic materials is 
generally high in liposome produced from particulate-baed proliposomes. Payne et al., 
(1986a) reported an entrapment efficiency of 100% for amphotercin B. On the contrary, 
the entrapment efficiecy of hydrophilic drug like propranolol hydrochloride were 
reported to be low, being in the range of 4-10% (Ahn et al., 1995). 
 
Solvent-based proliposomes 
Solvent-based proliposomes, also referred to as alcohol-based proliposomes or ethanol-
based proliposomes, depending on the solvent used to dissolve the lipid, were first 
introduced by Perrett et al. (1991). Solvent-based proliposomes offer a relatively simple 
means of producing liposomes from alcoholic phospholipid solutions. Ethanol-based 
proliposomes are concentrated ethanolic solutions of phospholipid consisting of ethanol, 
phospholipid and aqueous phase (5:4:10 w/w/w) which generate liposomes upon 
dilution with aqueous phase and shaking (Perrett et al., 1991; Dufour et al., 1996). The 
coexistance of ethanol and aqueous phase with phospholipids in this ratio (i.e. before 
dilution with aqueous phase) was found to form stacked (precipitated) bilayers. These 
form liposomes when more aqueous phase is added (Perrett et al., 1991). OLVs and 
MLVs were found to form upon hydration of alcohol-based proliposomes (Gregoriadis, 
1993; Elhissi et al., 2006a). 
The entrapment efficiency of liposomes prepared via this proliposome method is high 
for hydrophilic drugs (in the range of 35 to 85% depending on the formulation 
composition of the proliposomes) (Perrett et al., 1991; Turánek et al., 1997). The 
entrapment efficiency values of 81% for amphotercin B (Albasarah et al., 2010) and 
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62% for salbutamol sulphate (Elhissi et al., 2006a) using the ethanol-based 
proliposomes have been reported. 
 
1.10 liposomes in pulmonary delivery 
Liposomes have been investigated as carriers for controlled delivery of drug to the lung 
(Zeng et al., 1995). Liposomes are generally safe for inhalation since they can be made 
from compounds similar to the lung components, hence liposomes are biocompatible 
and biodegradable (Kellaway and Farr, 1990; Taylor and Farr, 1993; Justo and Moraes, 
2003). Typically, liposomal formulations are delivered to the lung in the liquid state, 
and nebulisers have been used extensively for the delivery of liposome aerosols in the 
liquid form (Schreier et al., 1993). However, the stability of liposomes in liquid 
formulations and leakage of the originally entrapped drug during nebulisation are 
serious limitations (Taylor et al., 1990). Liposomal dry powder formulations have been  
developed and investigated in order to solve the instability issues of liposomes (Joshi 
and Misra, 2001; Shah and Misra, 2004; White et al., 2005; Bi et al., 2008). Liposomal 
dry powder formulations have been reported to be very promising in the delivery of 
various theraputic agents to the lung. 
The feasibility of delivering liposome aerosols using pressurised metered dose inhalers 
was first demonstrated by Farr and Kellaway (1987). In their study, egg 
phosphatidylcholine was dissolved into a chlorofluorohydrocarbon blend, and the 
possibility of in situ formation of liposomes following deposition in the respiratory tract 
was shown. This delivery approach was confirmed by Vyas and Sakthivel (1994). 
Unlike pMDIs, DPIs deliver liposomes directely to the respiratory systems without the 
need for a propellant. Dry powder inhaler formulations of liposomes encapsulating the 
drug can be prepared by freeze drying or spray drying. After delivery of the 
―dehydrated‖ liposomes, the liposome powders can get rehydrated by the deposition on 
the epithelial surfaces of the respiratory tract, forming liposome vesicles (Chougule et 
al., 2007). Joshi and Misra (2001) and Huang et al. (2010) have demonstrated the 
feasibility of manufacturing DPI liposome formulations using freeze-drying for delivery 
to deep lung. 
Spray-drying proliposomal powders for delivery to the peripheral airways has been 
demonstrated to be convenient (Alves and Santana, 2004). The feasibility of producing 
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isoniazide (INH) proliposome dry powder formulation for aersol inhalation using DPI 
has also been demonstrated (Rojanarat et al., 2011). 
  
1.11 Bioadhesion and mucoahesion  
Bioadhesion involves material adhesion to biological cells for a prolonged time period 
(Smart, 2005). In 1980s, bioadhesives were used in drug delivery systems by 
incorporating adhesive molecules into pharmaceutical formulations to keep the 
formulation in contact with the absorption tissue, releasing the drug at the vicinity of the 
absorption site, thereby increasing the drug bioavailability and promoting local or 
systemic theraputic effects (Woodley, 2001; Hägerström, 2003).   
The adhesion of formulations to mucosal membranes in the lung can be reduced by the 
mucociliary escalator system. This is a natural defense mechanism of the body against 
the deposition of impurities on the mucous membranes, which may result in removal of 
the drug from the site of deposition before absorption can take place. Bioadhesives 
reduce the need for frequent dosing and promote patient compliance (Woodley, 2001). 
Hence, bio-adhesive systems can improve the treatment of diseases, helping to maintain 
an effective concentration of the drug at the site of action (Huang et al., 2000).  
Polymers derived from polyacrylic acid (e.g. polycarbophil and carbomers), polymers 
derived from cellulose (e.g. hydroxyethylcellulose and carboxymethylcellulose), 
alginates, chitosan and chitosan derivatives and lectins and their derivatives are popular 
bioadhesives (Grabovac et al., 2005; Smart, 2005). Mucoadhesive materials are water 
soluble or water insoluble polymers, which consist of swellable networks, joined by 
cross-linking agents. These polymers possess optimal polarity to ensure that sufficient 
wetting by the mucus is achieved and optimal fluidity to ensure adsorption and 
interpentration of polymer into mucus. 
 
 1.11.1 Mucoadhesion mechanisms 
The mucoadhesive agent spreads over the substrate to initiate and increase in the surface 
contact, promoting the diffusion of its chains into the mucus. Attractive and repulsive 
forces between the bioadhesive agent and mucus arise. For a mucoadhesive to be 
effective, the attraction forces should be predominant.  A partially hydrated polymer can 
be adsorbed by the substrate due to the facilitated attraction by the moistened surface of 
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the polymer (Lee et al., 2000). Generally, the mechanism of mucoadhesion is described 
in two steps (Figure 1.16). 
The first step (contact stage) involves an intimate contact between the mucoadhesive 
polymer and the mucous membrane, with spreading and swelling of the formulation, 
initiating its deep contact with the mucus layer (Hägerström, 2003). In the second step 
(consolidation stage) the mucoadhesive material is activated by the presence of moisture 
which plasticises the formulation, allowing the mucoadhesive molecules to link to the 
mucosal surfaces by weak van der Waals and hydrogen bonds (Smart, 2005). 
 
 
Figure 1.16: Two steps in the mechanism of mucoadhesion process: contact stage and 
consolidation stage (Taken from Carvalho et al., 2010). 
 
1.11.2 Ideal mucoadhesive polymer characteristics 
An ideal mucoadhesive polymer should have the following characteristic (Langer and 
Peppas, 1981; Jiménez-castellanos et al., 1993): 
   • It should be non-irritant and its degradation products should be non-toxic. 
   • It should adhere quickly to cells and should possess site-specifity. 
   • It should offer no hindrance to drug release. 
   • It must be stable during the shelf life of the dosage form. 
   • The cost of the polymer should be low.  
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1.11.3 Chitosan 
Chitosan (1,4-2-amino-2-deoxy-b-D-glucan) is a cationic mucoadhesive polymer 
derived from the natural polymer of chitin which is one of the most abundant 
polysaccharides in nature (Li and Birchall, 2006). Chitosan has been used in agricultural 
products, food, cosmetics, and pharmaceutical industries due to its high 
biocompatibility, and possibility to be chemically modified (Kato et al., 2003; Hirano, 
1996). The use of chitosan and its derivatives as absorption enhancers has been 
extensively demonstrated, with the results reporting that chitosan and its derivatives can 
significantely enhance the absorption of theraputic agents in vitro (Artursson et al., 
1994; Portero et al., 2002; Hamman et al., 2003) and in vivo following nasal 
administration (Illum et al., 1994), pulmonary delivery (Davis, 1999), oral 
administration (Thanou et al., 2001), ocular administration (Di Colo et al., 2004) and 
application on buccal mucosa (Senel et al., 2000). 
 
Advantages of chitosan for pulmonary delivery 
In pulmonary delivery, antimicrobial (Rabea et al., 2003) and antioxidant (Xie et al., 
2001; Fernandes et al., 2010) activities have been well investigated for various types of 
chitosan and its derivatives. This can also be regarded as extremely applicable for the 
development of pulmonary drug delivery systems. The processability of chitosan and 
several derivatives allows obtaining different types of systems such as powders or well 
structured micro and nanocarriers that can be engineered to have optimal aerodynamic 
particle diameters for deep lung deposition and prolonged retention (Li and Birchall, 
2006; Naikwade et al., 2009; Lauten et al., 2010; Nielsen et al., 2010). The presence of 
reactive amine groups grants chitosan the chimical versatility for modification and 
functionalisation (Figure 1.17)  (Kumar et al., 2004). 
 
 
Figure 1.17: Chemical structure of chitosan (Taken from Andrade et al., 2011). 
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Cationic chitosan polymer form ionic, hydrogen, or hydrophobic bonding with 
negatively charged chains of mucin in addition to the structural components of mucus 
fluids, which may provide evidence for the potential of chitosan in increasing the 
retention time of drug in the lung (Sogias et al., 2008). Chitosan increases the 
absorption of drugs by the paracellular route, particularly for macromolecules, due to 
the transient disruption of the tight junctions (Figure 1.18) (Thanou et al., 2001). This 
effect in pulmonary drug delivery was confirmed by Yamamoto et al. (2005) who used 
in vivo experiments in guinea pigs by comparing the pulmonary absorption of differen 
drugs using formulations with or without chitosan. Drug permeation was enhanced 
significantely in the presence of chitosan. 
Chitosan as a mucoadhesive polymer has been used to coat the surface of liposome 
vesicles, in order to increase the entrapment efficiency of drugs, prolong the  residence 
time of drug in the target site and promote the drug absorption from the lung epithelium. 
Zaru et al. (2009) have reported that the entrapment efficiency of rifampicin and the 
amount of mucin adsorbed on the surface of liposome vesicles have increased markedly 
after coating liposome surface with chitosan. The mucoadhesive properties and 
entrapment efficiency of liposome entrapped atenolol increased considerably by coating 
the liposome surface with chitosan compared to the un-coated liposomes (Karn et al., 
2011). 
Chitosomes are liposomes coated with chitosan polymer to provide a delivery system 
with enhanced bioadhesive properties. Thus, prochitosomes are dry free flowing 
granules of phospholipid and carbohydrates coated with chitosan polymer, which upon 
addition of aqueous phase, form chitosome vesicles. 
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Figure 1.18: Paracellular route of drug absorption using chitosan. (a) Tight junctions of 
normal epithelium. (b) Transient disruption of tight junctions by chitosan with 
enhancement of drug absorption. “1” represents the drug, “2” represents the tight 
junction, and “3” represents chitosan (Taken from Andrade et al., 2011). 
 
1.12 Hypothesis and objectives 
Amongst drug delivery systems, pulmonary administration of drugs is a promising 
route. Liposomes are promising carriers for overcoming the limitations of drug delivery 
via the pulmonary route. Issues like liposome instability in liquid formulations and 
scaling-up difficulty need further research. Literature findings highlighted the 
importance of chitosan as safe, biodegradable, biocompatible and bioadhesive polymer 
for pulmonary delivery. The combined advantages of liposomes and chitosan require 
further investigations. 
In this study, it was hypothesised that pulmonary administration of mucoadhesive dry 
powder prochitosome or chitosome aerosols would improves liposome stability and 
may potentiates enhance the retention time of drug within the lung. Dry powder 
prochitosomes or chitosomes have not yet been reported for pulmonary delivery.  
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Aims: 
1. To design and engineer microparticles of suitable size and morphology for delivering 
therapeutic agents to the lung. 
2. To explore the validity of spray-drying for generating mucoadhesive prochitosome or 
chitosome powders. 
3. To investigate the potential of prochitosome or chitosome powders for deep lung 
inhalation using dry powder inhaler devices. 
4. To evaluate the suitability of liposome or chitosome vesicles upon hydration of 
powders for delivery using medical nebulisers.  
 
Objectives: 
1. To establish optimal spray-dried inlet air temperatures for manufacture of 
microparticulate mannitol or lactose monohydrate (LMH) as core carriers in the 
preparation of proliposome or prochitosome powder formulations. 
2. To generate mannitol-based proliposomes or LMH-based proliposomes using various 
lipids to carrier ratios and investigate their potential in terms of morphology, 
crystallinity and aerosol characteristics for use in pulmonary delivery of salbutamol 
sulphate via dry powder inhalers.  
3. To produce prochitosome powders of various chitosan to lipid ratios and investigate 
the effect of chitosan concentrations on their suitability for pulmonary delivery of 
salbutamol sulphate or beclomethason dipropionate via dry powder inhalers or medical 
nebulisers. 
4. To prepare liposome or chitosome formulations using various types of sugar 
cryoprotectants and study the effects on the resultant liposomes and chitosomes 
characterisations before and after spray-drying. This should assess the potential 
suitability of the formulations for pulmonary delivery using salbutamol sulphate as a 
model drug and the Two stage impinger (TSI) or Next generation impactor (NGI) for 
aerosol collection and subsequent analysis from various stages. 
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2.1 Materials 
Beclomethasone dipropionate (BDP), cholesterol (CH), D-Mannitol, D-(+) - trehalose 
dihydrate and phosphate buffer saline were purchased from Sigma-Aldrich, UK. 
Sucrose (Sigma ultra; ≥ 99.5 %), mucin from porcine stomach type III and Bradford 
reagent were obtained from Sigma, Life science, UK. Deuterium oxide (D2O) (99.8 
atom % D), Water (high performance liquid chromatography; HPLC grade), absolute 
ethanol, methanol (HPLC grade; 99.9 %) and ethanol (96 %) were all purchased from 
Fisher Scientific, UK. Lactose monohydrate (LMH) was purchased from VWR, UK. 
Salbutamol sulphate (SS) (99 %), sodium 1- hexane sulfonate monohydrate (99 %) and 
acetic acid glacial (99 %) were purchased from Alfa-Aesar, UK. Protasan G213, an 
ultrapure chitosan glutamate salt, was obtained from Novamatrix, Belgium. Soya 
phosphatidylcholine (SPC, Lipoid S-100) was a gift from lipoid, Switzerland.  
 
2.2 Methods 
Lipid microparticles including proliposomes, prochitosomes and chitosomes were 
prepared and spray dried using the Büchi Mini Spray Dryer B-290 (Büchi Laboratory-
Techniques, Switzerland) to produce dried particles. The details of preparation methods 
are explained in each chapter whilst the general methodology is explained in section 
2.2.1. 
 
2.2.1 Spray drying 
The Mini Spray Dryer operates by employing a nozzle-spraying the liquid as droplets 
into a hot chamber. During the drying process the temperature of the material remains 
significantly below that of the drying air because of the evaporative cooling, as the 
drying time ranges from 0.1 seconds to a few seconds. The mini spray dryer permits the 
production of particles with a size range of 2-25 μm. The lower limit is given by the 
particle separation capacity of the cyclone used. Smaller particles can not be removed 
any further from the drying gas and hence they are trapped within the filter of the drier. 
A lipid dispersion containing drug and carrier were spray dried to obtain a dry powder 
of proliposomes, prochitosomes or chitosomes. Lipids were composed of a mixture of 
SPC and CH in a mole ratio of 1:1. The dispersion was fed into the Büchi Mini Spray 
Dryer B-290 equipped with a high performance cyclone (Büchi Labortechnik AG, 
Switzerland) with a 0.7 mm nozzle (Figure 2.1). The following operating conditions 
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were used: inlet temperature of 120°C, spray flow rate of 600 L/h, the pump was set up 
at 11% and the aspirator was set up at 100%. These conditions resulted in an outlet 
temperature of 73 ± 3°C. The dispersion was continuously stirred while being fed into 
the spray drier in order to provide homogeneity of the dispersion during spray drying. 
The powder was transferred from the collecting chamber to a desiccator in the fridge 
before carrying out further characterisation experiments. 
 
 
Figure 2.1:  The Büchi Mini Spray Dryer B-290.  
 
2.2.2. Hydration protocol for spray-dried powders  
Spray-dried powders were hydrated by addition of the desired type and amount of 
aqueous phase at a room temperature. Preparations were shaken by vortex mixing at 
maximum speed for 2 min to generate the liposome or chitosome dispersions. 
Dispersions were allowed to ―anneal‖ for approx 1 hour before carrying out further 
characterisation. Annealing of liposomes above the phase transition temperature (Tm) 
was reported to be desirable to overcome possible structural defects of the bilayers 
following the preparation of liposomes (Lawaczeck et al., 1976). 
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2.2.3 Production Yield  
The production yield of spray-dried powder of various batches were calculated using the 
weight of final product after spray drying with respect to the initial total weight of the 
carrier, drug and lipids used. The production yield (%) was calculated according to the 
following equation (Cevher et al., 2006): 
 
       
  
  
                                                                         
 
Where PY is the production yield; W
o
 = is the practical mass of spray-dried powder; 
and WT is the theoretical mass before spray-drying. 
 
                  
  
  
                                                      
Where, 
Pw is the practical weight of the drug after spray-drying 
Tw is the theoretical weight of the drug before spray-drying 
                            
                 
                    
                       
 
2.2.4 Powder Density 
The bulk density of the spray-dried powder was measured by using tapped density 
meter (ERWEKA
®
p Gmbh, D-63150 Heusenstamm/ Germany). A known mass of 
powder was poured into a calibrated measuring cylinder and the volume occupied by 
the powder was recorded. The tapped density of spray dried powder was determined by 
volume measurement of the tapped mass until no further changes in the powder volume 
were observed. The measurement was performed in triplicate. Carr‘s index values for 
each spray dried powder were derived from bulk density and tapped density 
measurements according to following equation. 
 
                   
            
              
                             
Eq.2.4 has been previously introduced by Kundawala et al. (2011) 
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The Carr‘s index values give indication about the powder flow properties. In accordance 
with the British Pharmacopoeia (2010), and as previously reported (Pilcer et al., 2006; 
Tajber et al., 2009), the Carr's index value ranging between 20-30% which indicates that 
the powder has excellent flow properties, and when the value is greater than 40% the 
powder is described as cohesive. 
 
2.2.5 Scanning electron microscopy  
Scanning electron microscopy (SEM) is a technique that employs electrons for image 
viewing; it needs the sample to be electrically conductive. In order to view non-
conductive samples, like most organic drugs, these must be coated with a thin layer of 
conductive material (e.g gold, platinium, etc.) using a sputter coater. 
Evaluation of particle size and morphology of dry samples was achieved by using SEM 
(Figure 2.2). A sample of spray-dried powder was sprinkled onto an aluminium stub and 
coated with gold by a sputtering technique using a JFC-1200 Fine Coater (JEOL, 
Tokyo, Japan) for 2 min. The particles were observed under SEM (Quanta-200, FEI) at 
20 kV (magnifications were 400x, 600x, 2000x, 4000x and 6000x) followed by saving 
the images of scanned particles using the software of the instrument.  
 
 
Figure 2.2: A presentation showing a scanning electron microscope (Quanta-200, FEI). 
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2.2.6 X-ray powder diffraction  
X-ray diffraction of spray-dried powders were conducted using an Equinox 2000 (Inel, 
France) (Figure 2.3) equipped with a diffracted-beam monochromator using Cu 
radiation. The spray-dried powder samples were spread on glass sample holders, each in 
an area of 4 cm with a depth of 1 mm. The powder surfaces were pressed and smoothed 
with a glass slide. Diffraction intensity was recorded at an angle of 2-theta.The total 
time of the diffraction scan was 20 min. The voltage and current generator were set up 
at 32 kV and 28 mA respectively.  
 
 
Figure 2.3: The X-ray powder diffractometer (Equinox 2000, France). 
 
2.2.7 Fourier Transform Infrared  
Infrared spectroscopy was used to identify the functional groups of the samples. The 
FT-IR spectrum was taken for the spray-dried powder and compared with the standard 
FT-IR spectra of each component of the powder before dispersion and spray-drying. A 
small quantity of the powder was placed on a magnetic holder of the FTIR instrument 
(Nicolet IS 10, Thermo Scientific, USA) where the beam was incident on the sample. 
The major and important peaks were reported in cm-1. 
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2.2.8 Preparation of phospholipid dilutions for construction of a calibration curve  
A calibration curve was produced in triplicate by dissolving 10 mg of SPC and 
cholestrol (1:1 mole ratio) within a flask using absolute ethanol. Rotavapor (R-215, 
Buchi, Switzerland) was used to evaporate the solvent at 45ºC under reduced pressure 
(Vacuum pump V-700, buchi, Switzerland). A thin film was formed and then hydrated 
with deionised water to make liposomal dispersion and then 1 mL of absolute ethanol 
for liposome disrupting was added to make it a solution of lipid. The sample was kept in 
oven overnight at 75ºC to evaporate the solvent and form a dry thin film of lipid. The 
film was dissolved and made up to 100 mL with chloroform (standard) and a range of 
lipid concentrations were used (Table 2.1) for calibration curve and vortexed vigorously 
for 1 min followed by 5 min centrifugation at 300 g. The upper black maroonish layer 
was discarded and the lower chloroform layer containing the amount of phospholipid 
was collected for analysis by UV-visible specrophotometer (Jenway, 7315 
Spectrophotometer, UK) at 488 nm to quantify the phospholipid (Stewart, 1980). 
 
Table 2.1: Concentration of phospholipid used for construction of the calibration curve. 
 
* The composition of ammonium ferrothiocyanate is described in section 2.2.9. 
 
2.2.9 Lipid recovery using phospholipid assay 
The phospholipid assay was performed to investigate the efficiency of phospholipids 
recovered following spray-drying. These experiments were performed to determine the 
amount of SPC content present in the spray-dryed powder. Phospholipid assay was done 
according to the protocol used by Elhissi et al. (2006b) which was adapted from Stewart 
(1980). Sample (5 mg) of the spray-died powder was dispersed in 1 mL of deionised 
water and vortexed for 2 min to form liposome or chitosome dispersions in a glass vial. 
Tube 
No. 
Standard 
(mL) 
Chloroform 
(mL) 
Ammonium 
ferrothiocyanate
*
 
(mL) 
Concentration 
(µg/2mL) 
UV 
absorbance 
1 0.8 1.2 2 80 0.126 
2 1 1 2 100 0.156 
3 1.2 0.8 2 120 0.211 
4 1.4 0.6 2 140 0.244 
5 1.6 0.4 2 160 0.314 
6 1.8 0.2 2 180 0.358 
7 2 0 2 200 0.412 
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Absolute ethanol (1 mL) was added to the dispersion to disrupt the liposomes or 
chitosomes and convert the dispersion into a clear ethanolic solution. Vials were kept 
overnight in oven (75°C) to evaporate the solvent and leave the phospholipid as a film 
on the inner walls of the vial. Chloroform (2 mL) was added to the glass vial to dissolve 
the phospholipid, followed by addition of an equal volume of ammonium 
ferrothiocyanate solution (prepared by dissolving 6 g of ammonium thiocyanate 
(NH4SCN) and 5.4 g of ferric chloride (FeCl3 6H2O) in 200 mL of deionised water). 
The phospholipid film developed a colour when phospholipid molecules react with 
ammonium ferrothiocyanate in a chloroformic solution (Stewart, 1980). The samples 
were vortexed for 2 min using the Whirl MixerTM (Fisherbrand, Fisher, UK) and left to 
stand for 2 hour. The lower chloroformic layer was aspirated and the amount of 
phospholipid complexed with ammonium ferrothiocyanate was estimated at 488 nm 
using UV-visible specrophotometer (Jenway, 7315 Spectrophotometer, UK).  
 
2.2.10 Transmission electron microscopy  
Spray-dried powder were weighed and hydrated to form liposome or chitosome 
dispersions (as described in Sections 2.2.2). A drop of liposome or chitosome dispersion 
was placed on carbon-coated copper grids (400 mesh) (TAAB Laboratories Equipment 
Ltd., UK). The sample was negatively stained with 1% phosphotungstic acid (PTA), 
and then viewed and photographed using a Philips CM 120 Bio-Twin TEM (Philips 
Electron Optics BV, the Netherlands). 
 
2.2.11 Size analysis studies  
Spray-dried powder was hydrated to form liposome or chitosome dispersions (as 
described in Sections 2.2.2) and their size and size distribution were determined using 
laser diffraction by employing the Malvern Mastersizer 2000 instrument (Malvern 
Instruments Ltd., UK). Volume median diameter (VMD) and Span were used to express 
the size and size distribution, respectively. The Span is a unit-less term introduced by 
Malvern Instruments to express the width of particle distribution based on 10% 
undersize, VMD (50% undersize) and 90% undersize, and it is calculated as Span = 
(90% undersize − 10% undersize) / VMD.  
During laser diffraction measurements a laser beam was focused on particles which, 
depending on their size, scatters the laser beam in certain angles. The smaller the 
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particle size, the higher the scattering angle and the smaller the scattering intensity. The 
intensity and angle of the scattered light were then measured by a series of 
photosensitive detectors attached to a computer which then calculated the size and size 
distribution of the particles (Figure 2.4). 
 
 
Figure 2.4: A schematic presentation of laser diffraction (Taken from Malvern-
instruments, 2012). 
 
2.2.12 Zeta potential analysis  
The zeta potential of liposomes or chitosomes generated by hydration of spray-dried 
powders was analysed using the Zetasizer Nanoseries (Malvern Instruments Ltd., UK). 
Liposomal or chitosomal suspensions were shaken and 70 μL was transferred using a 
Gilson pipette into a polystyrene latex cell (Malvern Instruments Ltd., UK). The 
temperature was set up at 25°C and an equilibration time of 2 min was allowed. 
A potential exists between the particle surface and the conducting liquid (Maherani et 
al., 2012) which varies according to the distance from the particle surface,  this potential 
at the slipping plane is called the Zeta potential (Figure 2.5). 
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Figure 2.5: A schematic presentation illustrating the principle of zeta potential employed 
by the Zetasizer instrument (Taken from Malvern-instruments, 2004). 
 
2.2.13 Mucoadhesion studies 
 
i) Effect of chitosan concentrations on mucin adsorption using UV-spectroscopy 
The ability of mucin to adsorb on the surface of liposome or chitosome vesicles was 
used to assess the mucoadhesive properties of the spray-dried powders after hydration 
with aqueous mucin solutions (Filipović-Grcić et al., 2001 and Zaru et al., 2009). Spray-
dried powders (25 mg) were dispersed in 1 mL aqueous solution of mucin (0.5 mg/mL), 
mixed and incubated at 37ºC for 1 hour. Then, the dispersions were centrifuged at 
10,000 RPM for 30 min, and the supernatant was used for the measurement of the free 
mucin content. The Bradford calorimetric method (Bradford, 1976) was used to 
determine the free concentration of mucin in order to assess the amount of mucin 
adsorbed to the liposome or chitosome vesicles. A mucin calibration curve was prepared 
using standard solutions of mucin (0.1, 0.25, 0.5, 0.75 and 1 mg/mL). All samples were 
incubated at 37ºC for 1 hour after addition of the Bradford reagent, and then the 
absorbance was determined at 595 nm using UV-visible spectrophotometer (Jenway, 
7315 Spectrophotometer, UK). The mucin content of each formulation was calculated 
from the standard calibration curve. 
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ii) Effect of chitosan concentration on mucin adsorption using Malvern zeta sizer 
To study the effect of chitosan on the bioadhesive properties of liposomes, zeta 
potential analysis was conducted by incubating the liposomal or chitosomal suspension 
with an equal volume of aqueous mucin solution (0.5 mg/mL) for 1 hour at 37ºC. The 
change in zeta potential was recorded in an attempt to detect possible interaction 
between chitosan and mucin. 
 
2.2.14 Entrapment efficiency studies of salbutamol sulphate   
 
i) Preparation of a standard calibration curve  
Accurately weighed 10 mg of SS was dissolved in 100 mL of deionised water to obtain 
a stock solution (100 μg /mL). From this solution volumes of 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 
mL were taken and pipetted into a series of 10 mL volumetric flasks. The volume in 
each flask was made up to 10 mL with deionised water in order to get drug 
concentrations in the range of 5 to 80 μg /mL (Figure 2.6). 
 
 
  Figure 2.6: Calibration curve of salbutamol sulphate. 
 
ii) Drug loading and entrapment efficiency measurements 
Spray-dried powders (10 mg) were hydrated with 1 mL of aqueous medium to form 
liposome or chitosome dispersions. The dispersions were transferred to a 10 mL 
volumetric flask. Methanol (1 mL) was added to dissolve the lipid. The solution was 
then adjusted to the final volume with deionised water and analysed by HPLC for its 
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drug content to determine the total drug loading (i.e. content of drug in the powder). To 
conduct the HPLC experiments, a buffer comprising sodium hexane sulfonate (5 mM) 
in water was mixed with methanol (75:25 v/v) to produce the mobile phase to which 
glacial acetic acid was added to constitute 1% of the total mobile phase volume.  
The HPLC (Agilent 1200 with UV detector; Hewlett-Packard Co., USA) was set up 
with a Symmetry C18 column (150 mm 4.6 mm, 5m; Waters Ltd, UK) and samples 
were analysed at 276 nm. The mobile phase flow rate was adjusted to 1 mL/min at 
40°C, and the volume of the automatically injected sample was set to 20 µL. A 
calibration curve of ascending SS concentrations was made and drug in the samples was 
accordingly analysed. All experiments were performed in triplicates. 
To determine the entrapment efficiency, 10 mg of spray-dried powder was hydrated 
with 50µL of aqueous medium and vortex mixed for 2 min to form liposome or 
chitosome dispersions. This was followed by addition of deionised water to make up the 
volume to 1 mL. The dispersion was then left for annealing for approx 1 hour. The 
dispersions were diluted to 8 mL with deionised water and centrifuged using a Beckman 
LM-80 ultracentrifuge (Beckman Coulter Instruments) at a speed of 55,000 rpm for 35 
min at 6°C, The supernatant was then collected and analysed for SS (the un-entrapped 
fraction). The entrapment efficiency (EE) was obtained using the following equation. 
 
       
                                  
                  
                       
 
2.2.15 Entrapment efficiency studies of beclomethason dipropionate 
 
i) Preparation of a standard calibration curve  
Accurately weighed 5 mg of BDP was dissolved in 100 mL of HPLC graded methanol, 
which gives a stock solution (50 μg /mL). From this solution volumes of 1, 2, 3, 4, 5, 6, 
7, 8, 9 and 10 mL were taken and pipetted into a series of 10 mL volumetric flasks in 
order to get drug concentrations in the range of 5 to 50 μg /mL upon making the volume 
up with methanol. The calibration curve was constructed using HPLC analysis (Figure 
2.7) as explained below.  
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Figure 2.7: Calibration curve of beclomethason dipropionate. 
 
ii) Drug loading and entrapment efficiency measurements 
Spray-dried powders (10 mg) were hydrated with 1 mL of aqueous medium to form 
liposome or chitosome dispersions. The dispersions were transferred to a 10 mL 
volumetric flask. Methanol (1 mL) was added to dissolve the lipid and BDP. The 
solution was then adjusted to the final volume with deionised water and analysed by 
HPLC for its drug content to determine the total drug loading (i.e. content of drug in the 
powder).  For the determination of entrapment efficiency, spray-dried powder was 
dissolved in D2O (higher density water) or deionised water. Thus, when conventional 
deionised water was used for separation, the free drug crystals and the drug-entrapped 
liposomes may together sediment upon centrifugation; this made the separation 
inefficient. For this reason, it was realised that using a dispersion medium with higher 
density than water might enhance the separation. The higher density dispersion medium 
D2O was used instead of deionised water, hence, upon centrifugation, the BDP-
entrapped liposomes floated at the top of liquid contents of the eppendorf tube whilst 
the free drug crystals sedimented. This enabled the separation of the un-entrapped drug 
from the entrapped fraction. The experiments were conducted by leaving the liposome 
samples to anneal at room temperature for approx 1 hour followed by centrifugation at 
13,000 rpm for 90 min using a bench centrifuge (Labnet Spectrafuge 24D 
Microcentrifuge, UK). The un-entrapped fraction of BDP was separated from the 
entrapped steroid and diluted with methanol to dissolve the phospholipid and BDP for 
subsequent HPLC analysis of the drug. The entrapment efficiency was determined using 
equation 2.6 (section 2.2.14). 
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BDP was assayed by employing a mixture of methanol and water (75:25 v/v) as a 
mobile phase at a flow rate of 1.7 mL/ min and UV detection at 239 nm. The 
temperature was set up at 40ºC with injection volume of 20 µL. The HPLC column 15 
cm x 4.6 mm C-18 was used (Waters Ltd, UK). The flow rate, mobile phase 
composition ratio and the injection volume were adapted from the HPLC method 
described by Batavia et al. (2001). A calibration curve of ascending BDP concentrations 
was made and drug in samples collected from liposomes were accordingly analysed.  
 
2.2.16 In vitro assessment of aerosol deposition  
 
i) Two-stage impinger studies 
The powder aerosolisation performance and particle deposition was determined in vitro 
using the Two Stage Impinger (TSI) (Copley Scientific Limited, Nottingham, UK; 
British Pharmacopoeia, 2000) also referred to as the Twin Impinger, or the Single Stage 
Glass Impinger (Figure 2.6). This apparatus comprises two stages which are the upper 
stage (Stage 1) representing the upper airways and the lower stage (stage 2) representing 
the lower respiratory airways. The Monodose inhaler (Miat S.p.A., Milan, Italy) was 
used as the model aerosol delivering device. The flow rate was adjusted to 60 L/min 
using Critical Flow Controller Model TPK 2000 and Flow meter model DFM 2000 
(Copley Scientific Limited, Nottingham, UK). At this flow rate, the cut-off aerodynamic 
diameter between the upper and lower stages of the impinger is 6.4 µm, hence particles 
below this size will deposit in the lower stage and be regarded ―respirableˮ or in ―fine 
particle fraction (FPF)ˮ (Hallworth and Westmoreland, 1987). Approx 25 mg of the 
powdered formulation containing SS or BDP was loaded into size 3 hydroxypropyl 
methylcellulose (HPMC) capsules, which were individually installed in the inhaler 
device. The Monodose inhaler device was attached to the impinger which contained 7 
and 30 mL of deionised water in stages 1 and 2, respectively to collect the aerosolised 
powder. Each capsule was actuated from the inhaler over 5 sec for each measurement. 
After inspiration, the TSI apparatus was dismantled and each stage, the inhaler device 
and emptied capsules were separately washed with appropriate volumes of deionised 
water, then the washed contents were placed into volumetric flasks. Three independent 
experiments were conducted for each formulation using three different batches. The 
amount of powder collected from each compartment was determined using HPLC as 
described in section 2.2.14 and 2.2.15.  
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The total amount of powder deposited in the inhaler device, stage 1 and stage 2 
represents the recovered dose (RD). The amount of powder deposited in stage 1 (S1) 
and stage 2 (S2) was the emitted dose (ED) and it was calculated as the percentage 
fraction of the RD (Eq. 2.7). The fine particle fraction (FPF) was defined as the 
percentage of RD deposited in stage 2 (Eq. 2.8). 
  
    
     
  
                                                                
     
  
  
                                                                        
 
 
Figure 2.8: The two stage impinger comprises the upper stage (stage 1) and the lower stage 
(stage 2) (Source: Copley Scientific Limited, UK). 
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ii) Next Generation Impactor studies 
In accordance with the United States Pharmacopeia (USP) specification on Aerosols, 
(2006), in Chapter 601, and as previously reported (Meenach et al., 2013; Wu et al., 
2013), the in vitro aerosol dispersion properties of the dry powder particles can be 
determined using the Next Generation Impactor (NGI) (Copley Scientific, UK) (Figure 
2.7) equipped with mouthpiece adaptor, induction port and pre-separator. NGI cups 
were coated with 1% w/v solution of silicon oil in Hexane and the effectiveness of 
coating was evaluated versus uncoated NGI cups. The NGI was coupled with a Copley 
TPK 2000 critical flow controller, which was connected to a Copley HCP5 vacuum 
pump (Copley Scientific, UK). The airflow rate (Q) was measured and adjusted prior to 
each experiment using a Copley DFM 2000 flow meter (Copley Scientific, UK).  
Two hydroxypropyl methylcellulose (HPMC) hard capsules (size 3, Qualicaps, Spain) 
were each loaded with 25 mg of spray-dried powder which were then loaded into DPI 
device, the Miat
®
 Monodose inhaler (Miat S.P.A., Milan, Italy) which was then tightly 
fitted into the induction port. The NGI was run at a controlled flow rate (Q) of 60 L/min 
with a delay time of 10 sec (NGI Flow controller) prior to the capsules being needle-
pierced within the device, where the particles were then drawn into the impactor for 10 
sec. This was done with a total of 2 capsules per sample for a total of 50 mg total per 
run. For each 50 mg run, the amount of particles deposited onto each stage was 
determined by washing the relevant stage with a mixture of deionised water and 
methanol (7.5 : 2.5 v/v). For the NGI flow rate of 60 L/min, the effective cut-off 
diameters for each impaction stage were calibrated by the manufacturer and stated as 
Stage 1 (8.06 µm); Stage 2 (4.46 µm); Stage 3 (2.82 µm); Stage 4 (1.66 µm); Stage 5 
(0.94 µm); Stage 6 (0.55 µm); Stage 7 (0.34 µm) and MOC (<0.34 µm). The fine 
particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted 
dose (ED) were calculated as follows: 
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The mass median aerodynamic diameter (MMAD) and geometric standard deviation 
(GSD) were determined using online software (MMAD calculator.com). All 
experiments were conducted in triplicate. 
 
 
Figure 2.9: NGI with induction port and preseparator (Source: Copley Scientific Limited, 
UK). 
 
2.2.17 Nebulisation studies  
 
i) Aerosol delivery of SS and BDP formulations using Two-stage impinger 
TSI (Copley Instruments, UK) (Section 2.2.16) was used for collection of aerosol 
droplets delivered using the air-jet nebuliser Pari LC Sprint attached to the TurboBoy 
compressor (Pari GmbH, Germany). The cut-off aerodynamic diameter between the two 
stages is 6.4 µm at 60 L/min. Deionised water was used as an aerosol collection medium 
in the TSI, so that 30 mL and 7 mL were placed in the lower and upper stages 
respectively. After assembling the two stages, 3 mL of liposomes or chitosomes were 
placed into the Pari nebuliser and the generated aerosol was directed towards the 
―throat‖ of the TSI. 
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ii) Determination of nebuliser performance 
In order to investigate the nebulisation time several end points were predetermined, and 
determination was based on whether the nebulisation time is regarded as time needed 
for the aerosol generation to cease or for the nebuliser to start sputtering (Kradjan and 
Lakshminarayan, 1985). In this study, the nebulisation time was determined as the 
duration of aerosol generation until the nebulization reaches the ―dryness‖ status (i.e. no 
aerosols are further generated). Liposomes or chitosomes (3 mL) were placed in the 
nebuliser with its mouthpiece being orientated towards the "throat" of TSI, and 
nebulisation commenced to ―dryness‖. The nebulisation time of the different 
formulations were then determined. 
Moreover, total aerosol mass output was determined by weighing the nebuliser before 
and after nebulisation of the formulations (Eq. 2.13). 
 
                 
                                      
                                         
                               
 
Also, total drug output was calculated from the total amount of the drug delivered to the 
upper and lower stages of the TSI (Eq. 2.14): 
 
                 
                     
                                                                 
          
 
iii) Aerosol droplet size analysis using laser diffraction 
The size distribution of aerosol droplets was analysed using the Malvern Spraytec laser 
diffraction instrument (Malvern Instruments Ltd., UK) (Figure 2.8). Liposomes or 
chitosomes (3 mL) were placed into a Pari-LC Sprint nebuliser attached to the 
TurboBoy compressor. The nebuliser was clamped 2.5 cm from the laser beam and 
aerosols traversed the beam 2.5 cm from the lens of the instrument and drown across it 
with a vacuum pump (Copley Scientific, UK). The aerosol size and Span were recorded 
at time intervals during nebulisation to ―dryness‖. 
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Figure 2.10: Schematic diagram illustrating aerosols size analysis using spraytec (Source: 
Malvern Instruments Ltd., UK) 
 
In addition to aerosol droplet size and Span, the percentage of aerosol droplets below 
5.4 µm, which accounts for the "fine particle fraction" (O‘Callaghan and Barry, 1997) 
was investigated in this study. Moreover, the FPF output was determined in relation to 
total drug output (Eq. 2.15). 
 
                                                               
 
2.3 Statistical analysis 
All experiments were performed in triplicates and values were expressed as mean ± 
standard deviations. Statistical significance was assessed using one way analysis of 
variance (ANOVA) and student t-tests, as appropriate. Values with P < 0.05 indicate 
that the difference is statistically significant. 
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3.1 Introduction 
Spray drying is a useful technique for preparing microparticles for inhalation. The 
process is rapid and converts liquid droplets to powders suitable for pulmonary delivery. 
It can be used not only for conventional drugs but also to produce protein/peptide 
loaded powders suitable for delivery (Elkordy et al., 2002; 2004; 2008; Haj-Ahmad et 
al., 2013). Spray-drying enables control of the particle size distribution, powder 
flowability and crystallinity and particle morphology. A typical pharmaceutical spray-
dryer produces particles with a wide size distribution ranging from 0.5 µm to a few 
hundreds of micrometers (Vehring, 2008). Separation of dried powder from the drying 
medium occurs in the cyclone compartment and the final product is collected into a 
collection vessel. The resultant product properties are dependent on the spray-drying 
conditions, such as feed solution composition (Chidavaenzi et al., 2001; Di Martino et 
al., 2001), inlet/outlet air temperature (Broadhead et al., 1994; Maa et al., 1997; Ueno et 
al., 1998), feed flow rate (Stahl et al., 2002) and air flow rate (Stahl et al., 2002).  
The drying temperature affects the dryer evaporative capacity at a constant air rate. The 
effect of temperature on the physicochemical characteristics of particles is highly 
dependent on formulation. Increase in the inlet air temperature increases the outlet 
temperature due to the increased heat energy. A clear correlation exists between the 
moisture content of spray-dried products and the outlet air temperature (Broadhead et 
al., 1994; Billon et al., 2000; Stahl et al., 2002). Billon et al. (2000) and Stahl et al. 
(2002) have reported that increased outlet air temperature resulted in a decrease in 
moisture content of the recovered product. Broadhead et al. (1994) and Stahl et al. 
(2002) have reported that particle size of spray-dried products increased with increasing 
the inlet air temperature. Broadhead et al. (1994) have also demonstrated that the yield 
of β-galactosidase increased with increasing inlet temperature during spray-drying. Maa 
et al. (1997) have shown that a decrease in the outlet temperature caused the spray dried 
particles to become more regular and spherical in shape.  
The control of particle deposition is a prevalent problem during spray-drying, 
particularly for amorphous materials with low glass-transition temperatures (Bhandari et 
al., 1997). These particles may adhere to the inner walls of the dryer chamber during 
spray-drying, leading to a low product yield (Yousefi et al., 2011). 
Glass transition temperature (Tg) is the temperature at which an amorphous system 
changes from a glassy to a rubbery state. Theoretically, in the glassy state, the high 
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viscosity of the matrix (10
12 
Pa.s) prevents the occurrence of diffusion controlled 
reaction (Carolina Schebor, 1999; Song Miao, 2006). Crystalline and amorphous forms 
show difference in particle size, particle shape, bulk density, physicochemical 
properties, chemical stability, water solubility, hygroscopicity, flow properties and 
compaction properties of the powder (Yousefi et al., 2011). 
Carrier particles are the main contents of inhalable powders and thus, any change in the 
physicochemical properties, such as particle size (Larhrib et al., 1999; Vanderbist et al., 
1999; Zeng et al., 2001), particle surface roughness (Larhrib et al., 1999; Zeng et al., 
2000; Larhrib et al., 2003), specific surface area (Steckel and Müller, 1997; Kawashima 
et al., 1998), particle shape (Larhrib et al., 1999;  Zeng et al., 2000; 2000b; Larhrib et 
al., 2003), crystallinity (Kawashima et al., 1998; Zeng et al., 2001), density (Bosquillon 
et al., 2001a) or water content (Podczeck, 1998) may affect powder deposition into the 
lung . 
Lactose is frequently used as a carrier in DPIs, due to its safety, availability, good 
physico-chemical stability and compatibility with the majority of small molecular 
weight drugs (Crowe and Crowe, 1988;Tee et al., 2000; Maas et al., 2011). There are 
numerous pharmaceutical excipients, such as mannitol (Tee et al., 2000; Cynthia 
Bosquillon et al., 2001; Lu and Hickey, 2005; Dierendonck et al., 2011), trehalose 
(Crowe and Crowe, 1988; Cynthia Bosquillon et al., 2001; Hincha and Hagemann, 
2004; Hinrichs et al., 2005), sucrose (Crowe and Crowe, 1988, Hincha and Hagemann, 
2004, Hinrichs et al., 2005), sorbitol (Tee et al., 2000; Hincha and Hagemann, 2004) 
and glucose (Martin A. Braun, 1996; Steckel and Muller, 1997), that meet the criteria 
required for incorporation as carriers in dry powder aerosol formulations. 
However, mannitol is highly suitable to substitute LMH as carrier in DPIs, because it 
does not contain animal material, does not carry reducing groups, is highly crystalline 
even upon spray-drying (Naini V. et al., 1998) and is approved for pulmonary delivery 
(Maas et al., 2011). Mannitol has been used widely in pharmaceutical industry, 
particularly as a stabilizing agent for proteins and peptides (Tee et al., 2000; Maas et al., 
2011). 
This chapter investigates the influence of various spray-drying air temperature on 
production yield, particle size, crystallinity and surface morphology of spray-dried 
aqueous solution of mannitol and LMH using a Buchi spray-dryer (B-290) to produce 
suitable mannitol or LMH microparticles as core carriers for preparation of 
prochitosomes. 
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3.2 Methodology 
 
3.2.1 Spray-drying of mannitol or LMH at different drying temperatures  
A solution of mannitol or LMH in deionised water (1% w/v) was sprayed through a 0.7 
mm nozzle using a B-290 mini spray dryer (Büchi, Switzerland) at an inlet temperature 
of 90, 130, 170 or 210°C and a spray flow rate of 600 L/h. The pump was set up at 17% 
and the aspirator was set up at 100%. The outlet temperature was 50 ± 2°C, 70 ± 2°C, 
90 ± 2°C and 120 ± 2°C respectively. The product was separated and trapped by the 
cyclone compartment and then deposited in the collecting chamber. The powders 
obtained were transferred from the collecting chamber into a desiccator for subsequent 
characterisation. 
 
3.2.2 Size analysis of spray-dried mannitol or lactose monohydrate  
Spray-dried mannitol or LMH were dispersed in isopropanol. The volume median 
diameter (VMD; 50% undersize) and Span were measured using laser diffraction 
(Malvern Mastersizer 2000, Malvern Instruments Ltd, UK) to present the size and size 
distribution respectively.   
 
3.3 Results and Discussion 
 
3.3.1 Characteristics of spray-dried mannitol  
Low concentration of aqueous mannitol solutions (1% w/v)) were spray dried at 
different inlet temperatures (90, 130, 170 and 210
o
C) and the resultant dry powder 
formulation was referred to as M90, M130, M170 and M210, respectively. The results 
have shown that the change in drying air temperature had great effects on production 
yield, surface morphology, crystallinity and size and size distribution of spray-dried 
mannitol particles. 
 
3.3.1.1 Production yield 
The mass yield was investigated with respect to initial mannitol or LMH formulations 
and determined by dividing the powder quantity obtained in the product collection 
vessel after spray-drying by the quantity introduced into the process. The powders from 
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the collection vessel were weighed directly after spray-drying and the results are shown 
in Figure 3.1. 
Figure 3.1 shows that the production yield of M90 was lower than M130, M170 and 
M210. At inlet temperature 90
o
C, deposition of particles in the cyclone compartment 
was observed due to insufficient droplet/particle drying within the drying chamber and 
higher moisture content of the particles (Maa et al., 1997; Maury et al., 2005; Imtiaz-Ul-
Islam and Langrish, 2009; Islam, 2010), resulting in greater adherence of the particles to 
the wall of the drying chamber and cyclone compartment and subsequently lower 
production yield. Recovery of the powder from spray-drying process depends on its 
free-flowing properties as high moisture content at low outlet temperature causes the 
product to stick to the surface of the bucket, resulting in reduced powder output.  
At inlet temperature 130
o
C (M130) the production yield of mannitol powder was higher 
(p<0.05) than that of M90. This can be attributed to the reduced moisture content of the 
particles at increasing drying temperature, resulting in having powders with better flow 
properties and reduced adhesive forces, leading to higher recovery of particles in the 
collection vessel. This finding is in agreement with previous studies (Broadhead et al., 
1994; Billon et al., 2000; Stahl et al., 2002; Siew Young Quek, 2007). At higher outlet 
temperature there is a greater temperature gradient between the atomized feed and 
drying air and this results in greater water evaporation (Tonon et al., 2008; Phisut, 
2012). 
 
Figure 3.1: Relationship between inlet temperature and production yield of spray-dried 
mannitol particles (Data are mean ± STD, n=3). 
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In contrast, further increase in the inlet temperature (M170 or M210) reduced the 
production yield compared to M130. This was possibly due to the M130 particles being 
small, uniform, and spherical and their surface was smooth (Figure 3.4c), resulting in 
having better flow properties and lower levels of deposition in the cyclone compartment 
with higher yields than larger and irregularly shaped particles of M170 and M210 
formulations. Increasing the inlet temperature enabled a significant amount of the spray 
dried particles to deposite in the cyclone rather than to be collected in the collection 
vessel. This seems to be the reason of decreasing the yield percentage significantly, 
because the yield was calculated as the percentage of material collected in the collection 
vessel not those deposited in the cyclone compartment.  
Furthermore, the low yield of M170 and M210 was possibly caused by melting of the 
powder and subsequent adhesion on the walls of the drying chamber and cyclone 
compartment, and therefore the yield was reduced (Dolinsky et al., 2000; Dolinsky, 
2001; Chegini and Ghobadian, 2007). The production yield of M170 was slightly but 
not significantly (p>0.05) higher than M210 formulation, which might be due to the 
higher temperature of the latter, causing the particles to adhere to the compartment 
walls. 
 
3.3.1.2 Particle size analysis 
Figure 3.2 shows particle size of M90 and M130 was significantly (p<0.05) smaller than 
particle size of M170 and M210 formulations. This might be due to increasing particle 
agglomeration after increasing the drying temperature making the particles melt and 
stick together in case of M170 and M210 formulations. This comes in agreement with 
Broadhead et al. (1994) who suggested that the increase in particle size of spray-dried 
product might be due to the increased agglomeration at higher inlet temperatures. 
Furthermore, the particle size of M210 was significantly smaller than M170, which 
might be attributed to the differences in particle shape of the particles upon spray-drying 
at different outlet temperatures. 
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Figure 3.2: Relationship between inlet temperature and size of spray dried mannitol 
particles (Data are mean ± STD, n=3). 
 
Figure 3.3 shows that the width of size distribution, represented by the Span values, was 
lower for M130 than for M90, M170 and M210 formulations. Size distribution of spray-
dried particles is influenced by the evaporation rate of the solvent (Wagenaar and 
Müller, 1994). Thus, droplets not uniformly dried as a result of changes in heat energy 
in the dryer may yield particles with broad size distribution. It might be postulated that 
an increase in drying temperature, which is associated with a non-regular particle shape 
of M170 and M210 formulations (Figure 3.3) have contributed to the production of 
wide size variations in the sample (i.e. broadened size distribution) and subsequently 
high Span values (Figure 3.3). 
 
0
2
4
6
8
10
12
M90 M130 M170 M210
Si
ze
 (
µ
m
) 
Formulations 
CHAPTER 3 
 
59 
 
 
Figure 3.3: Relationship between inlet temperature and Span of spray dried mannitol 
particles (Data are mean ± STD, n=3). 
 
3.3.1.3 Particle surface morphology 
SEM images of mannitol before and after spray-drying at different inlet air temperatures 
are shown in Figure 3.4. Mannitol particles prior to spray drying were long, irregular in 
shape, and had rough surfaces and broad size distribution, and variable appearance 
(Figure 3.4a). In contrast, after spray-drying, mannitol produced small spherical 
particles with a smooth surface when spray drying was performed using an inlet 
temperature of 90ºC or 130
º
C (Figure 3.4b, c), agreeing with the findings reported by 
Maa et al. (1997) who found that the decreased outlet temperature gave rise to more 
uniform and spherical shaped particles. In contrast, at the inlet temperature of 170
o
C 
(Figure 3.4d) and 210
o
C (Figure 3.4e), particles were large and had irregular shape with 
higher agglomeration tendency. This might be attributed to the fact that increasing the 
temperature can lead to rapid and complete evaporation of solvent from the droplets in 
the heating chamber of the spray dryer (Littringer et al., 2012), causing the particles to 
become non-uniform in shape. This contradicts with previous studies (Maas et al., 2011; 
Sg et al., 2010; Littringer, 2010) showing that particles have remained spherical with 
crystal formation on their surfaces after increasing the temperature to 90
o
C and 120
o
C. 
Spray drying at different conditions and using different carrier proportions such as the 
low aqueous concentration of mannitol used in this study could be the reason behind the 
conflicting findings of this report with the previous publications.  
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Figure 3.4: SEM images of (a) mannitol before spray-drying and (b) mannitol after spray 
drying with intlet temperature of 90ºC, (c) inlet temperature of 130ºC, (d) inlet 
temperature of 170ºC, and (e) inlet temperature of 210ºC (magnifications were 600x, 
4000x). 
 
3.3.1.4 Crystallinity of spray-dried particles 
X-ray powder diffraction (XRPD) is rapid and convenient for investigating whether a 
given material is crystalline or amorphous (Brittain, 2001). Accordingly, XRPD was 
used to evaluate the crystalline characteristics of mannitol before and after spray-drying 
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at various inlet air temperatures. XRPD showed that mannitol was crystalline before and 
after spray drying at all drying temperatures investigated, but the diffraction intensity 
decreased after spray-drying (Figure 3.5). This finding agrees with previous studies 
(Naini et al., 1998; Maas et al., 2011) which documented the crystalline property of 
mannitol after spray-drying of its aqueous solution. Noteworthy, crystalline materials 
are more stable than their corresponding amorphous forms during storage (Saleki-
Gerhardt et al., 1994; Pikal et al., 1978). Hence, the transition from amorphous to 
crystalline depends upon the mobility of the molecules during storage (Hancock et al., 
1995; Buckton and Darcy, 1999; Yu, 2001). 
 
 
  
  
Figure 3.5: XRPD of (a) mannitol before spray-drying, (b) inlet temperature of 90ºC, (c) 
inlet temperature of 130ºC, (d) inlet temperature of 170ºC and (e) inlet temperature of 
210ºC. 
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3.3.2 Characteristics of spray-dried lactose monohydrate 
Aqueous LMH solutions (1 % w/v) were spray dried at different inlet air temperatures 
(90, 130, 170 and 210
o
C) and the resultant formulations were respectively referred to as 
L90, L130, L170 and L210. In this work only the drying temperature was altered while 
the other spray drying conditions were unchanged. The results showed that the change 
in the drying temperature affects the production yield, size, size distribution, and 
particle surface morphology and crystallinity of LMH. 
 
3.3.2.1 Production yield 
The production yields of spray-dried LMH at different drying temperatures are shown 
in Figure 3.6. Results show that spray-drying of LMH at inlet temperature of 90
o
C 
(L90), formulation had the lowest yield (p<0.05). At low drying temperature, powder 
may deposit on the inner walls of the drying chamber. If droplet/particle drying was 
insufficient before impaction with the drying chamber walls, the particles are likely to 
adhere to the wall, resulting in formation of a wet deposit and powder recovery in the 
collection vessel might be reduced. Previous studies have reported that high residual 
moisture content of the powder at low drying temperature reduces powder recovery 
(Maa et al., 1997; Maury et al., 2005; Imtiaz-Ul-Islam and Langrish, 2009; Islam, 
2010). The narrow drying chamber of the Buchi mini spray-dryer evidently promotes 
powder adhesion at low drying temperatures, and the low production yield obtained in 
this study at low outlet temperature agrees with a previous study  conducted by Maa et 
al. (1997) who obtained yields of 30-50% using IgE antibody plus mannitol or lactose 
carriers when the outlet temperature was 50
o
C. 
Production yield of LMH increased significantly (p<0.05) when it was dried with inlet 
temperature of 130
o
C and 170
o
C (L130, L170) compared to L90 and L210 (Figure 3.6). 
This agrees with previous studies owing to the reduction in residual moisture content of 
the spray dried powder (Maa et al., 1997; Maury et al., 2005; Imtiaz-Ul-Islam and 
Langrish, 2009; Islam, 2010). 
The production yield of spray-dried LMH decreased significantly with further increases 
in the inlet temperature 210
o
C (L210) (Figure 3.6). The deposition of material in the 
drying chamber or cyclone and hence reduced powder production yield are attributed to 
the elevated temperature of the inner walls of the spray drier (Twall) which is almost 
equal  to the outlet temperature (Maa et al., 1997). At the inlet temperature of 210
o
C, 
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Twall increased to become similar to the temperature of the cyclone vortex, resulting in 
particle adhesion and compromised yield. This finding is in agreement with a previous 
study of spray-dried milk products containing lactose (Písecký, 1997). The sticky point 
of an amorphous powder is the temperature (Ts) at which inter-particulate cohesion 
sharply increases (Lazar et al., 1956). This temperature might be 10-20
o
C above Tg of 
the powder.  Ozmen and Langrish (2003) have reported that the sticky point should be 
considered also in relation to the nature of the drying chamber wall surface properties. 
 
 
Figure 3.6: Relationship between inlet temperature and production yield of spray-dried 
LMH particles. Data are mean ± STD, n=3. 
 
The glass transition temperature (Tg) of lactose is 101
o
C (Roos and Karel, 1991). The 
difference between outlet temperature and glass transition temperature (Tg-Toutlet) 
changed to negative when LMH was spray-dried at maximum inlet temperature 
(210
o
C). Thus, the reduced powder yield at high temperature is possibly a result of 
particle adhesion to the drying chamber and cyclone walls when the outlet temperature 
was higher than 10
o
C above Tg of the powder (Figure 3.6). Maury et al. (2005) have 
found that the production yield decreased with increasing the outlet temperature above 
the Tg, due to the change in Tg-Toutlet to negative, reaching a temperature that causes the 
spray-dried product to become sticky and the yield to become low. 
When the inlet temperature was 210
o
C, the major part of the product within the 
collection vessel was deposited during the first few minutes then particles started to 
deposit in the cyclone compartment. It has been previously reported that particles 
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initially deposited in the cyclone can prevent the subsequent incoming particles from 
deposition in the main collection vessel as those particles passing late will be attached 
to the particles that adhered earlier to the cyclone walls (Bhandari et al., 1997; Islam, 
2010). If particle temperature is higher than that of its Tg, then the viscosity can change 
to a value of  106-108 Pas due to particles being in rubbery states resulting in melting 
with subsequent stickiness to the walls of the spray drier.  
According to the WLF equation (Williams et al., 1955), solid phase crystallization is 
due to the difference between the real temperature of the particles (Tp) and their Tg (i.e. 
Tp-Tg) during spray drying (Langrish, 2008; Chiou et al., 2008a). A high degree of 
crystallinity was observed for spray-dried particles at high inlet gas temperature 
compared to particles with lower inlet gas temperature. It was therefore suggested that 
higher processing temperatures may lead to greater particle crystallization. 
Nevertheless, any increase in particle temperature and decrease in Tg would increase the 
temperature difference (Tp-Tg) and consequent increase in crystallization rate as 
suggested by WLF kinetics (Langrish, 2008). Solid phase crystallization involves 
heating the amorphous material above its Tg into the rubbery state. If the particle is kept 
in the rubbery state for enough time, crystallisation may occur, since crystallisation of 
spray-dried powders is likely to happen when the drying process is complete rather than 
while the material is being dried (Chiou et al., 2008). Highly crystalline particles might 
be expected to deposit less on the cyclone wall than amorphous rubbery particles. 
Transformation from rubbery to crystalline status takes time. Hence, a high particle 
temperature results in low wall deposition if the particles have sufficient time to 
crystallize before they impact on the walls of the dryer (Islam and Langrish, 2010). 
Furthermore, the product deposition on the cyclone walls can be explained by 
considering the rubbery state of the particles, which is associated with particle-particle 
cohesion or particle-cyclone wall adhesion (Truong et al., 2005). It is possible that the 
impaction of particles in their rubbery state to the cyclone walls has caused particles to 
stick to the smooth surfaces of the cyclone. 
  
3.3.2.2 Particle size analysis 
As seen in Figure 3.7, particle size of L90 was significantly larger (p<0.05) than that of 
L130 formulation. This might be due to the cohesive properties of particles dried at 
lower temperature (L90) and higher tendency of agglomeration compared to L130. 
Particle size of L90 and L130 was significantly smaller (p<0.05) than L170 and L210 
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formulations. The increased particle size of L170 may be due to the high drying 
temperature (170
o
C), resulting in formation of a skinny layer on the outer surface of the 
spray droplets. However, this layer is destroyed and the outer surface collapses when 
the inner water phase evaporates through the skin of droplet (Hsu et al., 1996; Stahl et 
al., 2002). The larger particle size of L210 might be due to the promoted particle 
agglomeration after increasing the inlet temperature, which makes particles melt and 
stick to each other, agreeing with Broadhead et al. (1994) who suggested that the 
increase in particle size of spray-dried product might be due to increased agglomeration 
at higher inlet air temperature. Furthermore, the particle size of L210 was significantly 
(p<0.05) smaller than that of L170, which might be attributed to the differences in 
particle shape of the formulations upon spray-drying at different drying temperatures.  
 
 
Figure 3.7: Relationship between inlet temperature and size of spray dried LMH particles 
(n = 3 ± SD). 
 
As seen in Figure 3.8, particle size distribution of spray-dried LMH at different drying 
temperatures represented by Span value was lower for L130 than L90, L170 and L210 
formulations. This can be attributed to the uniform, small, and spherical shape with 
lower tendency of particle agglomeration after spray-drying of L130 compared to L90, 
L170 and L210 formulations.  
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Figure 3.8: Relationship between inlet temperature and Span of spray dried lactose 
monohydrate particles (n = 3 ± SD).  
 
3.3.2.3 Particle surface morphology 
SEM images of LMH before and after spray-drying at different drying temperatures 
(Figure 3.9) showed that LMH particles prior to spray drying were irregular in shape, 
large in size and had rough surfaces (Figure 3.9a). In contrast, after spray-drying, LMH 
produced small and spherical particles with smooth surfaces using drying temperature 
of 90ºC or 130
º
C (Figure 3.9b, c). This agrees with the previous findings reported by 
Maa et al. (1997), who found that decreasing the drying temperature may result in 
formation of uniform and spherically shaped particles. However, at the inlet temperature 
of 170
o
C (Figure 3.9d), large sized spherically shaped particles with smooth surfaces 
were produced which has also been observed previously (Hsu et al., 1996; Stahl et al., 
2002; Maas et al., 2011). Furthermore, particles were irregular and had smooth surfaces 
after spray-drying at 210
o
C (Figure 3.9e), which might be due to melting of the particles 
at high temperature and increased agglomeration. 
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Figure 3.9: SEM Images of lactose monohydrate (a) before spray-drying or (b) after spray 
drying using inlet temperature of 90ºC (c) inlet temperature of 130ºC (d) inlet temperature 
of 170ºC and (e) inlet temperature of 210ºC (magnifications were 600x, 2000x).  
 
3.3.2.4 Crystallinity of spray-dried particles 
X-ray powder diffraction (XRPD) of LMH before and after spray-drying at different 
inlet air temperatures are shown in Figure 3.10. LMH was crystalline before spray-
drying (Figure 3.10a) whilst after spray drying, the material changed to amorphous 
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regardless of the inlet temperature (Figure 3.10b, c, d and e). This agrees with the 
previous literature reports (Briggner et al., 1994; Fäldt and Bergenståhl, 1994; White 
and Cakebread, 1966), which showed that LMH in aqueous solutions becomes 
amorphous after spray-drying. On the contrary, Chiou et al. (2008) reported that spray-
dried LMH at high inlet air temperature (210
o
C) produced crystalline particles. This 
might be due to differences in the concentration of LMH in aqueous solution or because 
spray-drying was performed using different conditions. 
 
   
  
    
Figure 3.10: XRPD of lactose monohydrate (a) before spray-drying, or (b) after spray 
drying using an inlet temperature of 90ºC, (c), inlet temperature of 130ºC, (d), inlet 
temperature of 170ºC, and (e) inlet temperature of 210ºC. 
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3.4 Conclusions 
Spray-drying of mannitol or LMH at different drying temperatures significantly affected 
the physicochemical properties of the resultant dried powders, such as production yield, 
particle size and size distributions, crystalline and surface morphology. The production 
yield of mannitol or LMH was low when the inlet temperature was 90ºC due to the 
insufficient drying. The production yield was also low at the highest inlet temperature 
(210ºC) as well, due to the stickiness of the particles and subsequent deposition in the 
drying chamber and cyclone compartment. The production yields were optimal when 
the inlet temperature was 130ºC for mannitol and 170ºC for LMH. 
Size of particles was smaller for mannitol and LMH particles produced when the inlet 
air temperature was 90ºC and 130ºC respectively. Size distribution (Span) of spray dried 
particles was lowest when the inlet temperature was 130ºC. XRPD analysis showed that 
mannitol and LMH were crystalline before spray-drying. However, after spray-drying, 
mannitol remained crystalline but with lower diffraction intensity whilst LMH changed 
to amorphous, for all drying temperature. SEM images showed that the inlet 
temperature of 90ºC or 130ºC LMH was more suitable to produce uniform and spherical 
particles of smaller size (less than 5 µm). 
Finally, it can be concluded that 130ºC was the most suitable drying temperature to 
produce mannitol or LMH microparticles for further use as core carriers in the 
preparation of proliposomes and prochitosomes. 
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4.1 Introduction 
Liposomes administered via inhalation have been investigated as a delivery system for 
controlled drug release in the lung (Zeng et al., 1995). The aim is to retain the drug in 
the lung for prolonged periods to reduce the need for frequent dosing, reduce the risk of 
systemic side effects and improve patient compliance (Zeng et al., 1995). 
Liposomes can be manufactured using various methods, but the most common one is 
the thin film hydration method. This method provides liposomes that poorly entrap 
hydrophilic drugs such as salbutamol sulphate (Ning et al., 2005; Elhissi et al., 2006). 
Liposomes have relatively low physicochemical stability as aqueous dispersions. Thus, 
to resolve this problem, liposomes can be stored as dry powders (Lo et al., 2004; 
Wessman et al., 2010). Freeze-drying has been extensively studied, however, it has a 
destabilising effect on liposomes upon rehydration of the powder (Crommelin and van 
Bommel, 1984).  
Proliposomes are dry free flowing particles of phospholipids and other excipients and 
they may generate liposomes when they come in contact with aqueous medium (Payne 
et al., 1986a). Proliposome technology may provide an economic and convenient 
alternative to freeze-drying for the production of stable phospholipid formulations 
(Ning et al., 2005). Proliposomes are physically and chemically more stable than 
liposomes and can be prepared with inclusion of  a wide variety of drugs including 
peptides (Ning et al., 2005).  
As an alternative to freeze-drying, spray drying can be employed for the preparation of 
stable liposomes powder. It can also be used to prepare dry proliposomes that generate 
liposomes upon addition of aqueous phase, which could be beneficial for formulation 
stability during storage (Alves and Santana, 2004). 
Spray-drying gives a low yield which is expected due to the higher drying temperature 
and low Tm of lipids. To protect liposomes during drying, cryoprotectants are used. 
Cryoprotectants function by forming a vitrified matrix around the lipid bilayer and 
replace the water in the dry state. Hence, liposomes may have better dispersion 
properties upon rehydration. 
Studies in this chapter involved the preparation of stable proliposome powders by 
addition of spray-dried carbohydrate microparticles (mannitol or LMH) to lipid (SPC: 
CH; 1:1 mole/mole) in a range of ratios. The carbohydrate / lipid mixture was dissolved 
in ethanol followed by spray-drying. The surface morphology and crystallinity of the 
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proliposome powders were studied using SEM and X-ray powder diffraction 
respectively. The deposition of powdered formulation in FPF was investigated using a 
TSI. Liposomes were formed after hydration of proliposome powders with aqueous 
medium and the entrapment efficiency of SS was determined using HPLC. Particle size 
(VMD), size distribution (Span) and zeta potential were studied. 
 
4.2 Methodology 
 
4.2.1 Production of microparticulated mannitol and lactose monohydrate by spray 
drying  
As described in chapter 3, a solution of mannitol or LMH in distilled water (1% w/v) 
was sprayed through a 0.7 mm nozzle using a B-290 spray drier (Büchi, Flawil, 
Switzerland) at an inlet temperature of 130°C, spray flow rate of 600 L/h, and a feeding 
rate of 17%. The outlet temperature was 70 ± 2°C. The product was separated and 
collected by the cyclone and directed into the collecting chamber. The resultant 
carbohydrate microparticles were used as carriers for the preparation of proliposomes. 
 
4.2.2 Production of proliposomes by spray-drying 
The ingredients of the proliposome formulations are shown in Table 4.1. Briefly, 
microparticulate mannitol or LMH were used as core carriers. A lipid solution 
containing salbutamol sulphate and microparticulate mannitol or LMH was spray dried 
to obtain the proliposomes.  
Lipids (100 mg) consisting of a mixture of SPC and CH (1:1 mole ratio) were dissolved 
in 100 mL of 96% ethanol to obtain an ethanolic lipid solution. SS (10 mg) was added 
and sonicated for 1 minute to obtain a clear solution. Microparticulate spray-dried 
mannitol or LMH in various ratios were dispersed in the solution and sonicated for 15 
min to deaggregate the carbohydrate particles before spray drying. The ethanolic 
suspension was continuously stirred while being fed into the spray drier in order to 
provide homogeneity of the suspension. The inlet temperature was 120°C and spray 
flow rate was 600 L/h, with a feed rate of 11% and the outlet temperature was 73 ± 3°C. 
The proliposome powder was stored in a desiccator ready for future use. 
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4.3 Results and discussion 
 
4.3.1 Proliposomes manufactured using spray drying 
Ten formulations with different lipid to carrier ratios were prepared using spray drying 
(Table 4.1). The effect of lipid to carrier ratio on production yield, particle morphology 
and drug crystallinity were investigated. FPF of the aerosolized particles was 
determined using the TSI. Moreover, vesicle size, size distribution and zeta potential 
and SS entrapment efficiency were investigated after hydration of the proliposome 
powder.  
 
Table 4.1: Composition of the proliposome formulations. 
 
*SPC: Soya phosphatidylcholine, CH: Cholestrol, SS: Salbutamol sulphate, LMH: Lactose monohydrate. 
 
4.3.2 Production yield and drug content uniformity of spray-dried powder 
Results of spray-dried production yield, drug recovery and drug content uniformity are 
shown in Table 4.2. Spray-drying parameters such as atomisation conditions, drying air 
flow rate, drying temperature and liquid feed solid content may affect the production 
yield of spray-dried materials (Maury et al., 2005). Since spray-drying parameters for 
all formulations were similar, the difference in production yield is expected to be due to 
the type of carrier used and the lipid to carrier ratio. It has been previously reported that 
the decline in production yield is likely to be due to the adherence of sprayed droplets 
and dry powder to the inner walls of the drying chamber or the poor efficiency of the 
cyclone at collecting the fine dry particles (Maa et al., 1998). 
Formulation Lipid : Carrier 
(w/w) 
Lipid (SPC:CH; 1:1)* 
(mg) 
Mannitol 
(mg) 
LMH* 
(mg) 
SS* 
(mg) 
F1 1:2 100 200 - 10 
F2 1:4 100 400 - 10 
F3 1:6 100 600 - 10 
F4 1:8 100 800 - 10 
F5 1:10 100 1000 - 10 
F6 1:2 100 - 200 10 
F7 1:4 100 - 400 10 
F8 1:6 100 - 600 10 
F9 1:8 100 - 800 10 
F10 1:10 100 - 1000 10 
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Table 4.2 shows that the production yield increased with increasing the carrier 
concentration, regardless of carrier type. The production yield of F1 was significantly 
less than F2 (p˂0.05), and the production yield of F2 was significantly less than F3, F4 
and F5 (p˂0.05). Statistically, no significant differences were observed between F3, F4 
and F5 (P>0.05). Additionally, the production yield of F6 was significantly (p˂0.05) 
less than F7 and subsequently the production yield of F7 was significantly (p˂0.05) 
lower than F8, F9 and F10. A trend of higher production yield for F9 and F10 than F8 
(p˃0.05) was observed. The low production yield of F1, F2, F6 and F7 might be due to 
the high lipid content in these formulations, resulting in greater adherence to the walls 
of the drying chamber.  
The production yield of mannitol-based proliposomes (F1, F2, F3, F4 and F5) was 
lower than that of LMH-based proliposomes (F6, F7, F8, F9 and F10). This might be 
due to the difference in the Tg of the carriers. Previous studies showed that the Tg is the 
most important parameter for influencing the possibility of sugars and sugar-rich 
materials to be spray-dried (Bhandari et al., 1997; Bhandari and Howes, 1999). Spray-
drying sugars above their Tg could make them sticky, resulting in adherence to the 
drying chamber (Roos, 1993). The Tg of LMH (Roos and Karel, 1991; Imtiaz-Ul-Islam 
and Langrish, 2009) was higher than the spray-drying outlet temperature used in this 
study. The melting point of mannitol was lower than used in the experiment. This made 
mannitol stickier during spray drying, resulting in more adherences to the inner walls of 
the drying chamber and lower production yield. 
The results of SS recovery are shown in Table 4.2. The recovery of SS increased with 
increasing the carrier ratio for both mannitol and LMH-based proliposome formulations. 
This can be attributed to the higher production yield after increasing the carrier ratio. 
Additionally, the low SS recovery with F1, F2, F6 and F7 might be due to including 
high amount of lipid causing greater adherence to the drying chamber walls resulting in 
the loss of SS incorporated in the lipid and lower drug recovery. 
Table 4.2 shows that the drug content uniformity was between 90 and 109%, indicating 
that spray-drying was able to produce uniform distribution of the active ingredient 
throughout the proliposome product. The drug content uniformity for LMH-based 
proliposomes was higher than that of mannitol-based proliposomes (Table 4.2). This 
can be attributed to the higher drug recovery with LMH-based proliposomes, which 
might be due to the irregular shape, rough surface and large size of LMH-based 
particles (Figure 4.5) compared to the uniform shape, smooth surface and smaller size 
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of mannitol-based particles (Figure 4.4). The irregular shape and rough surface of 
LMH-based particles may increase the interaction between the drug and carrier (Pilcer 
et al., 2012), resulting in higher drug recovery. 
 
Table 4.2: Production yield, drug recovery (%) and content drug uniformity using a range 
of spray-dried proliposome formulations. Data are mean ± STD, n=3. 
 
 
4.3.3 Particle surface morphology  
SEM images were presented to show the morphology of particles in formulations listed 
earlier in Table 4.2. SS raw material were needle-like or rod-shaped crystals, and even 
when the drug was spray dried from its ethanolic solution the structure was apparently 
unaffected (Figure 4.1a, b) as needle shaped particles before and after spray drying in 
ethanol (Figure 4.1a, b).  
 
 
Formulation 
Drug Recovery  
(%) 
Production Yield 
(%) 
Drug Content Uniformity 
(%) 
F1 41.81±0.73 41.66±2.08 100.48±4.39 
F2 45.00±1.00 47.33±1.52 95.08±1.05 
F3 53.60±0.95 59.0±3.00 90.96±3.27 
F4 55.90±1.70 62.0±2.00 90.16±0.61 
F5 53.33±1.10 57.66±2.08 92.51±1.46 
F6 57.25±0.44 52.66±1.52 109.25±3.83 
F7 63.09±0.16 59.0±1.00 106.95±2.05 
F8 64.28±0.13 64.66±1.52 99.58±2.55 
F9 68.24±0.29 67.66±1.52 100.88±2.71 
F10 67.93±1.47 67.33±2.08 100.93±3.13 
CHAPTER 4 
 
76 
 
  
Figure 4.1: SEM images of salbutamol sulphate (a) before spray drying and (b) after spray 
drying (magnification was 6000x). 
  
Figure 4.2a and Figure 4.3a show both mannitol and LMH particles prior to spray 
drying were irregular in shape, with relatively larger size, rough surfaces and high 
polydispersity. After spray drying of the ethanolic carrier suspensions, the resultant 
spray-dried particles had markedly different morphologies (Figure 4.2b; Figure 4.3b). 
Following spray drying, mannitol particles were more homogenous with more regular 
shape and appearance compared to LMH particles. 
 
  
Figure 4.2: SEM images of mannitol (a) before spray drying and (b) after spray drying 
from their ethanolic solution (magnifications were 400x, 2000x). 
 
Both types of carrier had smoother surfaces and were more spherical following spray-
drying. LMH particles after spray drying in ethanolic suspension were large and 
a 
a b 
b 
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irregular with rough surfaces, possibly because LMH solubility in ethanol was lower 
than that of mannitol. Furthermore, the larger size of spray-dried LMH and its higher 
porosity might be ascribed to its higher amorphous content than mannitol. 
 
  
Figure 4.3: SEM images of lactose monohydrate (a) before spray drying and (b) after 
spray drying in ethanol (magnification was 600x). 
  
SEM images of mannitol-based proliposomes are shown in Figure 4.4. Mannitol-based 
proliposomes were spherical for most formulations, which agrees with previous reports 
on this carrier using spray drying (Alves and Santana, 2004). Particles of F1 and F2 
formulations had small size, smooth surfaces and spherical shapes, and the particles 
agglomerated and formed large masses (Figure 4.4a, b), due to particle cohesiveness. 
This is expected to compromise the suitability of F1 and F2 formulations for deposition 
in ―deep lung‖. The agglomeration of particles might result from the presence of large 
amounts of SPC on the mannitol particle surface .  
F3 produced small spherical and porous particles with lower tendency for 
agglomeration (Figure 4.4c). Microporous particles have high void spaces, which 
promotes their performance as aerosols (Chan, 2006). F4 and F5 produced small, 
smooth and spherical particles with evidence of particle agglomeration (Figure 4.4d, e), 
which might be attributed to the high surface energy of small particles. This is expected 
to increase the particle cohesiveness and compromising powder flowability (Byron, 
1986). 
 
a b 
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Figure 4.4: SEM images of mannitol-based proliposomes: (a) F1, (b) F2, (c) F3, (d) F4 and 
(e) F5 (magnification was 2000x). Composition of the formulations is presented in Table 
4.1. 
 
c d 
b 
e 
a 
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Figure 4.5 shows that LMH-based proliposomes in all formulations were irregular, 
rough and of similar size, shape and appearance. This might be due to the fact that LMH 
is practically insoluble in ethanol. Hence, it possibly did not facilitate formation of 
uniformly sized droplets upon atomisation via spray drying. Analysis of surface 
morphology may help at prediction of the aerosol performance of particles (Pilcer et al., 
2012). Particles with smooth surfaces may enhance the DPI performance due to 
enhanced powder flowability and low cohesion between the particles (Kou et al., 2012). 
Spherical particles are more likely to deposit deeper in the lung and the size of 
proliposome particles influences their regional distribution in the respiratory tract 
following inhalation. Small particles with aerodynamic diameters in the range of 1-5 µm 
are likely to deposit in the ―deep lung‖ (Labiris and Dolovich, 2003; Daniher and Zhu, 
2008).  
According to the findings of this project that LMH-based proliposome formulations 
might be less appropriate for delivery from DPI devices than mannitol-based 
proliposomes because particle of LMH-based proliposomes are larger and irregular 
shaped, possibily resulting in compromised flowability, as expected from the SEM 
images (Figure 4.5). It is further suggested that the ideal proliposome formulation for 
use in DPIs is F3 with lipid to mannitol ratio of 1:6 w/w. 
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Figure 4.5: SEM images of lactose monohydrate-based proliposome formulations: (a) F6, 
(b) F7, (c) F8, (d) F9 and (e) F10 (magnification was 600x). Composition of the 
formulations is presented in Table 4.1. 
 
a b 
c d 
e 
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4.3.4 Crystallinity of spray-dried particles  
X-ray powder diffraction (XRPD) profiles of the structural components of SS are shown 
in Figures 4.6. The intensity peak of SS before and after spray drying indicates that the 
crystalline properties of the drug have been preserved. The intensity peak after spray 
drying increased slightly due to the effect of ethanol which may increase the 
crystallinity of the drug as confirmed by previous studies (Harjunen et al., 2002; Larhrib 
et al., 2003). Composition of the formulations is presented in Table 4.1. 
 
  
Figure 4.6: X-ray powder diffraction of salbutamol sulphate, (a) before spray drying and 
(b) after spray drying in ethanolic solution. 
  
Mannitol before spray drying showed a high degree of crystallinity (Figure 4.7a), whilst 
after spray drying, it had lower diffraction intensities (Figure 4.7b), indicating that 
spray-drying reduces the crystalinity of the sugar (Sebhatu et al., 1994). Previous 
studies have shown that the more amorphous the solid structure, the more easily it is 
dispersed in aqueous solutions (Kukuchi et al., 1991; Hancock and Zografi, 1997), 
which is highly desirable in pharmaceutical dry powder formulations. 
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Figure 4.7: X-ray powder diffraction of mannitol (a) before spray-drying and (b) after 
spray-drying in ethanolic suspension. 
  
Figure 4.7b shows that spray-dried mannitol in ethanolic suspension is crystalline to 
variable degrees for all mannitol containing formulations due to the high tendency of 
mannitol for crystallisation (Rojanarat et al., 2011, 2012a,b). Fowler (2006) has 
reported the amorphous property of SPC. The X-ray powder diffraction of SS did not 
appear in all formulations (Figure 4.8; Figure 4.10), due to the low concentration of the 
drug compared to mannitol, and also the drug might be coated with the lipid, making 
detection of crystallinity difficult. 
The X-ray powder diffraction profiles for mannitol-based proliposomes are shown in 
Figure 4.8. The crystalline properties of mannitol as carrier were predominant in all 
formulations due to the high amount of mannitol compared to lipid or the drug. X-ray 
diffraction showed slight changes in the intensity of the main peak of mannitol-based 
proliposome formulations (F1-F5). The intensity of the main peak increased slightly 
with increasing mannitol ratio due to the high crystalline properties of mannitol 
compared to SPC. The intensity peak of mannitol-based proliposome formulations (F1-
F5) decreased noticeably compared to mannitol alone, indicating an interaction between 
formulation components.  
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Figure 4.8: X-ray powder diffraction of mannitol-based proliposomes: (a) F1, (b) F2, (c) 
F3, (d) F4 and (e) F5. Composition of the formulations is presented in Table 4.1. 
 
 Figure 4.9, shows the X-ray powder diffraction patterns of LMH before and after spray-
drying in aqueous or ethanolic media. LMH was crystalline before spray-drying (Figure 
4.9a), and changed to amorphous after spray-drying in aqueous medium (Figure 4.9b). 
This finding agrees with previous literature reports using LMH (Briggner et al., 1994; 
Pia Fäldt, 1994; White and Cakebread, 1966). In contrast, LMH preserved its crystalline 
properties after spray-drying from its ethanolic solution, which might be due to the 
lower solubility of LMH in ethanol compared to water or other polymorph (Harjunen, 
2004). However, the intensity peak of LMH decreased after spray-drying from ethanol 
compared to before spray-drying (Figure 4.9c). 
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Figure 4.9: X-ray powder diffraction of lactose monohydrate: (a) before spray-drying, (b) 
after spray-drying from its aqueous solution and (c) after spray-drying from its ethanolic 
suspension.  
  
The X-ray powder diffraction patterns of LMH-based proliposomes are shown in Figure 
4.10. The crystalline properties of LMH as carrier is predominant in all formulations 
due to the high amount of LMH in formulations compared to lipid or the drug. X-ray 
showed slight differences in the intensity of main peak amongst LMH-based 
proliposome formulations (F6-F10). The intensity of main peak increased slightly with 
increasing LMH ratio due to the high crystalline properties of LMH compared to SPC. 
The peak intensity of LMH-based proliposome formulations (F6-F10) decreased 
noticeably compared to LMH alone, indicating an interaction between the formulation 
components.  
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Figure 4.10: X-ray powder diffraction of lactose monohydrate-based proliposomes: (a) F6, 
(b) F7, (c) F8, (d) F9, and (e) F10. Composition of the formulations is presented in Table 
4.1. 
 
4.3.5 Entrapment efficiency   
The entrapment efficiency was measured following hydration of the spray-dried 
proliposome powders with deionised water to form liposomes. SS encapsulated in 
liposomes was separated by ultracentrifugation. The supernatant containing free SS was 
analysed for its drug content to represent the un-entrapped fraction of the drug while the 
entrapped fraction of the drug was determined by difference (i.e. Entrapped fraction = 
total drug loading – un-entrapped fraction / total drug loading).  
The entrapment efficiency of SS in liposomes generated from mannitol-based 
proliposome or LMH-based proliposomes is shown in Figure 4.11. For mannitol-based 
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proliposomes, the slight difference in entrapment efficiency of SS amongst formulations 
might be due to the difference in surface morphology of the spray-dried particles or due 
to the different amount of lipid recovered after spray-drying. Surface roughness of 
carrier particles is an important factor in terms of the possible adherence of the 
micronised drug particles to the carrier (Kawashima et al., 1998; Pilcer and Amighi, 
2010). A rough particle surface may hold the drug strongly due to a larger contact 
surface area whereas a smooth surface is likely to release the drug more readily (Pilcer 
et al., 2012).  
For LMH-based liposome formulations, higher SS entrapment efficiency was obtained 
compared to mannitol-based liposomes (Figure 4.11). This might be due to differences 
in the morphology and surface characteristics of the spray-dried proliposome particles 
or difference in the solubility of the carrier upon hydration with water. SEM pictures 
showed that LMH-based proliposomes were irregular in shape, rough in surface and not 
identical in size, shape and appearance. Furthermore, F6 and F7 with low LMH content 
had higher entrapment efficiency than F8, F9 and F10 formulations, possibly because 
the lower concentration of lipid in F8, F9 and F10 resulted in formation of more dilute 
liposomes and hence lower proportions of SS were entrapped. LMH-based proliposome 
formulation with lipid to LMH ratio of 1:2 (F6) gave the highest entrapment efficiency 
owing to the high amount of lipid compared to other formulations. 
 
 
Figure 4.11: Entrapment efficiency of salbutamol sulphate in liposomes prepared using 
spray dried mannitol-based and LMH-based proliposomes (Data are mean ± STD, n=3). 
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4.3.6 Size analysis 
Size and size distribution of liposomes are important parameters especially when the 
liposomes are given by inhalation or via the parenteral route. Liposome size determines 
the fraction of entrapped drug cleared by the cell of reticuloendothelial system 
(Harashima et al., 1994). The size of liposomal vesicles generated from proliposome 
after reconstitution in deionised water was determined by laser diffraction ranged from 
3.38 to 6.01 µm for mannitol-based liposome and 3.23- 5.96 µm for LMH-based 
liposome formulations. Liposomes can be produced with a range of sizes which 
influences the retention time in the lung, drug encapsulation efficiency and the sustained 
released properties (Hupfeld et al., 2006). Liposomes promote the increase in the drug 
retention time and reduce toxicity of drugs after administration (Pilcer and Amighi, 
2010). F1 with mannitol-based proliposomes and F6 with LMH-based proliposomes 
showed the largest vesicle size measurements with highest entrapment efficiencies, 
while F4 and F10 showed the smallest size measurements with lowest drug entrapment 
efficiencies (Figure 4.12). The presence of higher concentrations of lipid in F1 and F6 
formulations compared to the other formulations could be the reason behind the highest 
entrapment values and largest vesicle size measurements. Drug release and absorption 
of liposome encapsulated drugs are influenced by several factors, such as size and lipid 
composition of liposomes. For example, the residence time of terbutaline within the 
lung increased by the presence of cholesterol and the use of phospholipids with 
saturated hydrocarbon chains (R. M. Abra, 1990). Larger liposomes with multiple 
bilayers may prolong the duration of drug action in the lung and the capacity of vesicles 
to encapsulate greater drug proportions. The size distribution (Span) is shown in Figure 
4.13. The Span values were around 2 or below except for F4, F8 and F9, with high 
variations in particle size possibly due to aggregation of the liposome vesicles. 
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Figure 4.12: Size of mannitol and lactose monohydrate-based liposomes as represented by 
VMD. Data are mean ± STD, n=3. 
 
 
 
Figure 4.13: Size distribution (Span) of mannitol and lactose monohydrate-based 
liposomes. Data are mean ± STD, n=3. 
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4.3.7 Zeta potential analysis  
Zeta potential may be used for the prediction of the stability profile of colloidal systems. 
Particles having high negative or positive zeta potential in suspensions may tend to 
repel each other, resulting in reduced tendency for aggregation (Laouini et al., 2012). 
Zeta potential values for mannitol-based and LMH-based liposomes are shown in 
Figure 4.14. The results in this study demonstrated negative zeta potential values for all 
formulations, indicating that lipid to sugar ratio had no marked effect on the surface 
charge of liposomes. The nature and density of charge on the liposome surfaces are 
important parameters that can influence the mechanism and extent of liposome-cell 
interaction (Sharma and Sharma, 1997). Zeta potential can possibly be manipulated by 
changing the lipid composition (Sharma and Sharma, 1997). Compared to charged 
vesicles, neutral liposomes may have weaker interaction with cells, and in such cases, 
the drug may enter cells after being released from liposomes extracellulary (Sharma et 
al., 1993). Straubinger et al., (1983), showed that the negatively charged liposomes are 
predominantly taken up by cells through coated-pit endocytosis. Negative surface 
charge may increase intracellular uptake of liposomes (Gabizon et al., 1990). 
 
 
Figure 4.14: Zeta potential (mV) of mannitol and lactose monohydrate-based liposomes. 
Data are mean ± STD, n=3. 
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4.3.8 Transmission electron microscopy 
TEM showed that liposomes generated from mannitol-based proliposomes were 
oligolamellar vesicles (OLVs) whilst those generated from LMH-based proliposomes 
were rich with elongated ―worm-like‖ structures and vesicle clusters (Figure 4.15). This 
finding agrees with a previous study  conducted by Elhissi et al. (2012) who showed the 
formation of ―worm-like‖ and elongated structures upon hydration of LMH-based 
proliposomes using TEM or light microscopy. This study has shown that liposome 
morphology was not dependent on lipid to carrier ratio or lipid composition but rather 
was highly dependent on carrier type (mannitol or LMH). Morever, Elhissi et al., (2012) 
used convention proliposomes manufactured by coating sugar carriers with lipids within 
a roatary evaporator. Hence, it is the carrier type in proliposomes that determines the 
resultant liposome morphology rather than the technique used to prepare the 
proliposomes. 
Elhissi et al., (2012) reported that carrier morphology may influence the hydration speed 
of lipid phase and subsequent deaggregation of the vesicles formed. Mannitol-based 
proliposomes may have better dispersion properties following hydration, which might 
be due to their small size, smooth surface and spherical shape as confirmed by SEM 
(Figure 4.4), resulting in predomination of spherical OLVs (Figure 4.15). In contrast, 
LMH powder is known to have slower dissolution rate and the spray-dried proliposome 
particles were larger, rougher and irregular shaped (Figure 4.5), possibly explaining that 
the different hydration patterns of the coated phospholipid have resulted in 
predomination of ―worm-like‖ structures (Figure 4.15). These findings indicate that 
morphology of proliposome particles and dissolution profile of the carrier (i.e. mannitol 
or LMH) had effects on the morphology of the generated liposomes. 
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Figure 4.15: TEM of (a) OLV liposomes generated by manual dispersion of mannitol-
based proliposomes and (b) elongated worm-like bilayer liposomes and liposome clusters 
generated from lactose monohydrate-based proliposomes using 1:6 w/w SPC to carrier. 
 
4.3.9 Powder aerosolisation and deposition profile in vitro 
Based on SEM study to assess the proliposome particle morphology using a range of 
LMH and mannitol-based formulations, it is predicted that proliposomes having 
spherical shape (i.e. enhanced flowability) and smaller physical size are likely to have 
higher deposition in the lower airways. However, it is important to bear in mind that 
SEM does not give information about particle aerodynamic size, which has a prime 
a 
b 
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influence on particle deposition in the peripheral airways. TSI was used to study the 
broad range of formulations in order to provide aerodynamic aerosol information. 
The deposition site and the efficiency of inhaled aerosols in the respiratory tract  are 
influenced by particle aerodynamic diameter, size distribution and shape (Pramod K. 
Gupta, 1991). Using the monodose DPI device (Miat, Italy), deposition of proliposomes 
in each stage of the TSI was measured by HPLC to determine the recovered dose 
(RD%), emitted dose (ED%) and fine particle fraction (FPF%) (Figure 4.16). The 
performance of proliposome aerosols using mannitol-based or LMH-based formulations 
was dependent on lipid to sugar ratio. 
The RD% in all formulations was very high (95.62 – 99.79%) but with LMH-based 
proliposomes it was slightly (p˂0.05) higher than mannitol-based proliposome 
formulations. Hence, proliposome powders have desirable flow properties regardless of 
carrier type and lipid to carrier ratio. However, the flowability of coarse LMH-based 
proliposomes was possibly better, since the ED was higher than mannitol-based 
formulations. It is also possible that the smaller size of mannitol-based proliposomes 
has increased the tendency of the mannitol formulations to cohere and adhere, resulting 
in reduced release of the powder from the inhaler‘s capsule (Kawashima et al., 1998). 
The ED was high in all formulations (in the range of 77.46 – 94.59%) but the main 
difference between mannitol-based proliposome and LMH-based proliposome 
formulations was in the FPF, since LMH-based proliposome particles had higher 
deposition in the upper stage of TSI (i.e. had lower FPF).  
FPF results correlated well with the SEM observations, as all LMH-based proliposome 
formulations (F6-F10) (previously shown to have large size and irregular shape; Figure 
4.5) had the lowest FPF values (0 - 3.99%) (Figure 4.16). Mannitol-based proliposomes 
were smaller and spherical shaped (Figure 4.4). Therefore, they had significantly higher 
FPF values (p˂0.05) (2.79 - 52.14%) compared to LMH-based proliposome 
formulations. Particles in the range of 1-5 μm may reach the lower respiratory tract 
(Daniher and Zhu, 2008). F1 had the lowest FPF amongest mannitol-based 
formulations, which might be attributed to the agglomeration of particles due to the 
presence of high lipid ratios. FPF values of 33.57 and 33.63% were observed for F2 and 
F5 formulations respectively, which were less than F3 and F4; this might be due to the 
presence of small cohesive particles with high tendency of agglomeration in F2 and F5 
formulations. In contrast, the high flowability (low agglomeration) of F3 and F4 
formulations might be the reason behind their higher deposition in FPF (Figure 4.16). 
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Figure 4.16: Recovered dose (%), emitted dose (%) and fine particle fraction (%) of mannitol-based and lactose monohydrate-based proliposomes using 
TSI (Data are mean ± STD, n=3). 
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4.4 Conclusions 
This study investigated the effects of the different carriers on the characteristics of SS 
proliposome formulations. The ratios of carrier to lipid were shown to influence the 
properties of spray-dried proliposome powders in terms of production yield, surface 
morphology, crystallinity and in vitro aerosol delivery. Subsequently, the characteristics 
of the generated liposomes in terms of size, size distribution, zeta potential, SS 
entrapment efficiency and liposomal vesicle morphology after hydration were also 
affected.  
The production yields of spray-dried LMH-based proliposomes were higher than 
mannitol-based proliposomes. X-ray powder diffraction showed that proliposomes were 
crystalline after spray-drying from their ethanolic suspension demonstrating an 
interaction between proliposomes ingredients.  
SEM images and TSI showed mannitol to be more suitable as carrier for use in DPI 
proliposome formulations because it produced spherical, smooth surface and small size 
particles after spray drying. On the other hand, LMH produced proliposome with 
irregular shape, rough surface and larger size, which were less suitable for delivery 
using DPIs. Lipid to carrier ratio of 1:6 (F3) had the highest FPF values amongst all 
formulations using TSI. 
Liposomes generated upon hydration of LMH-based proliposomes entrapped greater SS 
proportions than vesicles generated from mannitol-based formulations. The higher EE 
of SS following hydration of LMH-based formulations may be due to the larger size of 
the resultant vesicles. The zeta potential values were negative for the all formulations 
and lipid to sugar ratio had no influence on liposome surface charge. Furthermore, TEM 
showed that mannitol-based liposomes produced spherical liposomes, whilst LMH-
based proliposomes generated ―worm-like‖ structures and vesicle clusters. 
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5.1 Introduction 
The delivery of liposome based systems to the lung offers a number of advantages 
compared to drugs delivered in single phase solutions or conventional suspensions (Farr et 
al., 1985). The action of entrapped drug is localised in the deep lung and may last for much 
longer duration (Taylor et al., 1989). Liposomes are potentially suitable carrier systems for 
inhalation since they can be prepared from phospholipids with similar composition to 
endogenous lung surfactants, making them biocompatible and biodegradable (Karn et al., 
2011). 
Liposomal phospholipids have the tendency to hydrolyze and oxidise and may also 
aggregate and fuse. To overcome these instability manifestations, proliposome technologies 
have been introduced (Payne et al., 1986; Perrett et al., 1991). 
Proliposomes are stable phospholipid formulations and they can be prepared as powders or 
solution to generate liposomes upon dispersion in the aqueous phase. Research has shown 
that dry powder inhalers can be used to deliver ―respirable‖ proliposome powders prepared 
via spray-drying (Rojanarat et al., 2011;  2012a). Coating liposomes with appropriate 
polymers may overcome the instability issues of liposomes (Vyas et al., 2004; Xu et al., 
2007). Chitosan has been found to improve the stability of liposome vesicles and give 
mucoadhesiive properties (Henriksen et al., 1997; Takeuchi et al., 2003; Manconi et al., 
2010). Hence, mucadhesive polymers may increase the bioavailability of the drug in 
pulmonary systems by increasing the residence time in the lungs and enhancing the 
controlled release of the liposome-entrapped material (Takeuchi et al., 1996; Filipović-
Grcić et al., 2001a; Rytting et al., 2008; Zaru et al., 2009).  
Chitosan is widely used in formulation because it is biodegradable, biocompatible and has 
very low toxicity (Guo et al., 2003; Manca et al., 2012). In addition, chitosan enhances the 
dispersion properties of dry powders (Li and Birchall, 2006) and offer significant 
advantages for pulmonary delivery of macromolecules having local effect in the lung or 
systemic effect upon absorption through the pulmonary epithelium (Grainger et al., 2004; 
Lee et al., 2009). Among the formulations available for inhalation, dry powders are 
preferred due to their stability compared to the corresponding liquid formulations (Al-Qadi 
et al., 2012). 
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Chitosomes are liposomes coated with chitosan, thus combining the advantages of 
liposomes as carriers and chitosan as a bioadhesive (Takeuchi et al., 1996; Manca et al., 
2012). The mucoadhesive properties of chitosan are due to the molecular attractive forces 
formed by the electrostatic interaction between the positively charged chitosan molecules 
and the negatively charged mucosal surfaces (Takeuchi et al., 1996; Takeuchi et al., 2005). 
This chapter introduces novel prochitosome formulations of SS or BDP prepared using 
spray drying for delivery via dry powder inhalers. The spray-dried microparticulate 
mannitol was used as a prochitosome core carrier. Following the delivery of the inhalable 
spray-dried prochitosome formulations the exploitation of the aqueous environment in the 
lung may allow in-situ generation of chitosomes within the respiratory tract. The key 
parameters involved in the preparation of the prochitosomes or chitosomes were evaluated 
in these studies and optimum conditions were established. 
Prochitosomes or chitosomes prepared were characterised for production yield, 
morphology, crystallinity and in vitro assessment of particle deposition using TSI. In 
addition, the size, zeta potential, drug entrapment efficiency and mucoadhesion property of 
the reconstitute chitosomal vesicles were investigated.  
 
5.2 Methodology 
 
5.2.1 Production of prochitosomes using spray-drying  
Prochitosomes were developed by spray-drying of an ethanolic dispersion of lipids, drugs 
(SS or BDP), and microparticulate mannitol and chitosan glutamate. Lipid (SPC and CH in 
a molar ratio of 1:1) were weighed (100 mg) and dissolved in 100 mL of 96% ethanol to 
obtain an ethanolic lipid solution. SS (10 or 20 mg) or BDP (2.5 % mole ratio) was added 
to the ethanolic lipid solution and sonicated for 1 minute to obtain a clear solution. 
Microparticulate mannitol (600 mg) was dispersed in the solution, and the suspension was 
sonicated for 15 min in order to deaggregate the mannitol particles. Chitosan glutamate was 
added and the ratios of chitosan to lipid in formulations were 0:10, 1:10, 2:10, 3:10 and 
5:10 (w/w). The ethanolic suspension was continuously stirred whilst being fed into the 
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spray-drier to provide homogeneity. The inlet temperature of 120°C, spray flow rate of 600 
L/h and a feed rate of 11% were used, and the outlet temperature was 73 ± 3 °C. The 
resultant spray-dried prochitosome powder was transferred from the collection chamber 
into a desiccator for subsequent characterisation. 
 
5.3 Results and discussion 
 
5.3.1 Prochitosomes characterisation 
Prochitosomes were prepared using spray-drying to incorporate the hydrophilic drug SS or 
hydrophobic steroid BDP. Several ratios of chitosan to lipid (0:100, 10:100, 20:100, 30,100 
and 50:100 w/w %) were used. To make the formulation more stable cholestrol was 
incorporated in all formulations. As illustrated in Table 5.1, drug-free prochitosomes were 
prepared with different chitosan to lipids ratio, which are referred to DF-0, DF-10, DF-20, 
DF-30 and DF-50. 
 
Table 5.1: Drug-free prochitosome formulations and their composition 
  
* SPC: Soya phosphatidylcholine, CH: Cholestrol. 
 
SS prochitosomes were prepared using two different drug concentrations: 10 mg SS 
prochitosomes, which are referred to as SS-10(0), SS-10(10), SS-10(20), SS-10(30) and 
SS-10(50) (Table 5.2). Also, 20 mg SS prochitosomes were prepared and are referred to as 
SS-20(0), SS-20(10), SS-20(20), SS-20(30) and SS-20(50) (Table 5.2). 
 
Formulations Chitosan:Lipid 
(ratio) 
Chitosan 
(mg) 
Lipid (SPC:CH; 1:1)* 
(mg) 
Mannitol 
(mg) 
Drug 
(mg) 
DF-0 0:100 0 100 600 0 
DF-10 10:100 10 100 600 0 
DF-20 20:100 20 100 600 0 
DF-30 30:100 30 100 600 0 
DF-50 50:100 50 100 600 0 
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Table 5.2: Salbutamol sulphate 10 or 20 mg prochitosome formulations and their composition. 
  
* SPC: Soya phosphatidylcholine, CH: Cholestrol, SS: Salbutamol sulphate. 
 
Moreover, Prochitosome were prepared to incorporate BDP and are referred to as BDP-0, 
BDP-10, BDP-20, BDP-30 and BDP-50 (Table 5.3).  The effect of using various chitosan 
to lipid ratios on the production yield, powder density, particle morphology, powder 
crystallinity and aerosol peroformance of particles were investigated. Furthermore, after 
hydration of spray dried particles, the zeta potential, mucoadhesive properties, vesicle size, 
drug entrapment, and nebulisation efficiency were investigated for coated and un-coated 
vesicles. 
 
Table 5.3: Beclomethason dipropionate prochitosome formulations and their composition. 
  
* SPC: Soya phosphatidylcholine, CH: Cholestrol, BDP: Beclomethason diropionate. 
Formulations 
Chitosan:Lipid 
(ratio) 
Chitosan 
(mg) 
Lipid (SPC:CH; 1:1)* 
(mg) 
Mannitol 
(mg) 
SS* 
(mg) 
SS-10(0) 0:100 0 100 600 10 
SS-10(10) 10:100 10 100 600 10 
SS-10(20) 20:100 20 100 600 10 
SS-10(30) 30:100 30 100 600 10 
SS-10(50) 50:100 50 100 600 10 
      
SS-20(0) 0:100 0 100 600 20 
SS-20(10) 10:100 10 100 600 20 
SS-20(20) 20:100 20 100 600 20 
SS-20(30) 30:100 30 100 600 20 
SS-20(50) 50:100 50 100 600 20 
Formulations 
Chitosan:Lipid 
(ratio) 
Chitosan 
(mg) 
Lipid (SPC:CH; 1:1)* 
(mg) 
Mannitol 
(mg) 
BDP* 
(mg) 
BDP-0 0:100 0 100 600 4.9 
BDP-10 10:100 10 100 600 4.9 
BDP-20 20:100 20 100 600 4.9 
BDP-30 30:100 30 100 600 4.9 
BDP-50 50:100 50 100 600 4.9 
CHAPTER 5 
  
 
100 
 
5.2.2 Production yield and drug content uniformity of spray-dried powder 
Proliposome or prochitosome powders of SS and BDP were prepared using spray-drying. 
The total weight of the powder collected after spray-drying were expressed as the percent 
of the initial amount of the solids taken for dispersion preparation. Table 5.4 showed the 
values of production yield and content drug uniformity obtained after spray-drying. The 
lowest yield achieved was for BDP-0 (50.42 ± 2.47%) and the greatest was for SS-10-(50) 
formulation (63.57 ± 1.38%). Maury et al., (2005) have studied the effect of process 
variables (inlet air temperature, outlet air temperature, atomisation conditions, drying air 
flow rate and liquid feed concentration) on the production yield of spray dried powder. 
They found that increasing the trehalose concentration, decreased the production yield. 
Rabbani and Seville, (2005) have reported that increasing the viscosity of initial 
formulations resulted in reducing the production yield of spray-dried powder.  
In this study, because the spray-drying process parameters for all formulations were similar, 
the difference in the spray-dried production yield is very likely to be due to the presence of 
BDP, different concentration of SS or increasing chitosan to lipid ratio (i.e. increasing 
formulation viscosity prior to spray-drying).  
As seen in Table 5.4, no significant differences (p>0.05) in the production yield were found 
after increasing the chitosan concentration for all the formulations. However, a slight 
difference in the production yield between spray-dried powders of different batches might 
be due to the variation in outlet temperature (in the range of 70-76 ºC) or different particle 
size of the dried powder. The most common reasons for product loss during spray-drying 
were insufficient drying and leakage of powder between the filter plate and the vessel wall 
(Maa et al., 1998; Maury et al., 2005). Therefore, the decline in production yield during 
spray-drying could be attributed to powder adherence to the chamber wall and reduced 
cyclone efficiency in collecting the fine powder particles (Maa et al., 1998).  
Table 5.4 shows that the drug content uniformity of SS-10(0) and SS-10(10) formulations 
were significantly less (p˂0.05) than SS-10(20), SS-10(30) and SS-10(50). The drug 
content uniformity of SS-20(10) was significantly higher than SS-20(0), SS-20(20) and SS-
20(30). Such differences can be due to the difference in outlet temperature, particles size or 
production yield of spray-dried material. No differences (p>0.05) were detected for the 
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content uniformity of BDP due to large variability in the standard deviations between 
formulations. This indicated that spray-drying could be used for prochitosome production 
because it was able to produce a uniform distribution of the active ingredient within the 
spray-dried particles. 
 
Table 5.4: Production yield and drug content uniformity of spray-dried formuations. Data are 
mean ± STD, n=3. 
 
 
5.2.3 Powder density 
Several novel techniques have been developed to produce aerodynamically small particles 
that may offer maximum deposition of the drug in deep lung (Vanbever et al., 1999; Tsapis 
et al., 2002; Lo et al., 2004; Steckel and Brandes, 2004). Formulations having a tap density 
less than 0.4 g/cm
3 
and relatively large geometrical particle size ranging between 5 and 30 
µm, but with MMAD in the range of 1 to 5 µm could be suitable for deep lung deposition. 
Spray-drying has been reported to produce small, spherical and porous particles with low 
bulk density (Oliveira et al., 2005; Tajber et al., 2009; Rojanarat et al., 2012a; Rojanarat et 
al., 2012b).  
Formulations Production yield  
(%) 
Content drug uniformity 
(%) 
SS-10(0) 59.00±3.00 90.96±3.27 
SS-10(10) 63.43±1.06 92.16±1.75 
SS-10(20) 59.76±2.33 103.57±3.66 
SS-10(30) 61.12±2.54 109.69±5.90 
SS-10(50) 63.57±1.38 102.10±5.74 
   
SS-20(0) 54.63±2.81 87.87±3.14 
SS-20(10) 56.67±1.16 116.90±9.06 
SS-20(20) 54.89±10.93 86.60±13.82 
SS-20(30) 55.37±5.83 84.90±7.18 
SS-20(50) 61.14±2.01 101.54±3.52 
   
BDP-0 50.42±2.47 113.59±15.87 
BDP-10 57.94±1.96 105.45±17.63 
BDP-20 57.79±5.33 88.11±15.31 
BDP-30 59.87±3.26 84.15±11.29 
BDP-50 56.59±3.35 90.96±3.27 
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The results of powder density are shown in Table 5.5. The tapped density obtained for 
spray-dried particles in all formulations were below 0.4 g/cm
3
 and the geometric diameter 
was around 5 µm as confirmed by SEM, indicating particles might be suitable for deep lung 
deposition. No significant (p>0.05) difference in density was found when drug-free and 
drug-included formulations were compared. Moreover, no differences in the density were 
observed after increasing the chitosan ratio. 
The Carr's Index used for assessing the flow properties of solids was also determined from 
tapped and bulk density value. The flow properties of spray-dried particles were therefore 
determined using Carr's index. A values of less than 25% indicate good flow properties, 
whilst values above 40% indicate poor flow properties (Pilcer et al., 2006; Tajber et al., 
2009). As shown in Table 5.5, Carr's index values were between 23.56±2.15 and 
31.96±3.44. Thus, values were less than 40%, indicating all formulations have acceptable 
flow properties.  
Table 5.5, shows that there were no significant differences (p>0.05) between Carr's index 
of formulations having chitosan to lipid ratios of 0:10, 1:10 and 2:10. Furthermore, no 
significant differences (p>0.05) were detected between formulations having chitosan to 
lipid ratios of 3:10 and 5:10. Carr's index value for formulations with chitosan to lipid 
ratios of 0:10, 1:10 and 2:10 were significantly higher (p˂0.05) than formulations having 
chitosan to lipid ratios of 3:10 and 5:10 for drug-free and drug-included formulations. The 
reduced particle tendency for agglomeration after increasing chitosan ratio is possibly the 
reason behind improved powder flow properties by coating the sticky lipid surface of 
particles. These results agree with Pilcer et al., (2006) who reported that drug formulation 
coated with higher amount of lipids gave higher Carr's index values and poorer powder 
flowability. 
The information about tapped density and size of particles is necessary since it gives an 
indication about the flow properties of powder and a theoretical estimation of the powder 
aerodynamic diameter and its relation to particle size and tapped density are given in 
equation 5.1 (Hinds, 1999; Bosquillon et al., 2001): 
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      √
 
  
                                                    
 
Where, daer = particle aerodynamic diameter,  p = particle density, p1=1 g/cm
3
 and d= mass 
median particle diameter 
 
Table 5.5: Tapped density and Carr's index value of spray-dried formulations. Data are mean 
± STD, n=3. 
 
 
Formulations 
Tapped density  
(g/ml) 
Carr's Index  
(%) 
DF-0 0.34±0.04 29.44±1.34 
DF-10 0.28±0.02 29.13±0.83 
DF-20 0.30±0.01 27.41±1.23 
DF-30 0.29±0.02 24.81±1.19 
DF-50 0.27±0.02 23.10±1.87 
   
SS-10(0) 0.31±0.04 28.81±1.50 
SS-10(10) 0.29±0.02 28.73±1.07 
SS-10(20) 0.28±0.01 25.83±1.30 
SS-10(30) 0.27±0.02 23.85±0.84 
SS-10(50) 0.28±0.01 21.86±2.19 
   
SS-20(0) 0.28±0.01 28.77±1.27 
SS-20(10) 0.30±0.02 27.73±1.98 
SS-20(20) 0.29±0.01 25.00±0.30 
SS-20(30) 0.29±0.10 24.61±3.27 
SS-20(50) 0.28±0.01 23.66±2.11 
   
BDP-0 0.30±0.01 28.52±0.40 
BDP-10 0.28±0.01 28.48±1.03 
BDP-20 0.29±0.02 26.22±0.98 
BDP-30 0.26±0.01 23.81±0.57 
BDP-50 0.24±0.04 22.12±2.64 
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5.2.4 Particle surface morphology 
SEM was used to visualize the size, shape, and surface morphology of the spray-dried 
powders. As shown in Figure 5.1, SS particles were elongated and had plate-like shapes 
before and after spray-drying the ethanolic solution of the drug. In contrast, BDP showed 
irregular large particles before spray-drying but small, uniform and spherical shaped 
particles with smooth surfaces after spray-drying of the ethanol solution of the steroid 
(Figure 5.2). The difference between morphology of SS and BDP after spray-drying  might 
be due to the higher solubility of BDP in ethanol compared to the hydrophilic drug SS. 
 
  
Figure 5.1: SEM images of salbutamol sulphate (a) before spray drying and (b) after spray 
drying (magnification was 6000x). 
 
b a 
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Figure 5.2: SEM images of beclomethason dipropionate (a) before spray drying and (b) after 
spray drying (magnification was 6000x). 
 
As shown in Figure 5.3, mannitol particles had irregular shape with rough surfaces and 
large size. In contrast, after spray-drying they had uniform and spherical shape with smooth 
surface and particle size was around 3 µm. Spray-dried mannitol was used as core carrier in 
this study. 
 
  
Figure 5.3: SEM images of mannitol (a) before spray drying and (b) after spray drying 
(magnifications were 400x, 6000x). 
  
a b 
a b 
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SEM results showed that chitosan particles before and after spray-drying were typically 
smooth, spherical and small (approx 5 µm). Furthermore, the tendency of particles 
agglomeration seemed to be reduced after spray-drying (Figure 5.4).  
 
  
Figure 5.4: SEM images of chitosan (a) before spray drying and (b) after spray drying 
(magnification was 4000x). 
 
The morphology of SS-10 and BDP-prochitosomes are shown in Figure 5.5 and Figure 5.6. 
SEM images reveal no noticeable difference between SS and BDP formulations. 
Proliposomes and prochitosmes obtained by spray-drying seem to have desirable 
morphologies for deposition into deep lung. Most of the particles were porous, spherical 
and had rough surfaces with small size range (approx 2-7 µm) and some tiny or elongated 
particles adhering to the surface of larger particles. The production of porous and spherical 
particles with rough surface has occurred upon spray-drying the ethanolic suspension of 
drugs with carriers. The proliposome and prochitosome particles were expected to have 
appropriate aerodynamic properties for inhalation.  
 
a b 
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Figure 5.5: SEM images of salbutamol sulphate-10 formulations (a) SS-10(0), (b) SS-10(10), 
(c) SS-10(20), (d) SS-10(30) and (e) SS-10(50) (magnification was 6000x). Composition of the 
formulations is presented in Table 5.2. 
 
a 
e 
c d 
b 
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SEM images showed that some particles were not intact, which is evident from having a 
very thin or discontinuous surfaces following spray-drying in organic solvent. This was 
attributed to the high outlet temperature causing the droplets to evaporate quickly and 
produce deformed particles. The rate of drying may also affect the final particulate 
morphology. Faster drying tended to yield deformed particles. Gilani et al. (2005) have 
reported that spray-drying at higher concentration of ethanol may reduce the tendency of 
particle agglomeration due to rapid drying and reduced turbulence of the droplets, resulting 
in rapture of the particles, which was evident by the broken and hollow particles.  
Figures 5.5 and 5.6 showed that particle size of formulations with higher chitosan to lipid 
ratio (SS-10(30), SS-10(50), BDP-30 and BDP-50) were slightly larger than formulations 
containing lower chitosan concentrations (SS-10(10), SS-10(20), BDP-10 and BDP-20) or 
no chitosan at all (SS-10(0) and BDP-0). These finding can be attributed to the high 
viscosity resulting from inclusion of chitosan in the formulations, causing an increase in the 
size of atomized droplets during spray-drying. In general, the mean size of droplets formed 
by atomization is proportional to liquid viscosity and surface tension, indirectly affecting 
the spray-dried particle size. These results were supported by Wang and Wang (2002) who 
reported the spray drying of solutions with lower viscosities tend to produce small droplets 
size due to the rapid rate of evaporation. 
SEM images showed that particles without chitosan (SS-10(0) and BDP-0) or with low 
amount of chitosan (SS-10(10), SS-10(20), BDP-10 and BDP-20) had a higher tendency to 
agglomerate, possibly due to presence of sticky lipid on the surface of particles. Studies 
have also shown that smaller particles are more cohesive (Rasenack and Müller, 2004; 
Steckel and Brandes, 2004). Cohesive particles may have high aerodynamic size. SEM 
images showed particles size distribution to be broad, which is a consequence of the 
preparation method.  
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Figure 5.6: SEM images of beclomethason dipropionate formulations (a) BDP-0, (b) BDP-10, 
(c) BDP-20, (d) BDP-30 and (e) BDP-50 (magnification was 6000x). Composition of the 
formulations is presented in Table 5.3. 
 
e 
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SEM images for drug-free and SS (20 mg) formulations are not presented because no 
differences in comparison to BDP and SS (10 mg) formulations were observed. Therefore, 
results seem to indicate that the presence of active drugs does not affect the morphological 
characteristics of proliposome or prochitosome formulations manufactured by spray-drying. 
 
5.2.5 Crystallinity of spray-dried particles  
To investigate the feasibility of developing stable spray-dried prochitosomes for pulmonary 
delivery, the glassy phase (amorphous or crystallin) status of the prochitosome 
formulations was investigated by assessing their crystallinity using X-ray diffractometer. 
Figure 5.7 shows the XRPD of mannitol before and after spray drying. The presence of 
sharp diffraction peaks in the X-ray diffractogram obtained using mannitol raw material 
indicates the crystalline state of the sugar with high degree of order. The XRPD showed 
that the spray-drying process did not change the crystalline nature of mannitol. The peaks 
that represent the spray-dried mannitol (Figure 4.7b) correspond to those of the original 
mannitol (Figure 4.7a) but differ in intensity indicating that the powder is crystalline, 
agreeing with a study conducted by Sebhatu et al. (1994).  
 
  
Figure 5.7: X-ray powder diffraction of mannitol (a) before spray-drying and (b) after spray-
drying of its ethanolic suspension.  
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XRPD of chitosan starting material and chitosan after spray-drying are shown in Figure 5.8. 
The results showed that chitosan before and after spray-drying was an amorphous powder, 
which is evident as a characteristic amorphous halo in the XRPD.  
 
  
Figure 5.8: X-ray powder diffraction of chitosan (a) before spray drying and (b) after spray 
drying of its ethanolic suspension. 
 
XRDP also showed that spray-drying did not convert SS into amorphous, but has reduced 
the diffraction intensity of the crystalline powder, suggesting the long-term stability of the 
prochitosme formulations (Figur 5.9). Since spray drying did not convert SS into 
amorphous, this may give indication of long-term stability of the drug in spray-dried 
formulations. Further studies are required to investigate this assumption. 
 
   
Figure 5.9: X-ray powder diffraction of salbutamol sulphate (a) before spray drying and (b) 
after spray drying of its ethanolic solution. 
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The XRPD of the raw and spray-dried BPP are shown in Figure 5.10. The sharp peaks of 
the diffractogram of the BDP before spray drying confirmed the crystallinity of the drug. In 
contrast, after spray-drying, BDP became amorphous with a single broad peak with no 
long-range order, which is in agreement with previous investigations (Hancock and 
Zografi, 1997; Abdel-Halim et al., 2011).  
 
  
Figure 5.10: X-ray powder diffraction of beclomethason dipropionate (a) before spray drying 
and (b) after spray-drying of its ethanolic suspension.  
 
Since the same parameters of spray-drying were applied for all formulations, the difference 
in the crystal form of mannitol must be due to the presence of SS, BDP or chitosan.  The 
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ingredients hence the absence of peaks characterising SS, BDP or chitosan could be 
explained by the low sensitivity of the method with non-detection of these materials by X-
ray diffractometer. The effect of incorporation of drugs and different chitosan ratios were 
investigated based on the change in the intensity of the diffraction peaks.   
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profound in prochitosme formulations with highest chitosan to lipid ratio (SS-10(30), SS-
10(50) (Figure 5.11), BDP-30 and BDP-50 (Figure 5.12). Therefore, the difference in the 
intensity of peaks confirms the interaction between amorphous chitosan and proliposome 
components. 
 
   
   
    
Figure 5.11: X-ray powder diffraction of salbutamol sulphate-10 formulations (a) SS-10(0), 
(b) SS-10(10), (c) SS-10(20), (d) SS-10(30) and (e) SS-10(50). Composition of the formulations 
is presented in Table 5.2. 
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Figure 5.12: X-ray powder diffraction of beclomethason dipropionate formulations (a) BDP-0, 
(b) BDP-10, (c) BDP-20, (d) BDP-30 and (e) BDP-50. Composition of the formulations is 
presented in Table 5.3. 
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of lipid have been reported in previous studies (Guo et al., 2003; Darwish and Elmeshad; 
2009; Gradauer et al., 2012). A number of studies showed the interaction between chitosan 
and cholestrol (Rey Gómez-Serranillos et al., 2004; Pavinatto et al., 2005) and chitosan and 
phospholipid (Kim et al., 2001; Serfis et al., 2001; Brzozowska and Figaszewski, 2002). 
Therefore, the hydroxyl group of mannitol may interact with positively charged chitosan or 
with other components of the spray-dried prochitosomes. Changes in the FTIR spectra in 
the intensity of the hydroxyl groups of mannitol were observed. 
The mannitol spectrum (Figure 5.13; Figure 5.14) exhibited characteristic bands of O-H in 
the plane vibration (1418 cm
-1
) and O-H stretching vibration (1077 and 1016 cm
-1
). 
  
 
Figure 5.13: FTIR spectra of spray-dried mannitol, (P-0) SS-10(0), (P-1) SS-10(10), (P-2) SS-
10(20), (P-3) SS-10(30) and (P-5) SS-10(50). Composition of the formulations is presented in 
Table 5.2. 
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Figure 5.14: FTIR spectra of spray-dried mannitol, (B-0) BDP-0 (B-1) BDP-10, (B-2) BDP-20, 
(B-3) BDP-30 and (B-5) BDP-50. Composition of the formulations is presented in Table 5.3. 
  
Table 5.6 shows the intensity peaks of hydroxyl groups of mannitol were lower when sugar 
was used as core carrier in proliposome or prochitosome formulations compared to 
mannitol alone. This can be attributed to the effect of the excipients of the spray-dried 
formulations. The intensity peaks of hydroxyl group of mannitol were higher in 
proliposomes compared to prochitosome formulations. This might be due to an interaction 
between chitosan and other components of spray dried formulations. There were only slight 
changes in the intensity of FTIR peaks when the prochitosome formulations were compared 
(Table 5.6). No significant difference between drug-free and drug-containing formulations 
was observed since the concentration of the drug in formulations was low.  
Thus, in conclusion, there was some interaction between the components of spray-dried 
prochitosomes. Further investigations using other techniques are needed in the future to 
confirm the validity of these findings.  
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Table 5.6: Specific FTIR characteristics of drug-free and drug (salbutamol sulphate or 
beclomethason dipropionate) containing prochitosomes compared to spray-dried mannitol. 
 
 
 
5.2.7 Zeta potential analysis 
In vivo, the surface charge density affects the biodistribution of liposomes, and in vitro, a 
high zeta potential might contribute to the physical stability of liposomes by decreasing the 
rate of aggregation and fusion (Crommelin 1984). The formation of chitosan layer on the 
surface of liposomes was confirmed by comparing the zeta potential of the liposomes 
before and after coating with the polymer.  
Formulation 
O-H in plane 
vibration 
Intensity 
O-H stretching 
vibration 
Intensity 
Mannitol 1018., 1079 71, 74 1419 88 
     
DF-0 1017, 1078 40, 41 1418 77 
DF-10 1017, 1077 33, 34 1418 70 
DF-20 1017, 1076 29, 30 1418 69 
DF-30 1016, 1076 27, 27 1418 65 
DF-50 1017, 1077 32, 34 1418 70 
     
SS-10(0) 1017, 1077 44, 45 1418 76 
SS-10(10) 1017, 1078 38, 39 1419 76 
SS-10(20) 1017, 1076 35, 35 1418 73 
SS-10(30) 1017, 1076 31, 31 1418 69 
SS-10(50) 1017, 1076 28, 30 1418 68 
     
SS-20(0) 1017, 1078 42, 44 1418 79 
SS-20(10) 1016, 1076 27, 27 1418 68 
SS-20(20) 1017, 1076 28, 29 1418 67 
SS-20(30) 1017, 1077 28, 30 1418 68 
SS-20(50) 1017, 1077 32, 33 1418 70 
     
BDP-0 1018, 1078 58, 58 1418 87 
BDP-10 1017, 1076 45, 45 1418 77 
BDP-20 1017, 1077 37, 38 1418 77 
BDP-30 1016, 1076 30, 30 1418 71 
BDP-50 1016, 1076 29, 28 1418 71 
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The zeta potential of liposomes and chitosomes are shown in Figure 5.15. Liposomes had 
negative surface charges for both drug-free and drug containing formulations. The slightly 
negative zeta potential might be attributed to the negatively charged phosphate functional 
group of the lipid. The zeta potential of chitosomes increased significantly (p˂0.05) and 
became positive by inclusion of chitosan in ascending concentration (Takeuchi et al. 2001). 
All zeta potential values of chitosomes were positive because chitosan had high positive 
charge. Thus, the adsorption of chitosan increased the intensity of positive charge on the 
surface of vesicles (Takeuchi et al. 2001; Guo et al., 2003). The main interaction between 
positively charged chitosan and the opposite charge of liposomes was due to electrostatic 
interaction between the polymer and phospholipid (Galovic Rengel et al., 2002; Guo et al., 
2003; Takeuchi et al., 2003; Takeuchi et al., 2005; Gradauer et al., 2012). 
As demonstrated in Figure 5.15 the amount of SS did not affect the zeta potential of 
vesicles (p>0.05). Moreover, no significant difference between the zeta potential of SS or 
BDP vesicles was observed (p>0.05). In contrast, a slight difference was detected between 
the zeta potential of drug-free and drug-containing vesicles (Figure 5.15). The zeta potential 
of drug-free vesicles was higher than drug containing vesicles except for the DF-50 
formulation made using 5:10 chitosan to lipid ratio.   
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Figure 5.15: Zeta potential (mV) values of drug-free, salbutamol sulphate-10, salbutamol sulphate-20 and beclomethason dipropionate  
formulations. Data are mean ± STD, n=3.
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5.2.8 Mucoadhesion studies 
 
i) Analysis of mucoadhesive properties using UV-spectroscopy 
The importance of mucoadhesive properties of chitosan for enhancing the drug absorption 
and therapeutic activity has been reported in several studies (Lehr et al., 1992; Illum et al., 
1994; Lueßen et al., 1994; Fiebrig et al., 1995; Aspden et al., 1996). 
In this study, the mucoahesive properties of prochitosomes were assessed by dispersing the 
spray-dried powders in aqueous mucin solution. As can be seen in Figure 5.16, the 
percentage of mucin adsorbed on the vesicle surfaces increased significantly (p˂0.05) by 
increasing chitosan ratio. The amount of mucin adsorbed on the chitosome surface was 
significantly higher than liposome vesicles surface (p˂0.05). These results confirmed that 
spray-dried prochitosmes have higher ability to adsorb mucin than proliposomes following 
hydration. Such results are consistent with previous studies that reported the mucoadhesive 
properties of liposomes to increase upon coating the vesicle surfaces with chitosan 
(Takeuchi et al., 1996; Zaru et al., 2009; Karn et al., 2011).  
No significant difference (p˃0.05) was observed between SS-10 and BDP formulations in 
terms of mucin amount adsorbed on the vesicle surfaces. The interaction between mucin 
and chitosan is attributed to the electrostatic attraction between the positively charged 
moiety of chitosan and the negatively charged mucin (the negative charge of mucin is due 
to the ionization of sialic acid) (Lehr et al., 1992; Sogias et al., 2008).  
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Figure 5.16: Percentage of mucin adsorbed on the vesicle surfaces of salbutamol sulphate-10 
and beclomethason dipropionate formulations. Data are mean ± STD, n=3. 
 
 
ii) Analysis of mucoadhesive properties using zeta potential measurements 
The mucoadhesive properties of chitosomes were also studied by mixing equal volumes of 
vesicle suspensions and aqueous mucin solution. It was expected that the surface property 
of the vesicles may be changed by the adhesion of the mucin if the vesicle has a 
mucoadhesive property. The occurrence of such change was detected by measuring the zeta 
potential. 
Figure 5.17 showed that zeta potential of vesicle surfaces decreased significantly (p˂0.05) 
from highly positive to less positive values after mixing the vesicle dispersion with mucin 
solution. These results suggested that chitosomes had a high propensity to interact with 
mucin. The higher the ratio of chitosan in formulations, the more extensive the changes 
observed in the zeta potential. (Galovic Rengel et al., 2002; Takeuchi et al., 2005; Zaru et 
al., 2009). No significant difference (p>0.05) in mucoadhesion was observed between drug-
free and drug-enriched formulations (Figure 5.17). Moreover, the different concentration of 
SS (10 or 20 mg) had no effect on the mucoadhesive properties of the formulations 
(p>0.05) (Figure 5.17).   
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Figure 5.17: Zeta potential values (mV) of formulations after mixing with mucin solution. Data are mean ± STD, n=3.
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5.2.9 Size analysis 
The size of vesicles can affect the biological properties of formulation. The 
mucoadhesive properties of chitosomes have been reported to be dependent on vesicle 
size (Takeuchi et al., 2005). Figure 5.18 showed the comparison of vesicle size using a 
range of liposome and chitosome formulations. Vesicle size of drug-free formulations 
were smaller than drug-containing liposomes or chitosomes regardless of drug type 
(p˂0.05), which might be attributed to possible changes in the bilayer packing due to 
drug inclusion in liposomes or chitosomes. DF-50 had slightly smaller vesicle size 
compared to DF-0, DF-10, DF-20 and DF-30 (p>0.05), suggesting that chitosan in its 
highest concentration used may have decreased vesicle aggregation upon coating the 
bilayer surfaces, indicating an enhanced short-term stability of formulations as a result 
of chitosan incorporation. Vesicles size of SS-20 formulations was slightly but not 
significantly (p>0.05) larger than SS-10 formulations, possibly due to encapsulation of 
higher drug proportions. Vesicle size measurements of SS-10(30), SS-10(50), SS-
20(30) and SS-20(50) were slightly smaller than those of SS-10(0), SS-10(10), SS-
10(20), SS-20(0), SS-20(10) and SS-20(20), which can be attributed to the reduced 
aggregation of vesicles upon coating with high chitosan concentrations (Figure 5.18). 
Figure 5.19 shows that Span values of SS-20 vesicles were high, indicating less uniform 
size distribution of the vesicles compared to SS-10 vesicles and drug-free formulations. 
The high Span value could be attributed to increased vesicle aggregation (Elhissi et al., 
2006). 
Sizes of BDP liposomes were larger than BDP chitosomes (p˂0.05). Furthermore, 
chitosome vesicle size decreased with increasing chitosan ratio, again demonstrating the 
advantage of using chitosan to reduce aggregation. When BDP was used, no significant 
difference (p>0.05) between the Span value of formulations was observed (Figure 5.19). 
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Figure 5.18: Vesicle size of drug-free and drug-containing formulations. Data are mean ± 
STD, n=3. 
 
 
Figure 5.19: Size distribution (Span) of drug-free and drug-containing formulations. Data 
are mean ± STD, n=3. 
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5.2.10. Lipid recovery  
Phospholipid assay was performed to investigate the efficiency of phospholipid 
recovery following spray-drying. These experiments were conducted to investigate the 
amount of lipid content obtained from the spray-dried product. The percent of lipid 
recovery after spray-drying were determined from the percentage proportions of lipid in 
the spray-dried formulation in comparison to the original amount of lipid used before 
spray-drying. The lowest percent of lipid recovery was achieved for BDP-0 and the 
highest value was for SS-10(50) (Table 5.7). Differences in lipid recovery are caused by 
differences in the proportions of lipid adhering to the internal structures of the spray-
drier such as the drying chamber and the cyclone walls. The major aspects affecting 
lipid recovery are heat exposure and size of the atomized droplets ejecting from the 
dryer's nozzle. Lipid recovery after spray-drying lipid alone was almost zero (data not 
shown) due to the low Tg and very sticky nature of lipid at the high temperature (73±3 
ºC) of the spray-drier. Marsh et al. (1976) reported that the permeability of phospholipid 
vesicles increases during spray-drying process. Therefore, Mannitol was used as a 
stabilizing agent to increase the Tg of the lipid and recover higher lipid proportions from 
the spray-drier.   
Table 5.7 shows the lipid recovery for SS-10 prochitosomes was significantly higher 
(p˂0.05) than that of proliposome formulation. Lipid recovery for SS-20(30) and SS-
20(50) formulations was higher than those for SS-20(0), SS-20(10) and SS-20(20) 
formulations. Lipid recovery of BDP prochitosomes were higher than proliposomes, 
indicating that prochitosomes demonstrated better lipid recovery than proliposomes 
regardless of type of drug used. A slight increase in lipid recovery was observed when 
using the highest chitosan to lipid ratio (increased viscosity), possibly due to spraying 
larger droplets from the orifice nozzle after coating the droplet surface with chitosan 
allowing larger particles to be produced. Wang and Wang (2008) showed that spray-
dried particle size increased with increasing formulation viscosity. The reduced particle 
separation might be induced due to insufficient cyclone resistance, which was not able 
to collect such small powder particles, resulting in a reduction of lipid recovery for the 
small particles. On the other hand, coating of the droplet surface with chitosan might 
reduce stickiness of the particles to the drying chamber and thus lipid recovery was 
increased.  
The lipid content uniformity values showed the distribution of solid content within 
spray-dried particles. The percent of content uniformity regarding the amount of lipid 
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recovery are shown in Table 5.7. No significant (p>0.05) differences were found for 
lipid content uniformity amongst formulations except for SS-10(0) formulation, which 
is significantly lower (p˂0.05) than SS-10(20), SS-10(30) and SS-10(50) formulations. 
Spray-drying could thus be used for successful production of proliposomes and 
prochitosomes of SS and BDP because it was able to produce a uniform distribution of 
the lipid in all formulations. 
 
Table 5.7: Percent of lipid recovery and lipid content uniformity of prochitosome 
formulations. Data are mean ± STD, n=3. 
   
 
5.2.11 Transmission electron microscopy  
TEM was used to provide visual confirmation of the structure of liposomes or 
chitosomes using SS (Figure 5.20) or BDP (Figure 5.21) as model therapeutic 
molecules. Figure 5.20a, b and Figure 5.21a, b show liposomes to be highly spherical 
with evidence of aggregates formation. As can be seen in Figure 5.20c, d and Figure 
5.21c, d, the chitosome vesicles of SS and BDP were spherical or ellipsoidal in shape. 
The chitosan polymer appeared to make the vesicle membranes thicker and provide 
additional evidence for the ability of chitosan to coat the liposome surfaces. Liposomes 
Formulations 
Lipid recovery  
(%) 
Lipid content uniformity  
(%) 
SS-10(0) 54.63±2.80 92.83±8.04 
SS-10(10) 61.87±1.43 97.56±3.82 
SS-10(20) 64.55±1.03 108.16±5.83 
SS-10(30) 64.60±1.00 105.77±3.33 
SS-10(50) 67.37±1.00 105.99±2.19 
   
SS-20(0) 53.45±0.60 97.94±4.31 
SS-20(10) 53.71±1.45 94.76±1.34 
SS-20(20) 53.09±6.47 97.88±8.69 
SS-20(30) 55.10±0.43 100.25±10.71 
SS-20(50) 64.89±1.57 105.72±4.71 
   
BDP-0 42.11±6.60 80.36±17.04 
BDP-10 64.74±11.30 112.5±24.14 
BDP-20 55.60±6.76 93.99±17.48 
BDP-30 47.82±5.43 78.68±11.42 
BDP-50 53.86±5.35 93.64±11.92 
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may aggregate in different mechanisms in presence of polymers. For example, one 
polymer chain might bind to different liposomes, thereby cross-linking single particles, 
resulting in vesicle aggregation. Mertins and Dimova (2011) proposed this mechanism, 
by addition of chitosan to performed liposomes. Entanglement of polymer chains that 
were previously bound to different liposomes would be another possibility. Filipović-
Grcić et al. (2001b) found that the interaction between chitosan and liposomes is due to 
a combination of adsorption coagulation and bridging between them.  
 
   
   
Figure 5.20: TEM of SS-10(0) liposome (a, b) and SS-10(30) chitosome (c, d) vesicles. 
Composition of the formulations is presented in Table 5.2. 
 
a 
c d 
b 
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Figure 5.21: TEM of BDP-0 liposome (a, b) and BDP-30 chitosome (c, d) vesicles. 
Composition of the formulations is presented in Table 5.3. 
 
5.2.12 Entrapment efficiency 
 
5.2.12.1 Entrapment efficiency of salbutamol sulphate 
The entrapment efficiency of drugs in liposomes is affected by a number of factors, 
including drug physicochemical properties, and liposome size and bilayer composition 
(Muramatsu et al., 2000). In this study, the entrapment efficiency was measured using 
indirect method (Kim et al., 2005; Rojanarat et al., 2011). In the experiments the 
amount of lipid and drug were fixed, whilst the amount of chitosan varied amongst 
c d 
a b 
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formulations. Spray-dried powders were rehydrated with deionised water, hence free SS 
would dissolve instantly. After ultracentrifugation, SS-entrapped vesicles were 
sedimented as pellets at the bottom of the centrifuge tube. The entrapped SS content 
was measured by subtracting the amount of free drug from that of the total drug in the 
formulation. 
Figure 5.21 shows that the entrapment efficiency for the SS-10 batches was higher in 
chitosomes (SS-10(10), SS-10(20), SS-10(30) and SS-10(50)) compared to liposomes 
(SS-10(0)), especially for SS-10(20) and SS-10(30) (p˂0.05). These results were 
supported by a range of other investigators, who reported that increasing chitosan 
concentration caused an increase of the drug entrapment efficiency (Galovic Rengel et 
al., 2002; Zaru et al., 2009; Albasarah et al., 2010; Karn et al., 2011). In contrast, the 
entrapment efficiency of loperamide (Guo et al., 2003), insulin (Wu et al., 2003) and 
IgG (Arafat, 2012) was decreased upon coating liposome surface with chitosan. Li et al. 
(2009) and Liu and Park (2010) however found that addition of chitosan to liposomal 
dispersions had no effect on the entrapment efficiency of the drug. These contradictory 
results might be attributed to the use of different drugs or excipients within the 
liposomal formulations, or might be ascribed to the different procedures of liposomes 
manufacture or coating with chitosan.  
Figure 5.22 shows that no significant difference was observed (p˃0.05) between the 
entrapment efficiency of SS-10(20), SS-10(30) and SS-10(50). Furthermore, no 
significant difference (p˃0.05) was found between SS-10(0) and SS-10(10). On the 
other hand, the entrapment efficiency values of SS-10(50), SS-10(30) and SS-10(20) 
were higher than SS-10(10) and SS-10(0). The higher entrapment efficiency of 
chitosomes compared to liposomes might be due to the recovery of larger amounts of 
lipid when prochitosomes where used for spray-drying. This was confirmed earlier in 
the lipid recovery experiments using the Stewart assay (Table 5.7). Furthermore, the 
presence of a chitosan layer around the liposomes may reduce drug leakage, hence the 
entrapment becomes higher. 
The entrapment efficiency was found to decrease for SS-20 formulations (S-20(0), SS-
20(10), SS-20(20), SS-20(30) and SS-20(50)) upon increasing SS concentration (Figure 
5.22), which might be due to the insufficient amount of lipid available to entrap high 
proportions of SS. In our research group, Arafat (2013) has found that increasing the 
concentration of ovalbumin can decrease the entrapment efficiency using liposomes 
with similar lipid composition. Regarding the effect of increasing the ratio of chitosan, 
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polymer concentration had no effect on drug entrapment efficiency except for SS-
20(50), which had higher entrapment efficiency than SS-20(0) (p˂0.05).  
 
 
Figure 5.22: Entrapment efficiency of salbutamol sulphate-10 and salbutamol sulphate-20 
formulations. Data are mean ± STD, n=3. 
 
5.2.12.2 Entrapment efficiency for beclomethason dipropionate-based vesicles 
 
i) Optimization of separation speed using the Stewart assay  
In order to quantify the amount of phospholipid present, Stewart assay (section 2.2.9) 
was used to determine the optimal speed of bench centrifuge for the separation. 
Liposome pellets were found to sediment at the bottom of the eppendorf tube upon 
centrifugation in deionised water (Meisner et al., 1989; Taylor et al., 1990; Ma et al., 
1991). Thus, when conventional deionised water is used for separation, the free drug 
crystals and the drug-entrapped liposomes may together sediment, thus making the 
separation inefficient. Higher density dispersion medium (D2O) was used instead of 
deionised water, causing the BDP-entrapped liposomes to float at the top of eppendorf 
contents whilst the free drug crystals sedimented as pellets, hence enabling the 
separation of the un-entrapped drug from the entrapped fraction (Batavia et al., 2001).  
Spray-dried proliposome (BDP-0) (10 mg) samples were hydrated, annealed in 1 mL 
D2O for approx 1 hour and loaded into eppendorf tubes for centrifugation for 90 min at 
11,000 rpm. Soft creamy layer of liposomes formed at the top of the eppendorf's 
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contents (Batavia et al., 2001), whilst the BDP crystals accumulated as a spot at the 
bottom of the tube. The middle part of the tube was collected for phospholipid assay to 
ensure separation was efficient. The procedure was repeated for the same sample using 
different centrifugations speeds (i.e. 12,000 and 13,000 rpm). Figure 5.23 showed that 
the proportion of phospholipids decreased significantly in response to increasing the 
centrifuge speed. Therefore, higher speed of 13,000 rpm showed better separation of 
entrapped and un-entrapped BDP. 
 
 
Figure 5.23: Amount of lipid present in un-entraped (middle layer of eppindorf tube) 
liposome formulation in D2O at different speed using bench centrifuge for 90 min. Data 
are mean ± STD, n=3. 
 
ii) Optimization of separation speed using light microscopy  
Spray-dried proliposomes (10 mg) was hydrated and annealed in 1 mL D2O and 
examined under light microscope (Figure 5.24 & Figure 5.25). Gilson pipette was used 
to take liposomal D2O dispersions. Liposomes and BDP crystals have the same size 
range (Batavia et al., 2001). Hence, high speed bench centrifuge was selected and the 
optimum speed was determined to be 13,000 rpm since the amount of lipid detected in 
the middle layer of the eppendorf was the lowest. After 60 min of bench centrifugation, 
the samples were observed separately using light microscopy for the liposomal upper 
layer and the BDP crystals at the bottom of eppendorf. It was confirmed that the bottom 
spot part was the un-entrapped BDP crystals (Figure 5.24a & Figure 5.25a).  
At higher speed of centrifugation (13,000 rpm) for 60 min, BDP crystals sedimented 
(Figure 5.24a) and the upper layer consisted of liposomes with minimal number of BDP 
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crystals being observed (Figure 5.24b). Light microscopy was also used to observe the 
liposomal layer after 90 min at 13,000 rpm and as shown in Figure 5.25, the upper 
liposomal layer was free of BDP and all the un-entrapped BDP crystals were observed 
at the bottom of the tube (i.e. in the sedimented tube) (Figure 5.25). 
Both the Stewart phospholipid assay and light microscopy findings confirmed that 
centrifugation at 13,000 rpm for 90 min is optimum parameters to separate the liposome 
entrapped steroid from the un-entrapped (free) BDP crystals.  
 
   
Figure 5.24: Light microscopy of (a) sedemented spot containing beclomethason 
dipropionate (BDP) crystals and (b) supernatant layer containing both liposome and small 
amount of BDP crystals, using bench centrifuge for 60 min at 13,000 rpm. 
 
  
Figure 5.25: Light microscopy of (a) sedemented spot containing beclomethason 
dipropionate crystals and (b) supernatant layer containing only liposome, using bench 
centrifuge for 90 min at 13,000 rpm. 
 
a 
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iii) Entrapment efficiency of beclomethason dipropionate 
The entrapment efficiency was measured in this investigation using indirect method 
(Kim et al., 2005; Rojanarat et al., 2011). Spray-dried powder (10 mg) was placed in an 
eppendorf tube and hydrated by addition of 1 ml deionised water or D2O followed by 
annealing for approx 1 hour and centrifugation as described earlier using a speed of 
13,000 rpm for 90 min. For drug quantification using HPLC, the supernatant of sample 
dispersed in deionised water was taken by a Gilson pipette and diluted with methanol, 
while for sample dispersed in D2O the middle layer was collected for analysis. The spot 
containing BDP crystals (Figure 5.24 & 5.25) was also analysed separately and 
dissolved in methanol for determination of un-entrapped BDP, and added to the BDP 
quantity in the middle layer to constitute the total un-entrapped fraction. The entrapped 
BDP was determined by subtracting the amount of free drug from the total included in 
the formulation.  
Using deionsed water as dispersion medium, almost all phospholipid with entrapped 
and un-entrapped BDP sedimented at the bottom of the eppendorf tube. Un-entrapped 
BDP containing traces of liposomes were found floating at the top of the eppendorf 
tube. As can be seen in Figure 5.26, the entrapment efficiency of BDP as considered 
using deionised water as dispersion medium was around 98% for all formulations. This 
indicated no significant (p˃0.05) difference between liposomes and chitosmes. Thus, 
increasing chitosan to lipid ratio did not affect the entrapment efficiency of BDP in 
deionised water. 
However, in D2O liposomes or chitosomes were suspended as a creamy layers at the top 
of the eppendorf tube with no BDP crystals (Figure 5.25b) and the un-entrapped BDP 
crystals were accumulated like a spot at the bottom of the eppendorf tube (Figure 
5.25a). Therefore, the entrapment efficiency of BDP as determined using D2O was 
completely different from that in deionised water. D2O made the vesicles to be 
suspended at the top whilst BDP crystals sedemented at the bottom of eppendorf as un-
entrapped part. The middle part (un-entrapped BDP) was found to contain less of BDP 
crystals. Therefore, the spot contained most of the un-entrapped BDP.  
As seen in Figure 5.26, the entrapment efficiency of chitosomes (BDP-10, BDP-20, 
BDP-30 and BDP-50) was significantly higher (p˂0.05) than liposomes (BDP-0), with 
no significant differences between chitosome formulations (p˃0.05). Coating liposome 
with chitosan was found to increase the entrapment efficiency of drugs (Zaru et al., 
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2009; Albasarah et al., 2010; Karn et al., 2011). It was observed that the sediment spot 
contained most of the drug when using the liposome formulation (BDP-0). This higher 
amount of un-entrapped drug at the sediment is possibly attributed to the incompatible 
steric fit of the steroid in the bilayers (Shaw et al., 1976; Radhakrishnan, 1991). 
Furthermore, the amount of lipid recovered after spray-drying was higher for 
chitosomes compared to liposome as confirmed earlier by the Stewart phospholipid 
assay (Table 5.7), confirms the advantages of chitosomes over liposomes. 
 
 
Figure 5.26: Entrapment efficiency (%) of beclomethason dipropionate formulations. Data 
are mean ± STD, n=3. 
 
5.2.13 In vitro powder aerosolisation and particle deposition studies 
The effects of chitosan to lipid ratio and physical characteristics of the drug (SS and 
BDP) on the aerosolisations properties were studied to optimise their respirable 
fractions. Proliposome and prochitosom dry powders were produced using spray-drying. 
Therefore, the TSI was used to study the aerodynamic aerosol properties of the dry 
powder formulations. 
The recovered dose (RD) (the total amount of drug deposited in the inhaler device, and 
stage 1 and stage 2 of TSI), emitted dose (ED) (the amount of drug deposited in stage 1 
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and 2 of TSI) and the fine particle fraction (FPF) (the percentage of RD deposited in 
stage 2) (section 2.2.15) of each formulation were determined by HPLC. 
Figure 5.27 and Figure 5.28 show the high RD% (˃95%) of spray-dried powders for all 
formulations containing SS or BDP, suggesting high fluidisation capabilities of theses 
powders at 60 l/min. These findings can be attributed to the small, spherical and porous 
nature of the formulations (Figure 5.5 & Figure 5.6) and thus the appropriate flow 
properties of the spray-dried particles. No significant differences (p˃0.05) between 
proliposomes and prochitosomes were found with regard to the powder fraction left in 
the capsule and this was independent of drug type (i.e. SS or BDP).  
ED (%) of the powders is shown in Figure 5.27 and Figure 5.28 for SS and BDP 
formulations respectively. Formulations exhibited excellent aerosolisation properties in 
the TSI with emitted dose exceeding 80% and respirable fractions were as high as 70% 
for all SS and BDP formulations. The high amount of emitted drug dose can be 
attributed to the appropriate composition and good flow properties of the spray-dried 
powder.   
Figure 5.27 and Figure 5.28 show the deposition patterns of SS and BDP proliposome 
and prochitosome formulations respectively. Clear variation in aerosolisation efficiency 
(e.g. FPF%) were observed amongst formulations (Figure 5.27; Figure 5.28). This is 
possibly a reflection of the use of chitosan as a dispersibility enhancer (Makhlof et al., 
2010; Kundawala, 2011). 
However, incorporation of chitosan in lipid formulations improved the particle 
aerosolisation and the drug deposition in the lower stage of TSI (FPF) (Figure 5.27 & 
Figure 5.28). Thus, it seems that the prochitosome formulations of SS-10(30), SS-
10(50), BDP-30 and BDP-50 are most appropriate as they have the highest deposition 
profiles in the lower impinger stage. The FPF values were 58.12±2.86%, 70.25±2.61%, 
61.89±9.04% and 61.56±3.13% for SS-10(30), SS-10(50), BDP-30 and BDP-50 
respectively. In contrast, the FPF values were 52.18±0.88%, 51.65±1.79%, 
53.29±1.52%, 53.81±3.36%, 57.76±0.02% and 54.66±2.79% for SS-10(0), SS-10(10), 
SS-10(20), BDP-0, BDP-10 and BDP-20 respectively. The high FPF of formulations 
achieved upon using high chitosan ratios can be attributed to the ability of chitosan to 
reduce the inter-particulate cohesion, resulting in improved dispersibility of the powders 
and enhanced aerosol performance. This is in agreement with the previous reports of Li 
and Birchall (2006) and Kundawala (2011). The low FPF of proliposome or 
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prochitosome with low amount of chitosan can be attributed to particle-sticking and 
high cohesiveness (Pilcer et al., 2006).  
The FPF results are in accordance with Carr's index values, since these values decreased 
with increasing chitosan ratio (Table 5.5). In fact, increasing chitosan content of the 
prochitosome formulations to maximum chitosan to lipid ratio (SS-10(30), SS-10(50), 
BDP-30 and BDP-50) has reduced particle agglomeration, and consequently 
demonstrated high FPF values (Figure 5.27 & Figure 5.28). Carr's index values of less 
than 25 indicate good flow properties, while values above 40 indicate poor powder 
flowability. Table 5.5 illustrated lower Carr's index values for SS-10(30), SS-10(50), 
and BDP-30 and BDP-50 formulations. On the other hand, the results showed that all 
the formulations having Carr's index values below 40, were potentially appropriate for 
deep lung inhalation as demonstrated by the high FPF values (Figure 5.27 & Figure 
5.28). 
 
 
Figure 5.27: Percent of salbutamol sulphate powder formulations deposited at different 
stages of the Two-stage impinger. Data are mean ± STD, n=3. 
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Figure 5.28: Percent of beclomethason dipropionate powder formulations deposited at 
different stages of the Two-stage impinger. Data are mean ± STD, n=3. 
 
5.2.14 Nebulisation studies 
The nebulisation time for SS or BDP liposomes and chitosomes was also investigated in 
this study using the Pari Turbo Boy air-jet nebuliser. Kendrick et al. (1997) studied the 
importance of the time consumed to deliver nebulised drug on patient compliance. As 
demonstrated in Figure 5.29, the time required for nebulisation of various SS and BDP 
formulations were shorter than nebulisation time of deionised water (P˂0.05). The 
nebulisation time of SS-10(0), SS-10(10) and SS-10(20) were similar (P˃0.05), and the 
time needed for nebulisation of SS-10(30) and SS-10(50) were shorter than that for SS-
10(0), SS-10(10) and SS-10(20) (P˂0.05). The shorter time of nebulisation of liposomal 
or chitosomal formulations compared to deionised water, could be attributed to the 
properties of liposomal or chitosomal dispersions. Previous reports have shown that 
reduction in surface tension as a result of phospholipid incorporation could enhance the 
nebulised aerosol performance (Ghazanfari et al., 2007; Elhissi et al., 2013). Thus, the 
shorter nebulisation time for liposomes or chitosomes compared to deionized water 
could be attributed to presence of lipid. Further investigations are needed to explore the 
validity of this assumption.  
Figure 5.29 shows that for all BDP formulations the nebulisation time of liposomes was 
longer than that of chitosomes. The shorter nebulisation time of chitosomes compared to 
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liposomes is possibly due to their smaller size of vesicles when chitosome formulation 
was used. Bridges and Taylor, (2000) and Gaspar et al., (2008) found that increasing 
vesicle size may reduce the rate of nebulisation (i.e. prolong nebulisation time). 
Furthermore, the nebulisation time of BDP chitosomes was slightly (P˂0.05) shorter 
than SS-chitosomes (Figure 5.29), which might be due to the slightly smaller size of 
aerosol droplets for BDP-chitosome compared to SS-chitosome, as confirmed by the 
laser diffraction study (Figure 5.32). 
 
 
Figure 5.29: Nebulisation time of salbutamol sulphate and beclomethason dipropionate 
liposome and chitosome formulations. Data are mean ± STD, n=3. 
 
Despite the fact that nebulisation was carried out to ―dryness‖, nebulisation does not 
result in complete atomisation of the formulation, hence, mass output does not reach 
100% (i.e. some liquid remains as a dead or residual volume within the nebuliser) (Clay 
et al., 1983; Bridges; Taylor, 2000; Manca et al., 2012). In this study, the effect of 
different formulation on the mass output and drug output was investigated.  
Figure 5.30 demonstrated that mass output was slightely different for different SS or 
BDP liposome or chitosome formulations (around 80% for all formulations). Bridges 
and Taylor (2000) showed that the mass output of liposomes was less than 80% using 
an old design of the Pari-LC nebuliser. In contrast, in a recent study using modern 
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design of the pari nebuliser, Albasarah et al. (2010) have reported that the mass output 
of liposomes or liposomes coated chitosan exceeded 90%.  
 
 
Figure 5.30: Mass output (%) of salbutamol sulphate and beclomethason dipropionate 
liposome and chitosome formulations. Data are mean ± STD, n=3. 
 
In addition to nebulisation time and total formulation mass output, the drug output for 
SS and BDP formulations was investigated. Figure 5.31, displayed no significant 
differences amongst either SS or BDP formulations (P˃0.05). In contrast, the drug 
output using SS was higher than output using BDP (P˂0.05). The low drug output of 
BDP formulation might be due to fusion or aggregation of vesicles, due to the high 
shearing force within the nebuliser (Elhissi et al., 2006; Elhissi et al., 2007). 
Furthermore, SS and BDP output in all cases were lower than that total mass output 
(Figure 5.30 and 5.31). This is agreement with Albasarah et al. (2010) who found that 
amphotercin B output was less than total mass output using Pari-LC air jet nebuliser. 
This effect has also been reported previously for air-jet nebulisers, as there is 
preferential loss of solvent vapor during atomisation (Ferron et al., 1976). 
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Figure 5.31: Drug output (%) of salbutamol sulphate and beclomethason dipropionate 
liposome and chitosome formulations.  Data are mean ± STD, n=3. 
 
In the present study, the effect of using the different chitosan to lipid ratios on the 
nebulised droplet size distribution of the generated aerosols using SS and BDP was 
investigated. Figure 5.32, shows the aerosol size of SS and BDP formulations as 
measured using the Spraytec laser diffraction instrument. 
Figure 5.32 shows that the sizes of aerosol droplets for liposomes were similar (P˃0.05) 
to chitosome aerosols droplets regardless of drug type. Spraytec results showed that the 
VMD aerosol droplets were below 5.4 µm for all formulations, which suggested that the 
aerosolised drugs are likely to be delivered in high in ―respirable fractions‖ (Dolovich et 
al., 2005; O‘Callaghan and Barry, 1997). The Span values of liposome formulations 
were found to be slightly but insignificantly higher (P˃0.05) than those of aerosolised 
chitosome formulations, regardless of drug type (Figure 5.33); however, it is worth to 
note that the standard deviation values were high.  
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Figure 5.32: Aerosol droplet size of salbutamol sulphate and beclomethason dipropionate 
liposome and chitosome formulations.  Data are mean ± STD, n=3. 
 
 
Figure 5.33: Span of salbutamol salphate and beclomethason dipropionate liposome and 
chitosome formulations.  Data are mean ± STD, n=3. 
 
The effect of chitosan to lipid ratio on the deposition profile of nebulised drug in the 
TSI was investigated. SS and BDP liposomes or chitosomes were successfully delivered 
to the impinger. All SS formulations showed high drug proportions delivered to the 
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38.01±7.32%, 40.93±2.85%, 36.73±9.63%, 42.93±2.02% and 41.73±1.25 for SS-10(0), 
SS-10(10), SS-10(20), SS-10(30) and SS-10(50) formulations respectively, with a 
statistically no significant difference (P˃0.05) between the formulations. In contrast, SS 
proportion delivered to the upper stage was lower, being 31.84±9.51%, 32.39±6.98%, 
34.34±5.45%, 22.63±2.38% and 26.71±3.79% for SS-10(0), SS-10(10), SS-10(20), SS-
10(30) and SS-10(50) formulations respectively. Furthermore, for drugs remained 
undelivered in the nebuliser the values were similar to those of the upper, being 
28.03±2.97%, 26.67±7.51%, 28.91±4.17%, 34.46±2.02% and 31.55±3.17% for SS-
10(0), SS-10(10), SS-10(20), SS-10(30) and SS-10(50) respectively. 
 
 
Figure 5.34: Drug deposition (%) of salbutamol sulphate liposome and chitosome 
formulations.  Data are mean ± STD, n=3. 
 
In contrast, BDP formulations provided much lower BDP output compared to SS 
formulations (Figure 5.35) and subsequently low BDP deposition with high variability 
in the lower stage of the impinger was observed. BDP delivery to the lower stage was 
19.19±10.05%, 29.02±8.82%, 23.33±4.94%, 33.52±7.88% and 29.53±4.19% for BDP-
0, BDP-10, BDP-20, BDP-30 and BDP-50 respectively, with no significant difference 
(P˃0.05) between the formulations. The fraction of BDP delivered to upper stage was 
31.11±3.18%, 25.77±6.52%, 24.61±2.43%, 21.53±3.7% and 26.49±1.57% for BDP-0, 
BDP-10, BDP-20, BDP-30 and BDP-50 respectively, with no significant difference 
(P˃0.05) between the formulations. In contrast, the fraction of BDP left in the reservoir 
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was relatively high, being 51.52±4.04%, 45.21±13.01%, 52.04±7.37%, 44.94±8.4% and 
44.05±5.85% for BDP-0, BDP-10, BDP-20, BDP-30 and BDP-50 respectively, with no 
significant difference (P˃0.05) among the formulations (Figure 5.35). 
 
 
Figure 5.35: Drug deposition of beclomethason dipropionate liposome and chitosome 
formulations.  Data are mean ± STD, n=3. 
 
The proportion of drug (especially) BDP delivered to the lower stage was slightly 
higher (P˃0.05) for chitosomes compared to liposomes (Figure 5.36), which can be 
attributed to the larger aerosol droplet size for liposome, as displayed by laser 
diffraction (Figure 5.32). These findings  agree with Albasarah et al. (2010), who 
demonstrated that the fraction of amphotercin B delivered to the lower impinger was 
slightly higher with chitosan-coated liposomes compared to liposomes.  
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Figure 5.36: Fine particle fraction of salbutamol sulphate and beclomethason dipropionate 
liposome and chitosome formulations using a Two-stage impinger. Data are mean ± STD, 
n=3. 
 
The FPF output relative to the total drug output results was also determined in this study 
for the different liposome or chitosome formulations of SS and BDP. Figure 5.37 
demonstrate that no significant differences (P˃0.05) between FPF output analyzed by 
Spraytec and FPF obtained from TSI for all formulations. Furthermore, The FPF output 
of SS slightly higher than BDP formulations (P˃0.05). This can be ascribed to the lower 
BDP output compared to SS formulations (Figure 4.35) and subsequently lower FPF of 
the steroid.  
 
Figure 5.37: Fine particle fraction output of salbutamol sulphate and beclomethason 
dipropionate liposome and chitosome formulations using spraytec. Data are mean ± STD, 
n=3. 
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5.4 Conclusions 
This study has shown that spray-drying was appropriate to produce novel mucoadhesive 
prochitosome formulations that upon hydration generated chitosomes incorporating SS 
(10 and 20 mg) and BDP. The size, shape and density of spray-dried particles suggest 
suitability of the formulations for deep lung deposition. The intensity peak of XRDP 
and FTIR, for all data obtained indicated the occurance of interaction between different 
components of the of spray-dried proliposome or prochitosome formulations. Tapped 
density values were less than 0.4 g/cm
3
 for all formulations and Carr‘s index values 
were less than 40%, indicating that all formulations have acceptable flow properties 
particularly those containing high chitosan concentrations. Particles prepared by spray-
drying were small, spherical, porous and presented very high FPF, particularly when 
increasing chitosan concentration. Due to the particle properties, good flowability was 
observed, making powders potentially very suitable for delivery into deep lung as dry 
powder inhaler formulations.  
The results from this chapter confirmed the superiority of prochitosomes and 
chitosomes over proliposome and liposome formulations. The incorporation of the 
mucoadhesive agent chitosan into liposome formulation was established. Chitosomes 
was observed to significantly increase the positive charge of liposomes. The 
mucoadhesive properties of liposomes increased with increasing chitosan ratio, and the 
size of vesicles decreased slightly with increasing chitosan ratio.  
The validity of liposomes or chitosomes via spray-drying method for the entrapment of 
different drug molecules such as SS and BDP was also demonstrated in this study. The 
drug entrapment efficiency using chitosomes was significantly higher than liposomes, 
with only slight differences in drug entrapment efficiency when the different chitosome 
formulations were compared. Moreover, the entrapment efficiency of SS decreased 
significantly after increasing the amount of drug, whilst the entrapment efficiency of 
BDP was higher than that of SS.  The effect of centrifugation speed and time for 
separation of BDP crystals was also evaluated, and in light of the findings using D2O 
the centrifugation speed of 13,000 rpm for 90 min was chosen as optimal for separation 
of unentrapped BDP and subsequent determination of the drug entrapment efficiency. 
The results from this study have demonstrated that formulations containing different 
chitosan concentrations varied in their nebulization performance. Moreover, marked 
differences existed in the nebulization time, drug output, mass output and FPF values 
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between different formulations. In addition to different chitosan concentrations, the 
nature of drug was found to affect the performance of the nebulisers. However, the 
results from this study have demonstrated that nebulisation time of chitosomes was 
shorter than that of deionized water and liposomes, particularly with increasing chitosan 
ratio. No significant differences were detected amongst either SS formulations or BDP 
formulations mass output. The drug output of SS formulations was higher than that of 
BDP formulations. FPF of SS containing formulations were slightly higher than that of 
BDP formulations. 
Overall, the validity of the spray-drying method for the generation of suitable 
prochitosome powders that are able to deliver hydrophilic or hydrophobic drugs was 
established. Moreover, optimal parameters for the production of powders and their 
characterization after hydration were elucidated. 
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6.1 Introduction 
The use of liposomes in drug delivery offers many advantages, mainly because they are 
composed of naturally occurring lipids, making them biocompatible, biodegradable and 
non-immunogenic. The various methods of liposome preparation give rise to vesicles of 
different size and morphology (Gregoriadis, 1993, Basu and Basu, 2002, Weissig, 2010). 
Solvent-based proliposomes, also referred to as alcohol-based proliposomes or ethanol-
based proliposomes were first introduced by Perrett et al., (1991). This is an alternative 
method to particulate-based proliposomes which generate a mixture of OLVs and MLVs 
upon addition of aqueous phase above Tm of the lipid employed (Gregoriadis, 1993; Elhissi 
et al., 2006). High entrapment efficiency was reported for hydrophilic drugs encapsulated 
in liposomes prepared via the solvent-based proliposome method in the range between 65 
and 80%, depending on the lipid composition of the proliposomes (Perrett et al., 1991).   
Liposomes have relatively low physiochemical stability in solution, hence to solve this 
problem liposomes are manufactured as dry powders (Lo et al., 2004; Wessman et al., 
2010). Spray-drying have therefore been employed to stabilize liposomes during storage 
(Lo et al., 2004, Rojanarat et al., 2012, Ingvarsson et al., 2013). However, low dry yield is 
expected due to the high drying temperature of the spray drier and low phase transition 
temperature of the lipid. In order to protect liposomes during drying, lyoprotectants might 
be used. Carbohydrates, such as trehalose, glucose, lactose, mannitol and sorbitol (Crowe 
and Crowe, 1988; Hincha and Hagemann, 2004; Hinrichs et al., 2005; Lu and Hickey, 
2005) are commonly used stabilisers during drying processes, because they are generally 
safe, and can stabilise sensitive structures such as proteins and liposomes (Bosquillon et al., 
2001).  
Preparation of dry powder formulations for inhalation is an attractive approach because 
drug solubility and stability can be improved. Further advantages are low susceptibility of 
dry powder to microbial growth and suitability of dry powder formulations for delivery 
using hydrophilic or hydrophobic drugs (Irngartinger et al., 2004). 
Recently soluble and particulate carriers based on chitosan and its derivatives have attracted 
enormous interest for delivery of therapeutic drugs and proteins via mucosal routes 
(Hamman et al., 2003; Amidi et al., 2006; Mao et al., 2006). Due to its mucoadhesive 
properties, controlled release properties, permeation-enhancing effect and ability to open 
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tight junctions between epithelial cell, chitosan is a promising material for various drug 
delivery systems (Vila et al., 2004; Bowman and Leong, 2006; Chopra et al., 2006; Mao et 
al., 2006). 
Chitosomes are liposomes coated with chitosan, which combine the advantages of 
liposomes and chitosan (Takeuchi et al., 1996; Manca et al., 2012). The mucoadhesive 
properties of chitosan are due to the molecular attractive forces formed by the electrostatic 
interaction between positively charged chitosan and negatively charged mucosal surfaces 
(Takeuchi et al., 1996; Takeuchi et al., 2005). 
In this chapter, liposome and chitosome powders have been developed using ethanol-based 
proliposome method. The resultant liposome or chitosome dispersions including various 
carriers (mannitol, LMH, trehalose or sucrose) were spray-dried and the suitability of the 
powders for pulmonary delivery was evaluated. Moreover, this study was conducted to 
improve the entrapment efficiency of SS, since the entrapment values obtained using 
prochitosomes was relatively low. 
Liposomes and chitosomes before and after spray-drying were characterized for size, 
surface charge, mucoadhesion properties, drug entrapment efficiency. The spray dried 
powder was studied in terms of production yield, lipid recovery, morphology, crystallinity 
and in vitro performance for delivery using TSI and NGI. 
 
6.2 Methodology 
 
6.2.1 Production of liposomes and chitosomes using spray-drying  
Lipid (SPC and CH in a molar ratio of 1:1) were weighed (100 mg) and dissolved in 
absolute ethanol (120 mg) at 70°C. SS (10 mg) was dissolved in deionised water and 0.5 
mL was added quickly to the lipid solution followed by vortex mixing to generate 
concentrated liposomes. The dispersions were then further diluted to 10 mL with deionised 
water including carriers (mannitol, lactose monohydrate, trehalose or sucrose) in 1:6 w/w 
lipids to carrier ratio. Chitosomes were prepared by adding chitosan glutamate (3:10 w/w 
polymer to lipid ratio). Liposomes or chitosomes were spray˗dried using B-290 Buchi mini 
spray dryer. The inlet temperature was 120°C and spray flow rate was 600 L/h, with a feed 
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rate of 11%, and the outlet temperature was 73 ± 3°C. Spray-dried powder was transferred 
from the collecting chamber into a desiccator for storage before use further 
characterisation. 
 
6.3 Results and Discusion 
 
6.3.1 Liposome and chitosome characterisation 
Dry liposomes or chitosomes powders were prepared for inhalation using the ethanol based 
proliposome method and spray-drying and parameters were optimised to design 
formulations for deep lung delivery using dry powder inhaler devices. Chitosomes were 
prepared by incorporating chitosan and lipid in 3:10 w/w ratio. In order to make the 
formulation more stable and resistant to high temperature in the spray drying chamber, 
cholestrol was incorporated. Carriers (mannito, LMH, trehalose or sucrose) were 
incorporated within formulations to determine which cryoprotectant could provide the 
greatest chemical and physical stability to formulations.  
Non-carrier based liposomes and chitosomes were prepared, which are referred to as NC-L 
and NC-C respectively (Table 6.1). Liposomes were prepared with different carriers 
(mannitol, LMH, trehalose or sucrose), which are referred to as M, L, T and S respectively 
(Table 6.1). Chitosomes were prepared with different carriers (mannitol, LMH, trehalose or 
sucrose), which are referred to as MC, LC, TC and SC respectively (Table 6.1).  
SS was used as a model drug in this chapter and the effects of incorporating chitosan and 
various carriers on production yield, powder density, particle morphology, particle 
crystallinity and drug deposition profile in TSI or NGI were investigated. After rehydration 
of the spray dried particles, the surface charge, mucoadhesive properties, vesicle size, drug 
entrapment efficiency, and lipid recovery were all studied for liposomes and chitosomes. 
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Table 6.1: Composition of liposome and chitosome formulations. 
  
* NC-L: Non-carrier based liposomes, NC-C: non-carrier based chitosomes. All other formulations contain 
carrier: (M: mannitol-based liposomes, L: lactose-based liposomes, T: trehalose-based liposomes, S: sucrose-
based liposomes, MC: mannitol-based chitosomes, LC: lactose-based chitosomes, TC: trehalose-based 
chitosomes, SC: sucrose-based chitosomes). 
 
6.3.2 Production yield and drug content uniformity of spray-dried powders 
Spray-drying of liposomes and chitosomes after incorporation of various carriers (mannitol, 
LMH, trehalose or sucrose) which were selected because of their safety, and ability to 
stabilise delicate structures such as proteins and liposomes (Bosquillon et al., 2001). 
Liposome (NC-L) and Chitosome (NC-C) spray-dried (i.e. in absence of carrier) resulted in 
no yield (i.e. yield was 0.0 %). This may be due to the sticky nature of lipid, causing the 
particles to deposit in the dryer chamber of the drier (Table 6.2). 
As shown in Table 6.2, the production yield of liposomes and chitosomes containing 
trehalose or LMH was significantly higher (p˂0.05) than formulations containing sucrose 
or mannitol, with the yield being in the following order: trehalose ꞊ LMH ˃ sucrose ˃ 
mannitol. Furthermore, the production yields of sucrose-based liposomes and chitosomes 
were higher (p˂0.05) than those of mannitol. The difference in production yield might be 
due to the difference in the melting point of the carriers. The melting point of the carriers 
were in the following order trehalose (203 ºC) = LMH (202.8 ºC) ˃ sucrose (186 ºC) ˃ 
mannitol (165 – 169 ºC). Hence, spray-drying of sugars having lower melting point can 
Formulation
*
 
Lipid 
 (SPC:CH 1:1) (mg) 
Carrier weight 
(mg) 
Carrier 
type 
Chitosan 
(mg) 
SS 
 (mg) 
NC-L 100  - 0 10 
NC-C 100  - 30 10 
      
M 100 600 Mannitol 0 10 
L 100 600 LMH 0 10 
T 100 600 Trehalose 0 10 
S 100 600 Sucrose 0 10 
      
MC 100 600 Mannitol 30 10 
LC 100 600 LMH 30 10 
TC 100 600 Trehalose 30 10 
SC 100 600 Sucrose 30 10 
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make them sticky with subsequent tendency to adhere to the drying chamber during spray-
drying, resulting in decline of production yield. The production yield of chitosomes was 
similar to that of liposomes regardless of formulation composition (Table 6.2).  
As shown in Table 6.2, the drug content uniformity for all carrier-containing formulations 
was desirable (ranging between 86 - 106 %), indicating that spray-drying is appropriate for 
the production of particle with uniform drug distribution in the powder bulk. The drug 
content uniformity in mannitol-based formulations was higher than (p˂0.5) formulations 
containing other carriers. This is because of the lower production yields of mannito-based 
formulations following spray-drying (Table 6.2). Moreover, no significant differences 
(p>0.05) were observed between the drug content uniformity of LMH, trehalose and 
sucrose-based formulations. The drug content uniformity of liposomes was slightly higher 
than chitosomes because of the lower production yield of liposomes compared to 
chitosomes. 
Table 6.2: Production yield and drug content uniformity of spray-dried liposome and 
chitosome formulations. Data are mean ± STD, n=3. 
 
 
6.3.3 Particle surface morphology 
The surface morphology and size of various cryoprotectant powders before spray-drying 
were studied using SEM and compared with spray-dried liposomes and chitosomes 
(Figures 6.1 - 6.3). SEM images showed that the carriers had irregular shape, rough surface 
Formulations 
Production yield  
(%) 
Drug content uniformity  
(%) 
NC-L 0.00±0.00 0.00±0.00 
NC-C 0.00±0.00 0.00±0.00 
   
M 52.00±1.25 106.00±2.67 
L 62.00±2.00 91.20±3.14 
T 63.30±1.52 93.50±2.30 
S 56.30±0.57 93.89±1.10 
   
MC 53.30±1.04 97.63±3.60 
LC 63.27±1.25 86.30±1.52 
TC 64.50±1.32 87.00±1.73 
SC 57.30±1.52 92.20±2.30 
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and were relatively large before spray-drying. By contrast, after incorporation into 
liposome or chitosome formulations and spray-drying, particles became spherical, regular 
in shape and smaller in size, indicating the potential suitability of the resultant liposome 
and chitosome powders for deep lungs inhalation (Yu and Chien, 1997; Schulz, 1998; 
Thami Sebti, 2006). 
 
   
   
Figure 6.1: SEM images of carriers before spray-drying (a) mannitol (b) lactose monohydrate 
(c) trehalose and (d) sucrose (magnification was 400x). 
 
The morphologies of spray-dried liposome and chitosome particles were primarily 
dependent on the type of carrier and the differences in morphologies were clearly evident 
(Figure 6.2 & Figure 6.3). Generally, spray-dried particles were apparently smooth and 
spherical for all formulations. For spray-dried mannitol-based liposomes, small and 
a 
c d 
b 
CHAPTER 6 
 
154 
 
spherical particles with high tendency of agglomeration were obtained with some tiny 
particles (less than 1 µm) adhering to the surfaces of the large aggregated particles, due to 
the sticky nature of lipid on the surface of particles. These observations agree with previous 
studies (Alves and Santana, 2004; Rojanarat et al., 2011). The particles were in the size 
range of approx 1-7 µm (Figure 6.2a). Larger particles with less tendency of agglomeration 
were obtained when chitosan was incorporated in formulation. The particles were most 
homogeneous when mannitol was used with chitosomes (Figure 6.3a). The relatively large 
particle size of spray-dried chitosomes was probably due to the high solution viscosity of 
the droplet size atomized. Generally, the mean size of droplets formed by atomization 
increases as liquid viscosity and surface tension increase. Hence physicochemical 
properties of the liquid may influence the properties of the final spray-dried powder 
significantly. Wang and Wang (2008) also reported that solutions with lower viscosities 
might be atomised into smaller droplets during spray-drying. 
SEM images showed that LMH and trehalose-based particles were spherical and more 
regular in shape than mannitol-based particles. As shown in Figure 6.2b, c & Figure 6.3b, c, 
the size of discrete dried liposomes was smaller but formed very large agglomerates 
compared to chitosomes when LMH or trehalose were used as carriers. Compared to 
liposomes, the lower tendency for agglomeration by chitosome particles might be attributed 
to the repulsive forces between the particles due to the positive charge of chitosan or 
possibly the formation of a polymeric coat on the surface of the particles. Previous studies 
have shown that size of the dried particles is inversely related to their cohesiveness 
(Rasenack and Müller, 2004; Steckel and Brandes, 2004). 
Although the discrete particles were spherical and smooth when sucrose was used as 
carrier, the spray-dried particles formed massive agglomerates, owing to the hygroscopic 
nature of sucrose as reported by previous studies (Lo et al., 2004; Jovanović et al., 2006). 
Figure 6.2d & Figure 6.3d are SEM images for sucrose-based liposome and chitosome 
powders respectively. As with other carriers, when sucrose was used, the tendency of 
particle agglomeration was less for chitosomes compared to liposomes.  
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Figure 6.2: SEM images of spray-dried liposomes with (a) mannitol (b) lactose monohydrate 
(c) trehalose and (d) sucrose (magnification was 6000x). Composition of the formulations is 
presented in Table 6.1. 
 
a 
d c 
b 
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Figure 6.3: SEM images of spray-dried chitosomes with (a) mannitol (b) lactose monohydrate 
(c) trehalose and (d) sucrose (magnification was 6000x). Composition of the formulations is 
presented in Table 6.1. 
 
6.3.4 Crystallinity of spray-dried particles 
The characteristics of spray-dried liposomes and chitosome with various carriers were 
assessed using XRPD. As shown in Figure 5.8, chitosan before or after spray-drying was 
amorphous, this was evident by the amorphous halo in the XRPD, and comes in agreement 
with Corrigan et al. (2006) and Naikwade et al. (2009), who reported that chitosan is an 
amorphous material regardless of spray-drying.  
b 
d c 
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The XRPD of mannitol, LMH, trehalose and sucrose before spray-drying are shown in 
Figure 6.4. The presence of sharp diffraction peaks in the XRPD for all carrier row 
materials indicate their crystallinity. 
 
   
  
Figure 6.4: X-ray diffraction patterns of crystalline carrier raw materials before spray-
drying: (a) mannitol (b) lactose monohydrate (c) trehalose and (d) sucrose . 
 
XRPD patterns of spray-dried mannitol-based liposomes (Figure 6.5a) show that spray-
drying did not completely abolish the crystalline nature of mannitol but caused reduction in 
the intensity of peaks.  Ingvarsson et al. (2013) have also found that spray-dried mannitol-
based liposomes were highly crystalline. The change in the intensity of XRPD of spray-
dried liposomes compared to mannitol alone is an indicating of an interactions occurred 
between different components in the spray-dried liposome formulations, agreeing with the 
finding of Rojanarat et al. (2011). The X-ray of mannitol-based chitosomes showed slight 
changes in the peak intensity due to the coating of liposome surface with chitosan (Figure 
6.6a). 
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Figure 6.5: X-ray diffraction patterns of carrier-based liposomes using: (a) mannitol (b) 
lactose monohydrate (c) trehalose and (d) sucrose as carriers. Composition of the 
formulations is presented in Table 6.1. 
 
Unlike the mannitol carrier, when spray-drying of vesicles took place using LMH, trehalose 
or sucrose-based as carriers the resultant powders were highly amorphous, which is evident 
by the wide-angle X-ray diffractograms showing the typical amorphous halo. This finding 
is in agreement with Ingvarsson et al. (2013) using LMH or trehalose-based liposome 
powders. Elamin et al. (1995) have also reported that sucrose and LMH changed from 
crystalline to amorphous upon spray-drying. The XRPD showed that spray-dried LMH, 
trehalose and sucrose-based chitosomes were similar to liposomes but with slight changes 
in the intensity of peaks. Compared to crystalline pharmaceutical material, the high internal 
energy and specific volume of the corresponding amorphous form can enhance material 
dispersion properties and hydration characteristics in vitro and possibly in vivo within the 
aqueous milieu of the lung (Hancock and Zografi, 1997).  
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Figure 6.6: X-ray diffraction patterns of carrier-based chitosomes using: (a) mannitol (b) 
lactose monohydrate (c) trehalose and (d) sucrose as carriers. Composition of the 
formulations is presented in Table 6.1. 
 
6.3.5 Lipid recovery  
The amount of lipid recovered after spray-drying was investigated using the Stewart assay 
(Stewart, 1980) to quantify the recovered proportion of phospholipid in the spray-dried 
powder with relevance to the original amount of phospholipid used prior to spray-drying 
(section 2.2.9). In this study, since spray-drying parameters for all formulations and the 
originally used phospholipid contents were similar, the difference in the percentage of lipid 
recovery was attributed to the different types of carriers or to the inclusion of chitosan.  
Lipid recovery was 0.0 % when liposomes (NC-L) and chitosomes (NC-C) were spray-
dried in absence of carriers (Table 6.3) since all materials spray-dried have deposited in the 
internal structures of the drier rather than the collecting chamber. This can be attributed to 
the low Tm and sticky nature of lipid. The inclusion of carriers enhanced the lipid recovery. 
As shown in Table 6.3, the percentage of lipid recovery for LMH and trehalose-based 
formulations were significantly higher (p˂0.05) than that using mannitol or sucrose-based 
formulations. Differences in lipid recovery among various formulations might be ascribed 
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to differences in the melting point of various carriers. The higher lipid recovery of trehalose 
and LMH-based formulations than sucrose and mannitol-based formulations might be due 
to lower melting point of later formulations which made them more sticky with subsequent 
propensity for adherence to the drying chambers during spray-drying. No significant 
differences (p˃0.05) were observed between mannitol and sucrose-based formulations or 
between LMH and trehalose-based liposomes and chitosomes. 
Lipid recovery was higher (p˂0.05) for chitosan-coated liposomes, regardless of the carrier 
type due to the reduced surface stickiness of the dried particles upon coating with chitosan 
and hence the lipid was protected from the high temperature of spray-drying. However, The 
amount of lipid recovery was highest when trehalose was used as carrier, agreeing with 
previous studies that reported that trehalose prevented fusion and leakage of liposomes 
during spray-drying (Crowe et al., 1996, Tsvetkova et al., 1998).  
 
Table 6.3: Lipid recovery of spray-dried liposome and chitosome formulations using various 
carriers. Data are mean ± STD, n=3. 
   
 
 
 
 
 
 
 
 
 
 
          * Composition of the formulations is presented in Table 6.1. 
Formulations* 
Lipid recovery 
(%) 
NC-L 0.00±0.00 
NC-C 0.00±0.00 
  
M 78.00±2.00 
L 89.60±2.36 
T 92.32±1.56 
S 82.00±1.50 
  
MC 91.35±1.18 
LC 99.00±1.13 
TC 100.04±1.55 
SC 89.23±1.57 
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6.3.6 Transmission electron microscopy  
In order to visualise the morphology and confirm the formation of liposomes and 
chitosomes after hydration of spray-dried powders, TEM was used. Liposome dispersions 
generated from mannitol, trehalose or sucrose-based powders were spherically shaped 
oligolamellar vesicles (OLVs), whilst those generated from LMH-based liposomes were 
smaller, more aggregated, and were rich in elongated "worm-like" bilayer clusters (Figure 
6.7). This difference in morphology might be attributed to the difference in the solubility 
characteristics of the carriers.  
The high dissolution rate of mannitol, trehalose and sucrose may have affected the 
rehydration of the lipid phase, resulting in predomination of spherical OLVs. In contrast, 
the slower dissolution of LMH powders may have changed the hydration patterns of the 
phospholipid, resulting in predomination of the "worm like" clusters in LMH-based 
formulation. This is in agreements with Elhissi et al. (2012), who found that rotary 
evaporator made LMH-based proliposomes generated worm-like structures after manual 
dispersion, whilst sorbitol and sucrose-based proliposomes generated spherically shaped 
vesicles. 
As shown in Figure 6.8, the possible presence of chitosan coat on liposomes was visualised 
using TEM. Therefore, because of hydrophilicity of chitosan, the stained areas of chitosan-
coated liposomes corresponded to chitosan/dye complex was represented by a dark area 
surrounding the lipid bilayers (Wu et al., 2004). The chitosan coat surrounding the 
liposomes may indicate the attachment of the polymer to the lipid bilayer. 
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Figure 6.7: TEM images of spray-dried liposome (after hydration) containing: (a) mannitol, 
(b) lactose monohydrate, (c) trehalose and (d) sucrose were used as carriers. Composition of 
the formulations is presented in Table 6.1. 
  
 
a 
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Figure 6.8: TEM images of spray-dried chitosome (after hydration) containing: (a) mannitol, 
(b) lactose monohydrate, (c) trehalose and (d) sucrose were used as carriers. Composition of 
the formulations is presented in Table 6.1. 
 
 6.3.7 Zeta potential analysis 
As shown in Figure 6.9, the zeta potential of liposomes before spray-drying was not 
affected (p>0.05) by inclusion of carriers when compared to the non-carrier based 
liposomes (NC-L). By contrast, the zeta potential of chitosomes decreased significantly 
(p˂0.05) after incorporation of carriers when compared to the non-carrier based chitosome 
(NC-C). This decrease in surface charge of chitosomes indicates interaction between the 
carriers and the polymer. However, when the different carriers were compared, no 
significant differences (p>0.05) in zeta potential were observed prior to spray-drying 
(Figure 6.9). 
a 
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Figure 6.9 showed that no significant differences (p>0.05) in the zeta potential values were 
observed between liposomes with different carriers after spray-drying (i.e. all formulations 
had almost neutral surface charge). In contrast, the zeta potential of MC was significantly 
higher than LC, TC and SC, which might be attributed to the higher recovery of chitosan 
after spray-drying with MC formulation compared to LC, TC and SC. Zeta potential of 
vesicles, especially chitosomes increased after spray drying compared to the measurements 
conducted before spray-drying (Figure 6.9).  
The increase (p˂0.05) in the zeta potential by addition of chitosan before and after (Figure 
6.9) spray-drying might be attributed to the positive charge effects of chitosan on the 
surface charge (Davis, 1999, Zaru et al., 2009; Behera et al., 2011). The increase in the zeta 
potential of liposome after incorporation of chitosan indicates that chitosan has adsorbed 
onto the surface of liposome via electrostatic interaction between the slightly negative 
surface of liposomes and the positive charge moiety of the polymer (Guo et al., 2003; 
Takeuchi et al., 2005; Zaru et al., 2009) or via hydrogen bonding between the phospholipid 
headgroups in the liposome bilayers and the polysaccharide molecules of the chitosan 
(Perugini et al., 2000). 
Cationic liposomes have been reported to be beneficial for drug delivery as this property 
might prevent particle recognition by macrophages, thus the clearance rate of formulation 
from the body might be reduced, resulting in prolonged pharmacologic effects (Sharma and 
Sharma, 1997).  
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Figure 6.9: Zeta potential (mV) of liposomes and chitosomes before and after spray-drying. 
Data are mean ± STD, n=3. 
 
6.3.8 Mucoadhesion studies 
 
i) Analysis of mucoadhesive properties using UV-spectroscopy 
The importance of mucoadhesive properties of chitosan has been reported in several studies 
(Lehr et al., 1992; Illum et al., 1994; Lueßen et al., 1994; Fiebrig et al., 1995; Aspden et al., 
1996). The strong interaction between negatively charged mucin and possitvely charged 
chitosan has been proven (Robinson and Mlynek, 1995; He et al., 1998). It has also been 
shown that coating of chitosan on the surface of liposomes may improve the adsorption of 
formulation onto mucosal surfaces (Takeuchi et al., 1996). The mucoadhesive properties of 
spray-dried liposomes and chitosomes were investigated by dispersing the spray-dried 
powder in an aqueous mucin solution (explained in section 2.2.13).  
As shown in Figure 6.10, the amount of mucin adsorbed onto chitosomes was significantly 
higher (p˂0.05) compared to adsorption onto liposome surfaces. These results indicate that 
liposome surfaces have been coated with chitosan. These findings may also indicate that 
compared with liposomes, chitosomes have higher ability to bind with mucin. The 
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enhanced bioadhesive properties of liposomes when coated with chitosan polymer have 
been shown (Takeuchi et al., 1996; Zaru et al., 2009; Karn et al., 2011), carrier type did not 
significantly affect the mucin adsorption on the liposomes or chitosomes, possibly 
indicating that sugars were important mainly as carriers not as promoters of the bioadhesive 
properties. 
 
 
Figure 6.10: Mucin adsorbed (%) on the surface of spray-dried liposomes and chitosomes 
using UV-spectroscopy. Data are mean ± STD, n=3. 
 
ii) Analysis of mucoadhesive properties using zeta potential measurements  
Zeta potential was used for the determination of the adsorption of mucin onto the surfaces 
of rehydrated liposomes and chitosomes. The zeta potential of liposomal vesicles changed 
from neutral to negative after mixing with mucin solution before and after spray-drying 
(Figure 6.11), indicating that liposomes have interacted with mucin.  
Figure 6.11 shows that the zeta potential of chitosomes before and after spray-drying 
decreased significantly (p˂0.05) from higher positive shifted to lower positive surface 
charge. These results suggested that chitosomes had a high affinity for binding with mucin 
compared to liposomes, agreeing with previous studies (Galovic Rengel et al., 2002; 
Takeuchi et al., 2005; Zaru et al., 2009).  
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Figure 6.11: Mucoadhesive properties of liposomes and chitosomes before and after spray-
drying using zeta potential measurements. Data are mean ± STD, n=3. For composition refer 
to Table 6.1. 
 
6.3.9 Size analysis 
The mucoadhesive property of smaller size chitosomes is the result of chitosan coating, 
which may result in prolonged retention of the drug in the respiratory tract (Takeuchi et al., 
2005). In order to compare the protective ability of different carriers, the size and size 
distribution of liposomes and chitosomes with various cryoprotectants before and after 
spray-drying was investigated (Figure 6.12; Figure 6.13). 
As demonstrated in Figure 6.12, the size of non-carrier based liposome (NC-L) was 
significantly less than (p˂0.05) non-carrier based chitosomes (NC-C), indicating the 
presence of a polymer coat on the surface of liposomes. This finding was agree to previous 
studies; they reported that the size of liposome increased after coating its surface with 
chitosan (Filipović-Grcić et al., 2001; Guo et al., 2003; Wu et al., 2004; Kim et al., 2005).  
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The addition of carriers to the liposome and chitosome preparations before spray-drying 
showed a significant effect on the size and Span measurements. The results revealed no 
significant difference (p˃0.05) between the size of non-carrier based liposome (NC-L) and 
mannitol, LMH and trehalose-based liposomes before spray-drying. In contrast, the vesicles 
size of sucrose-based liposomes were significantly smaller than non-carrier based liposome 
(NC-L), which might be due to the high dissolution rate of sucrose or lower aggregation of 
sucrose-based vesicles as confirmed by the Span measurements (Figure 6.13).  
When different carriers were used before spray-drying in chitosome formulations (MC, LC, 
TC and SC) a marked effect on the size of chitosomal vesicles was observed (p˂0.05). The 
size of chitosomes in presence of carriers before spray-drying decreased significantly 
(p˂0.05) compared to the carrier-free chitosome formulation (NC-C). The decrease in 
vesicle size might be due to the hypertonic effect on chitosomes as a result of carrier 
inclusion, forcing water to move from inside to outside the vesicles, and hence decreased 
size was observed as a result of ―shrinkage‖ of the vesicles (Figure 6.13).  
The effect of different types of carrierss on the size and Span of liposomes and chitosomes 
vesicles after spray-drying are shown in Figure 6.12 and Figure 6.13 respectively. No 
significant differences (p˃0.05) were observed between the size of mannitol, LMH and 
trehalose-based liposomal vesicles, whilst the size of sucrose-based liposomes was higher 
(p˂0.05) than formulations incorporating other carriers. The large vesicles size of the 
sucrose containing formulations might be attributed to the higher aggregation of the 
vesicles. As demonstrated in Figure 6.12, the size of chitosomal vesicles (MC, LC, TC and 
SC) after spray-drying decreased significantly (p˂0.05) compared to liposomal vesicles (M, 
L, T and S) in all formulations. 
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Figure 6.12: Vesicle size of liposomes and chitosomes before and after spray-drying. Data are 
mean ± STD, n=3. 
 
Figure 6.13 elucidates the effect of various carriers on the Span value of liposomes and 
chitosomes before and after spray-drying. The Span values of vesicles before spray-drying 
were higher than after spray-drying except for sucrose including formulations. Furthermore, 
the Span values of chitosomes were lower than those of liposomes in all formulations. 
Overall, spray-drying and inclusion of chiotsan have both decreased vesicle aggregation 
and enhanced the dispersion properties of the formulations. 
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Figure 6.13: Span values of liposomes and chitosomes before and after spray-drying. Data are 
mean ± STD, n=3. 
 
6.3.10 Entrapment efficiency  
The entrapment efficiency of the bronchodilator drug SS was also investigated for various 
formulations using an indirect method described by Kim et al. (2005) and Rojanarat et al. 
(2011). Liposome or chitosome entrapped SS was separated via ultracentrifugation, 
resulting in sedimentation of vesicles (with the entrapped drug) at the bottom of the 
centrifuge tube while the free drug (un-entrapped SS) was left at the single phase solution 
of the supernatant. The entrapped SS content was measured by subtracting the amount of 
free drug from that of the total quantity included in the formulation. 
As shown in Table 6.4, the entrapment efficiency of SS in non-carrier based liposomes 
(NC-L) in the absence of carriers was approx 60%, which are similar to the values 
previously reported by Elhissi et al. (2006). Significantly higher entrapment efficiency was 
seen with the inclusion of chitosan in the formulations (Table 6.4), which is in agreement 
with the studies conducted by Galovic Rengel et al., (2002), Phetdee et al., (2008), Zaru et 
al., (2009), Albasarah et al., (2010) and Karn et al., (2011). However contrary to most 
literature findings, the entrapment efficiency of loperamide, insulin and IgG antibody 
decreased when liposomes were coated with chitosan (Guo et al., 2003; Wu et al., 2003; 
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Arafat, 2012). Other investigators such as Li et al. (2009) and Liu and Park, (2010) have 
found that inclusion of chitosan with liposomes had no effect on drug entrapment 
efficiency. These contradictory results might be attributed to the use of different drugs or 
excipients within the liposomal formulations, or might be ascribed to the different 
manufacturing procedure of liposomes coating. Thus, drug entrapment is dependent on both 
bilayer properties of liposomes and nature of the drug used.  
The entrapment efficiency values of SS before spray-drying decreased slightly after 
inclusion of carriers, possibly due to the hypertonic environment outside the liposomes (as 
a result of carrier addition) forcing the water to move from inside liposomes to outside. 
This may have affected the packing patterns of the bilayers, causing drug leakage.  
The effect of inclusion of carriers and chitosan on the entrapment efficiency of SS after 
spray-drying was also investigated (Table 6.4). The entrapment efficiency values in 
liposomes and chitosomes increased significantly (p˂0.05) for all formulations upon 
rehydration of the spray-dried powders, due to the higher lipid recovery (Table 6.3) 
compared to drug recovery (Table 6.2) after spray-drying, thus making lower proportions of 
SS available for entrapment in higher concentrations of lipid. The entrapment efficiency 
values of SS also increased with the inclusion of chitosan in all carriers containing 
formulations. The presence of a polymer coat on the liposomes could have increased the 
bilayer thickness and reduced the rate of drug leakage from the vesicles. Moreover, the 
entrapment efficiency in trehalose-based formulations was slightly higher than other carrier 
containing formulations, suggesting that trehalose offered higher stabilizing effects on the 
liposome bilayers compared to the other cryoprotectants. Other studies have reported the 
benefits of using trehalose as carrier in spray-dried liposome formulations (Ishikawa et al., 
2004 ;Kim et al., 1999), which could be via the formation of hydrogen bonds between the 
sugar molecules and the phosphate groups of phospholipids (Crowe et al., 1996). 
Elhissi et al. (2006) have demonstrated that entrapment efficiency of hydrophilic drugs in 
liposomes generated from ethanol-based proliposomes were very high compared to other 
methods of liposome preparation, which might be attributed to the two-step hydration 
protocol and the oligolamellarity of the liposomes prepared via this method.  
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Table 6.4: Entrapment efficiency of salbutamol sulphate liposomes and chitosomes before and 
after spray-drying. Data are mean ± STD, n=3. 
  
 
6.3.11 In vitro aerosol dispersion performance studies using Two-stage impinger 
The aerodynamic behaviours of spray-dried liposome and chitosome powders were 
assessed using the TSI when four different cryoprotectants (mannitol, LMH, trehalose or 
sucrose) were used. These findings were also compared with the deposition profile of SS 
using Ventolin
®
 capsules available in the market.  
The total amount of powder deposited in the inhaler device, stage 1 and stage 2 was the 
recovered dose (RD). The amount of powder deposited in stage 1 (S1) and 2 (S2) was the 
emitted dose (ED) and it was calculated as the percentage of the RD (Eq. 6.1). The fine 
particle fraction (FPF) was defined as the percentage of RD deposited in stage 2 (Eq. 6.2).  
 
    
     
  
                                                                   
     
  
  
                                                                            
 
Formulation 
Entrapment efficiency (%) 
Before spray-drying 
Entrapment efficiency (%) 
After spray-drying 
NC-L 57.71±0.13  
NC-C 59.37±0.25  
   
M 54.46±0.55 58.10±0.20 
L 54.92±0.33 58.33±0.18 
T 55.10±0.50 59.36±0.19 
S 54.10±0.36 58.81±0.10 
   
MC 57.51±0.45 62.15±0.13 
LC 56.64±0.31 62.82±0.10 
TC 58.33±0.28 63.06±0.21 
SC 56.36±0.47 61.94±0.51 
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In this study, size 3 hydroxypropyl methyl cellulose (HPMC) capsules were used instead of 
hard gelatin capsules because their mechanical strength is unaffected by low levels of 
moisture content and their polymeric material does not undergo cross linking at high 
storage temperatures. Figure 6.14 illustrates aerosol powder performances of Ventolin
®
 in 
comparison with spray-dried liposome and chitosome formulations of SS.  
For all formulations, recovery (RD %) was found to be higher than 90%, suggesting high 
fluidisation capabilities of theses powders at 60 L/min. The high recovery might be 
attributed to the spherical and superior performance of the spray-dried particles, which was 
confirmed earlier by SEM (Figure 6.2; Figure 6.3). The RD% values of mannitol and 
sucrose-based formulations were higher than those of Ventolin
®
, LMH and trehalose based 
formulations, which could be due to the lower adherent tendency of mannitol and sucrose 
to the capsule shell. Moreover no significant differences (p˃0.05) were found when the 
RD% of mannitol and sucrose-based formulations were compared or when the comparison 
was conducted between LMH and trehalose-based formulations. 
The emitted dose and FPF findings are illustrated in Figure 6.14. The ED % of mannitol 
and sucrose-based liposomes were significantly higher than LMH and trehalose-based 
liposomes. On the contrary, the FPF% of mannitol and sucrose-based liposomes were 
significantly lower than LMH and trehalose-based liposomes. This indicates that mannitol 
and sucrose-based liposomes had emitted the maximum amounts of drug into impinger 
compartments whilst only small amount were delivered into the impinger's lower stage. 
Thus, the FPF values were 14.39±1.81%, 32.29±0.15, 48.99±2.22% and 50.12±2.15% for 
mannitol, sucrose, LMH and trehalose-based liposome formulations, respectively. The 
differences in FPF% might be attributed to the enhanced flow properties and minimal 
agglomeration of LMH and trehalose-based particles formulations due to their shapes, 
resulting in increasing FPF.  
However, the FPF values were higher for the chitosomes, being 23.48±3.38%, 
33.89±0.66%, 54.88±1.85% and 55.9±2.74% for mannitol, sucrose, LMH and trehalose-
based chitosomes, respectively (Figure 6.14). The higher FPF for the chitosome 
formulations might be attributed to the improved flow properties of the particles upon 
coating the sticky lipid surfaces with the polymer. Overall, the results revealed that 
trehalose-based formulations exhibited the best aerosol powder performance among the 
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DPIs formulations in term of flow properties and FPF, owing to the more uniform shape 
and enhanced flow properties of trehalose-based particles (Figure 5.2c; Figure 5.3c). 
Furthermore, the FPF values for the spray-dried liposome or chitosome formulations were 
significantly higher (p˂0.05) than that of Ventolin® with all spray-dried formulations 
except for mannitol-based liposomes which had lower FPF and mannitol-based chitosomes 
which exhibited no difference in FPF compared to Ventolin
®
. These findings clearly 
demonstrated that optimisation of spray-dried liposomal or chitosomal formulations could 
provide enhanced FPF of SS compared with the well-established Ventolin
®
 product of the 
drug. The ability of liposomes to control the drug release and localize its action in the lung 
(Schreier et al., 1993) could further consolidated with the bioadhesive nature of 
phospholipids and chitosan and offer marked advantages for future delivery of SS using the 
formulation strategy of this study. Further studies (e.g in vivo study) are needed to 
investigate the validity of this hypothesis. 
 
 
Figure 6.14: Deposition of spray-dried liposome and chitosome dry powders into different 
stages of the Two-stage impinger.  Data are mean ± STD, n=3. 
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6.3.12 In vitro aerosol dispersion performance studies using Next generation impactor 
After delivering commercially available Ventolin
®
, and spray-dried liposomal and 
chitosomal powders using the TSI (Section 6.3.11), results illustrated that the respirable 
fraction of spray-dried chitosomal formulations were generally higher (p˂0.05) than values 
for Ventolin
®
 and spray-dried liposomal formulations (Figure 6.15).  In light of findings 
using TSI, spray-dried chitosomal formulations were chosen for further investigations of 
drug deposition profile using NGI. The NGI was chosen due to its advantages over the 
Anderson Cascade Impactor (ACI), including dose to dose reproducibility, higher 
throughput, and ability to sharply classify particles by aerodynamic size (Marple et al., 
2003a, Marple et al., 2003b). 
The aerosol dispersion properties of the spray-dried chitosomal particles were evaluated 
using NGI coupled with a Monodose DPI device (Section 2.2.16). Also, coating of the NGI 
cups with 1% (w/v) silicon in Hexane was evaluated versus un-coated cups. Coating is 
necessary to prevent the particles from bouncing, resulting in improved capture (Akihiko et 
al., 2004, Eugene et al., 2010). 
Figure 6.15 shows the DPI aerosol deposition profile for spray-dried chitosomes. The 
percentage of powder remained in the capsule and DPI device were higher (p˂0.05) for LC 
and TC formulations compared to MC and SC formulations. In contrast, the fraction of 
powder deposited in the induction port and pre-separator parts were higher (p˂0.05) for 
MC and SC formulations compared to LC and TC based formulations. These findings 
indicate the higher tendency of LC and TC powders to stick to the capsule and DPI device 
wall compared to MC and SC powders.  
However, after delivering LC and TC powders from the device, a larger fraction of particles 
deposited into the NGI stages, which might be due less agglomeration and better particle 
flow properties of LC and TC compared to MC and SC powders (Figure 6.2b,c; Figure 
6.3b, c). Moreover, higher proportions were deposited in the induction port for MC and pre-
separator stage for SC, indicating the higher tendency of agglomeration of these particles, 
resulting in reduction of particle deposition in NGI stages.  
Particle deposition on stages 3-7 for LC and TC was higher (p<0.05) compared to MC and 
SC particles. The particles collected from stages 5-7 might be eligible for deposition in the 
alveolar region of the lung due to diffusion (i.e. Brownian motion) (Suarez and Hickey, 
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2000). In contrast, particles deposited in stages 1-4 would be likely to deposit 
predominantly in the middle-to-deep lung regions by sedimentation due to gravitational 
settling (Edwards, 1995; Suarez and Hickey, 2000; Hickey and Mansour, 2008; Carvalho et 
al., 2011). Larger particle size of MC and SC formulations was confirmed as deposition in 
the upper stage of the impinger was high compared to LC and TC formulations (Figure 
6.15). Particle deposition in the lower stages of the impactor was higher after coating the 
NGI cups (Figure 6.16).  
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Figure 6.15: Aerosol dispersion performance as % remained in capsule, dry powder inhaler device and % delivered to: induction 
port, pre-separator and each stage of impactor before coating at an airflow rate (Q) of 60 L / min for spray-dried chitosomes. For Q 
= 60 L/min, the effective cut-off diameters for each impaction stage are as follows: stage 1 (8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 
µm); stage 4 (1.66 µm); stage 5 (0.94 µm); stage 6 (0.55 µm); and stage 7 (0.34 µm).  Data are mean ± STD, n=3. 
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Figure 6.16: Aerosol dispersion performance as % remained in capsule, dry powder inhaler device and % delivered to: induction 
port, pre-separator and each stage of impactor after coating at an airflow rate (Q) of 60 L / min for spray-dried chitosomes. For Q = 
60 L/min, the effective cut-off diameters for each impaction stage are as follows: stage 1 (8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 
µm); stage 4 (1.66 µm); stage 5 (0.94 µm); stage 6 (0.55 µm); and stage 7 (0.34 µm).  Data are mean ± STD, n=3. 
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Table 6.5 and Table 6.6 show the aerosol performance for the spray-dried chitosome 
formulations before and after coating the NGI cups. The ED values were very high 
(88% - 97% for un-coated NGI cups and 92% - 99% for coated NGI cups), indicating 
the superior aerosolization efficiency of chitosome aerosols. The ED values for MC and 
SC were significantly higher (p˂0.05) than LC and TC, due to the larger particle size 
(agglomeration) of MC and SC, resulting in better delivery from the capsule. The ED 
values increased slightly (p˃0.05) for MC, LC and SC whilst significantly (p˂0.05) for 
TC after coating the NGI cups. 
Tables 6.5 and 6.6, show the MMAD values were in the range of 2.94 - 4.97 µm before 
coating NGI cups and 2.90 - 4.87 µm after coating NGI cups. The GSD values were in 
the range of 1.62 - 1.77 for all formulations. The most important factor in this study is 
the MMAD, which is a function of particle size, shape and density.  
To deliver the dry powder formulation to deep lung, the MMAD of the formulation 
should be less than 5 µm (Rojanarat et al., 2011; Meenach et al., 2013; Wu et al., 2013; 
Duan et al., 2013), thus all spray-dried chitosome formulations developed in this study 
have fulfilled this requirement. The smaller MMAD of LC and TC than SC and MC 
powders could be due to their uniform particle size, better flow properties and lower 
agglomeration tendency as shown earlier by SEM (Figure 6.2b, c; Figure 6.3b, c).  
Therefore, the MMAD values are in the optimal size range of 2.5 - 3 µm for LC and TC 
aerosol powders, which is optimal for targeting the peripheral airways (Wu et al., 2013). 
Moreover, the MMAD of all spray-dried chitosome formulations decreased slightly 
after coating the impactor cups (Table 6.6). These findings were in agreement with 
previous studies that demonstrated lower MMAD following the coating of NGI cups 
(Akihiko et al., 2004; Eugene et al., 2010).  
 
Table 6.5: Aerosol dispersion performance properties of aerosolised spray-dried 
chitosomes before coating impactor cups including emmited dose (ED), mass median 
aerodynamic diameter (MMAD), geometrical standard deviation (GSD), fine particle 
fraction (FPF) and respirable fraction (RF). Data are mean ± STD, n=3. 
   
Formulations 
ED 
(%) 
MMAD  
(µm) 
GSD 
 
FPF 
(%) 
RF 
(%) 
MC 97.89±0.51 4.97 1.75 17.86±2.86 79.89±2.64 
LC 91.37±0.41 2.99 1.72 40.12±3.34 95.21±0.57 
TC 87.30±2.43 2.94 1.77 41.65±1.98 95.85±1.49 
SC 97.40±0.88 4.33 1.66 34.00±2.17 87.90±1.37 
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Table 6.6 shows that FPF values correlated with MMAD. The FPF values of TC and LC 
were significantly higher (p˂0.05) than SC and MC, being %41.65±1.98, %40.12±3.34, 
%34,00±2.17 and %17.86±2.86 for TC, LC, SC and MC, respectively. Hence, it was 
found that MMAD values from smallest to largest were in the order: TC and LC than 
SC and MC. Furthermore, the FPF values increased after coating NGI cups compared to 
un-coated NGI cups. The increase in FPF values was again attributed to the decrease in 
MMAD after coating the impactor cups. The values of RF correlated with FPF before 
and after NGI coating of cups. The RF values are therefore very high for all spray-dried 
chitosome formulations in the range of 80% - 95%, particularly for LC and TC 
formulations (95%), which can be attributed to the higher %FPF of LC and TC. 
 
Table 6.6: Aerosol dispersion performance properties of aerosolised spray-dried 
chitosomes after coating impactor cups including emmited dose (ED), mass median 
aerodynamic diameter (MMAD), geometrical standard deviation (GSD), fine particle 
fraction (FPF) and respirable fraction (RF).. Data are mean ± STD, n=3. 
 
 
Overall, superior aerosol dispersion performance was demonstrated for the spray-dried 
LMH and trehalose-based chitosome formulations using TSI and NGI upon drug 
delivery using the Monodose DPI inhaler device. 
 
6.4 Conclusions 
Liposome and chitosome powders of SS were designed and developed successfully by 
spray-drying of vesicles generated from ethanol-based liposomes using mannitol, LMH, 
trehalose or sucrose as cryoprotectants. The nature and physicochemical properties of 
the incorporated carriers were found to play an important role in determining the 
characteristics of the developed liposome and chitosome formulations.  
The incorporation of the mucoadhesive agent chitosan into liposome formulations (i.e. 
by preparing chitosomes) was investigated. Chitosan incorporation into formulations 
can potentially offer enhanced mucoadhesion properties, positive charge of the 
  Formulations 
ED 
(%) 
MMAD  
(µm) 
GSD 
 
FPF 
(%) 
RF 
(%) 
MC 99.10±0.31 4.87 1.62 22.11±3.16 85.03±0.02 
LC 92.19±0.03 2.90 1.71 46.58±5.03 95.0±0.24 
TC 95.92±1.18 2.89 1.79 46.94±0.50 93.26±2.99 
SC 98.12±0.91 4.28 1.66 36.20±0.98 88.06±1.41 
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liposomes, enhanced drug entrapment efficiency, whilst the size of liposome decreased 
significantly.  
XRPD indicated that there was some interaction between the components of chitosome 
powders produced using spray-drying. Furthermore, the XRDP data illustrated that 
LMH, trehalose and sucrose-based powders changed to amorphous state, whilst 
mannitol-based powders kept their crystallinity after spray-drying. SEM showed that 
LMH and trehalose-based powders were more uniform, spherical and had fewer 
tendencies for agglomeration when compared to mannitol and sucrose-based powders. 
The physicochemical characterisation and aerosol dispersion performance of the 
particles using TSI and NGI indicated that they would be suitable for delivery of SS to 
deep lung using DPI devices. The FPF of LMH, trehalose and sucrose-based 
formulations were significantly higher than the market available formulation of SS 
(Ventolin
®
) using TSI. The aerosol dispersion parameters of FPF and RF were also 
higher for LC and TC than MC and SC using NGI. The MMAD values of LC and TC 
were low and in the optimal range for targeting the peripheral airways. The aerosol 
performance was enhanced after coating NGI cups compared to un-coated cups. 
Overall, the developed mucoadhesive spray-dried chitosomes generated from ethanol-
based liposome method were able to entrap high proportions of SS. These formulations 
particularly those containing LMH and trehalose as cryoprotectants were found to have 
relatively superior aerosolization performance using DPI devices. 
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7.1 General conclusions 
Although proliposomes can be prepared by various methods, spray-drying was 
employed as a one-step process for the generation of small particles (˂ 5µm) for 
pulmonary delivery. This study was specifically conducted to design novel 
mucoadhesive prochitosome and chitosome powders via spray-drying using SS or BDP 
as model drugs, followed by aerosolisation to TSI or NGI impactor using dry powder 
inhaler devices. Moreover, the effects of particle morphology, powder density and 
crystallinity on the aerosolisation properties of formulations were investigated. 
Following hydration of spray-dried powder in aqueous medium, liposome or chitosome 
vesicles were investigated in terms of zeta potential, mucoadhesive properties, vesicle 
size, drug entrapment efficiency and potential for delivery of formulations via medical 
nebulisers and the properties of generated aerosols were investigated. 
Studies were conducted to demonstrate the effect of spray-drying inlet temperature 
(90ºC, 130ºC, 170ºC or 210ºC) on the physicochemical properties of mannitol and 
lactose monohydrate. The results from those studies showed that spray-drying 
temperature can affect the production yield, particle morphology, particle size and 
powder crystallinity. The highest production yields were obtained when the inlet 
temperature was adjusted to 130ºC. Particles had small size and uniform and spherical 
shape when they were spray dried at 90ºC or 130ºC inlet air temperatures. Compared to 
powder before spray drying, spray-dried mannitol kept its crystalline property but the 
diffraction intensity was reduced. In contrast, lactose monohydrate changed to 
amorphous state upon spray-drying. However, particles generated using spray-drying 
inlet air temperature of 130ºC were found to be suitable for use in the preparation of 
proliposome or prochitosome powders. 
The effect of various lipids to carrier (mannitol or lactose monohydrate) ratios (1:2, 1:4, 
1:6, 1:8 or 1:10) on the potential use of proliposomes for pulmonary delivery was 
investigated. The results demonstrated that altering the ratio of lipid to carier influenced 
the properties of proliposome powders in terms of production yield, surface 
morphology, crystallinity and powder aerosolisation. The zeta potential, size, size 
distribution and drug entrapment efficiency of liposomal vesicle upon hydration of 
proliposome powders were affected by formulation.  
The production yield of formulations containing lactose monohydrate was higher than 
those containing mannitol. The production yield was also increased upon increasing 
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carrier to lipid ratio. X-ray powder diffraction showed that proliposomes were 
crystalline upon spray-drying, and hence, there was some interaction between 
proliposome components. Particle morphology and aerosol performance studies 
demonstrated that proliposomes made using mannitol as carrier are very likely to be 
highly suitable for use in pulmonary drug delivery because the spray-dried particles 
were uniform, small and spherically shaped. Furthermore, the formulation containing 
lipid to mannitol ratio of 1:6 had higher fine particle fraction, and warrants further 
characterisation.  
The liposome vesicles generated upon hydration of proliposome powder showed that 
lactose monohydrate-based formulations produced liposomes which entrapped higher 
proportions of salbutamol sulphate compared to mannitol-based liposomes. The 
entrapment efficiency was highest with formulation containing lipid to carrier ratio of 
1:2. Negative zeta potential values for all the formulations indicate that altering lipid to 
carrier ratios had no affect on the surface charge of liposomes. Larger vesicles size 
showed higher proportion of entrapped drug. TEM showed that liposomes containing 
mannitol were spherical vesicles, whilst ―worm-like‖ vesicle clusters were produced for 
liposomes containing LMH. 
Studies to incorporate chitosan polymer as mucoadhesive agent into spray-dried 
formulations were conducted with aim of prolonging the retention time of drug in the 
lung. The results from these studies showed that chitosan can be efficiently incorporated 
into liposome formulations. The concentration of chitosan has markedly influenced the 
properties of the dry powders, and highly affected the characteristics of liposome or 
chitosome vesicles upon hydration in aqueous medium. 
Prochitosome powders were produced using various chitosan to lipid ratios (0:10, 1:10, 
2:10, 3:10 or 5:10) SS and BDP were used as model hydrophilic and hydrophobic 
therapeutic agents respectively. SEM showed that the particles were small, spherical 
and porous. Moreover, FPF values were high particularly with formulations containing 
high chitosan to lipid ratios (3:10 or 5:10 w/w). The change in XRPD intensity peaks 
and FTIR profile indicated that there was interaction between the components of 
prochitosome powder. Carr's index values were between 23.56±2.15 and 31.96±3.44. 
Since values were found to be less than 40%, formulations were judged to have 
acceptable flow properties. By contrast, formulations containing high chitosan to lipid 
ratios (3:10 or 5:10 w/w) had lower Carr's index values and hence excellent flow 
properties. 
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Mucoadhesive studies showed that the zeta potential and the amount of mucin adsorbed 
onto vesicle surfaces increased with increasing chitosan ratios, and vesicle size 
decreased upon increasing chitosan concentration. The entrapment efficiency values of 
SS and BDP were higher for the chitosan-coated liposomes (i.e. chitosomes) than 
uncoated liposomes. Moreover, the entrapment efficiency was higher for BDP 
compared to SS. Furthermore, the entrapment efficiency decreased upon increasing SS 
concentrations in formulations. This can be explained by small size of chitosomes and 
hence the vesicles accommodated lower proprtions of SS (water soluble drug). 
A marked influence of formulation on the performance of medical nebuliser and the 
performance of aerosols was observed. For instance, the use of chitosomes or liposomes 
compared to deionised water was found to shorten the nebulisation time. All 
formulations had high mass output with no significant differences amongst SS or BDP 
containing formulations. FPF was higher for SS containing formulations compared to 
those containing BDP. 
Liposome or chitosome powders were produced by spray-drying using various sugars as 
carriers (mannitol, LMH, trehalose or sucrose). The nature and physicochemical 
properties of the cryoprotectant were found to influence the characteristics of the 
resultant liposome and chitosome formulations. SEM showed that spray dried LMH and 
trehalose-based particles were more uniform, spherical and with lower tendency of 
agglomeration compared to spray-dried mannitol and sucrose-based powders.  
The aerosolisation studies demonstrated that chitosome powders were potentially 
suitable for delivery to deep lung using DPI devices. Using TSI for studying aerosol 
deposition, FPF of LMH, trehalose and sucrose-based formulations were higher than 
Ventolin
®
. The MMAD values of chitosome formulations containing LMH or trehalose 
were low and in the optimal range (2.90; 2.89 respectively) for targeting the peripheral 
airways. The aerosol distribution performance increased significantly after coating NGI 
cups compared to un-coated cups (Table 6.5; Table 6.6). 
This study has clearly demonstrated that the mucoadhesive lipid microparticles 
produced by spray-drying can be successfully employed for pulmonary delivery of 
hydrophilic or hydrophobic drugs. The findings further demonstrated the feasibility of 
using prochitosome or chitosome powders in pulmonary delivery, particularly using dry 
powder inhaler formulations. 
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7.2 Future work 
Prochitosome or chitosome powders prepared by various methods exhibited different 
thermal behaviour, thus the in vivo behaviour of these powders in the lung might be 
different in terms of powder hydration, drug release, liposome bio-distribution, drug 
entrapment efficiency and clearance after intratracheal instillation or inhalation. 
Therefore, the suggested future work: 
1. Prochitosome or chitosome powders will be hydrated in simulated lung fluids, and 
characterized upon hydration for surface charge, vesicles size, mucoadhesive properties, 
and drug entrapment efficiency. 
2. The drug release profile of spray-dried powders upon hydration in deionised water or 
simulated lung fluid need to be investigated. 
3. The stability studies of prochitosome or chitosome powders at different temperatures 
(i.e. room temperature, fridge temperature, freezer temperature and accelerated 
temperature) need to be carried out. 
4. The delivery of the powders using other types of dry powder inhaler devices needs 
further investigation. Effect of carrier types and formulation such as morphology, 
powder density and crystallinity may comprise an essential component. 
5. The delivery of chitosome vesicles using ultrasonic and vibrating mesh nebulisers 
must also be investigated. The determination of the effects of formulations such as 
liposome size, bilayer rigidity, liposome concentration, and chitosan concentration and 
preparation fill volume will be interesting to study in the future. 
6. In this study, it has been shown that the entrapment efficiency of salbutamol sulphate 
was relatively not high using prochitosome technology. Further investigation is needed 
to improve the entrapment efficiency of the drug. Thus, different lipid composition and 
bioadhesive polymers will be used in the future investigations. 
7. Toxicological studies of prochitosome or chitosome powders will be conducted by 
using cell cultures (normal human bronchial epithelial cells and small airway epithelial 
cells) and in vivo findings using model animals. Immunological response of the powder 
may involve studied that can estimate the alveolar macrophage activity. A correlation 
between in vitro and in vivo studies needs to be established, in order to reduce the in 
vivo work and enhance the reliability of the in vitro studies. 
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8. For measurements with large standard deviations, further repetition is needed; this 
may reduce variability between the measurements. 
9. Finally, delivery of labile materials such as proteins or pDNA using spray-dried 
prochitosomes or chitosomes technologies will be investigated.  
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